Therapeutic and diagnostic agents and uses thereof

By developing specific binding molecules for HCMV US28 protein, the treatment problems brought about by the polymorphisms and mutations of US28 protein in the prior art have been solved, efficient targeting of HCMV-infected cells and clearing of latent viruses, and improved treatment Effect.

CN119095614APending Publication Date: 2024-12-06THELPER AS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031443.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-28
Filing Date
2023-01-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing HCMV therapeutic agents are difficult to effectively target polymorphisms and mutations of the US28 protein, resulting in poor treatment effects and inability to target latent viruses, increasing the treatment challenges.

Method used

A binding molecule has been developed to target the N-terminal and third extracellular loop region of the US28 protein of HCMV, which is highly specific and viral strain agnostic, and can effectively bind and target cells expressing US28, reducing the number of healthy cells. Nonspecific binding enhances the targeting ability of HCMV-infected cells.

Benefits of technology

High specific targeting of HCMV-infected cells is achieved, reducing the toxic effect on healthy cells, and can target a variety of HCMV virus strains and mutations, providing continuous therapeutic effects, and enhancing the removal of latent viruses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005064566240000141
    Figure BDA0005064566240000141
  • Figure BDA0005064566240000151
    Figure BDA0005064566240000151
  • Figure BDA0005064566240000161
    Figure BDA0005064566240000161
Patent Text Reader

Abstract

The present invention provides binding molecules having one or more (preferably all) of the following: highly specific binding to the US28 protein of human cytomegalovirus (HCMV), very low levels of non-specific binding to healthy (uninfected) cells, and / or viral strain agnostic binding capacity; and a nucleic acid molecule encoding the binding molecule. The binding molecule is designed to bind to a newly identified epitope region within the extracellular domain 1 (ECD1) of the US28 protein of human cytomegalovirus (HCMV), i.e. The first of the four extracellular domains exhibited by US28, corresponding to positions 1 to 37 of the US28 protein sequence as defined by SEQ ID NO: 5. The binding molecules of the present invention have been demonstrated to have excellent binding properties, including specific binding specificity for invasive and / or metastatic HCMV infected cancers, including breast cancer. In certain preferred embodiments, the binding molecules are selected from the group consisting of antibodies (including, for example, BiTE antibodies) and chimeric antigen receptors (CARs) or functional variants, fragments, fusion proteins, and / or conjugates thereof. Also provided are cells expressing the binding molecules, such as CAR-expressing cells, including CAR-T cells, CAR-NK cells, and CAR-M cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of virology. More specifically, this invention relates to therapeutics and diagnostic agents that target specific regions of proteins such as the US28 protein encoded by human cytomegalovirus (HCMV), and related therapies, including but not limited to HCMV-infected cancers and other conditions associated with latent or lysed HCMV infection.

[0002] References

[0003] The enumeration or discussion of obviously previously published literature in this specification shall not be construed as an admission that such literature is part of the current state of technology or common knowledge. The disclosed references are hereby incorporated by way of citation to provide exemplary procedures or other detailed supplements to the content described herein. Background Technology

[0004] Human cytomegalovirus (HCMV), also known as human herpesvirus 5 (HHV-5), is a common opportunistic DNA virus carried by 56-94% of the global population (Geisler et al., Cancer, 2019, 11:1842; Zuhair et al., Review of Medicine and Virology, 2019, 29(3):e2034).

[0005] In most immune-active individuals, HCMV infection is asymptomatic, undiagnosed, and considered harmless because the host immune system can effectively control viral replication (Boeckh and Geballe, J Clin Invest, 2011.121(5): 1673-80).

[0006] Like all herpesviruses, HCMV establishes a lifelong, persistent latent infection after the initial infection. Latent infection is characterized by low-level or absent viral replication, with the viral genome primarily residing on CD34. + The hematopoietic progenitor cell population resides in the bone marrow (Collins-McMillen et al., Viruses, 2018.10(8)).

[0007] It is assumed that latent HCMV can be intermittently reactivated in a random manner unless it is continuously controlled by the host's immune system. For this reason, the virus can cause complications in certain situations, such as in immunocompromised patients, in whom not only primary HCMV infection but also reinfection or reactivation can cause life-threatening disease, attacking many organs and leading to considerable morbidity and mortality (Boeckh and Geballe, ibid.; Griffiths et al., J Pathol, 2015, 235(2): 288-97).

[0008] HCMV is one of the most common congenital viral infections and a leading cause of birth defects (Davis et al., Birth Defects Research, 2017.109(5): 336-346). It is becoming increasingly clear that HCMV infection may also play a role in the pathogenesis of atherosclerosis, autoimmune diseases, and several malignancies (particularly glioblastoma multiforme) during life (Soderberg-Naucler, J InternMed, 2006.259(3): 219-46; Cobbs, Curr Opin Virol, 2019.39: 49-59). In addition, HCMV serum status may affect the clinical course of burns, trauma and sepsis (Soderberg-Naucler, 2006, ibid.; Limaye et al., JAMA, 2008.300(4): 413-22; Osawa and Singh, Crit Care, 2009.13(3): R68).

[0009] Latent HCMV infection can be reactivated during the inflammatory process when progenitor cells differentiate into monocytes / infiltrating macrophages or dendritic cells (DCs), and these cells can disseminate the virus to peripheral organs (Soderberg-Naucler et al., Cell, 1997, 91:119-126). Reactivated HCMV carried by these inflammatory cells can reach all body tissues and infect and replicate in a wide range of cell types (Ljungman et al., Infect.Dis.Clin.North.Am., 2010, 24:319-337). The infection is further spread through all bodily fluids, including saliva and breast milk (Hamprecht et al., The Lancet, 2001, 357:513-518). Ninety percent of breast milk samples from women who are seropositive for HCMV contain the virus, and it contributes to approximately 30% HCMV prevalence in children under one year of age. Therefore, breastfeeding and parental contact constitute an important route for infants to acquire HCMV infection in early childhood or childhood (Hamprecht et al., 2001, ibid.).

[0010] Cytomegalovirus genome and genetic diversity:

[0011] As discussed by Berg et al., 2019, PLoS ONE 14(9):e0222053, the CMV genome consists of a single linear double-stranded DNA with a size of approximately 235 kb. It contains more than 750 translated ORFs (Stern-Ginossar et al., Science, 2012, 338(6110):1088-93), which can be divided into two regions: a unique long (UL) region and a unique short (US) region, which are flanked by terminal and internal inverted repeat sequences.

[0012] Cytomegaloviruses have adapted a variety of strategies to evade immune detection and facilitate the spread of infection. These strategies are based on the manipulation and regulation of the host's immune response during infection, for example, by expressing viral-encoded homologs of receptors and ligands important for the normal functioning of the human immune system. CMVs possess an unprecedented number of tools available for modulating the host's immune response by encoding two to three times more gene products than other herpesviruses (many of which have been shown to interact with and manipulate the human immune system (Mocarski, Trends Microbiol., 2002; 10(7):332-9)).

[0013] Genetic variation is significant among circulating CMV strains, and recent studies have reported that 75% of strains contain breakpoint mutations and polymorphisms in several genes (Sijmons et al., Journal of Virology, 2015, 89(15):7673-7695). To exclude breakpoint mutations caused by successive passages, the authors used only strains passaged 1 to 2 times and directly verified most of the observed mutations from clinical samples. For the genes UL40 and UL111A, functional knockout mutations were found in 9.9% and 5.5% of the studied strains, respectively (Sijmons et al., 2015, ibid.). UL111A is a functional interleukin-10 homolog that can suppress normal immune responses (Mocarski, 2002, ibid.; Engel and Angulo, Advances in Experimental Medicine and Biology, 2012, 738:256-76). The signal peptide of UL40 promotes the expression of HLA-E on the surface of infected cells. HLA-E is a ligand of the natural killer cell inhibitory receptor (Wilkinson et al., J Clin Virol., 2008; 41(3):206-12).

[0014] Other highly variable CMV genes include the chemokine homolog UL146 (Dolan et al., J Gen Virol., 2004, 85(Pt 5):1301-12), which has been identified with 14 different genotypes; the chemokine scavenging receptor (Kledal et al., FEBS Lett., 1998; 441(2):209-14), and the G protein-coupled receptor US28, which has been reported to have a large number of N-terminal polymorphisms (Goffard et al., Virus Genes, 2006; 33(2):175-81; Arav-Boger et al., J Infect Dis., 2002; 186(8):1057-64).

[0015] Berg et al., 2019 (ibid.) reported that this level of genetic diversity was not observed in other herpesviruses (Sijmons et al., 2015, ibid.) and raises the following questions: Why do CMVs impose such changes in important immune regulatory genes and how do they affect virus-host interactions?

[0016] It is believed that most HCMV pathogenesis is related to the viral latency period, which is closely related to the virus's ability to evade humoral and cellular host immune responses through various mechanisms (Manandhar et al., *International Journal of Molecular Sciences*, 2019, 20(15)). One of the most important aspects of these mechanisms is the high and constantly changing genetic diversity of HCMV. The HCMV genome varies among different individuals and even within the same host (Gorzer et al., Journal of Virology, 2010, 84(14):7195-7203; Renzette et al., PLOS Pathogens, 2011, 7(5):e1001344; Renzette et al., New Perspectives in Virology, 2014, 8:109-15; Renzette et al., Proceedings of the National Academy of Sciences of the United States of America, 2015, 112(30):E4120-8; Renzette et al., Journal of Virology, 2017, 91(5)). New host infections produce viral strains unique to each infected individual and generate selection events in which a new genotype becomes dominant due to the selective pressure of the immune response (Renzette et al., 2011, ibid.). It is possible that both viral and host factors contribute to promoting viral genetic drift during HCMV infection (Vabret et al., Trends Immunol, 2017, 38(1):53-65; Christensen and Paludan, Cell Mol Immunol, 2017, 14(1):4-13). Furthermore, each patient is likely infected with multiple CMV strains as previously well-reported in the literature (Renzette et al., 2015, ibid.). The presence of multiple strains in the same individual allows for recombination from different HCMV strains. Recombination is considered a major driver of HCMV genetic diversity (Suarez et al., Journal of Infectious Diseases, 2019, 220(5):781-791; Sijmons et al., 2015, ibid.; Lassalle et al., Virus Evol, 2016, 2(1):vew017; Cudini et al., Proceedings of the National Academy of Sciences, 2019, 116(12):5693-5698). Reclassification of highly diverse regions will generate new combinations to ensure effective immune evasion, which can also affect viral pathogenicity.Consistently, mixed HCMV infection has been associated with poorer clinical outcomes in immunocompromised individuals in several studies (Coaquette et al., Clin Infect Dis, 2004, 39(2):155-161; Lisboa et al., Transplant Infect Dis, 2012, 14(2):132-140; Houldcroft et al., Front Microbiol, 2016, 7:1317).

[0017] Furthermore, HCMV diversity is driven by genetic polymorphisms that are unevenly distributed throughout the genome (Sijmons et al., 2015, ibid.). Stronger selection occurs in protein regions exposed on the surface of viral particles and for viral proteins expressed at the host cell membrane in extracellular domains (Mozzi et al., PLOS Pathogens, 2020, 16(5):e1008476). Selective pressure exerted by the host immune system likely plays a major role in the formation of genetic diversity among circulating HCMV strains. Thus, several sites targeted by positive selection are located within epitopes recognized by human antibodies or in protein regions that directly interact with host molecules involved in the immune response (Sijmons et al., 2015, ibid.; Mozzi et al., 2020, ibid.). These characteristics are consistent with the ongoing hide-and-seek interplay between HCMV and the human immune system.

[0018] The variability and constant mutation of HCMV strains place stringent demands on both virological diagnostics and the development of HCMV vaccines and drugs, and impose limitations on current antiviral treatments. HCMV vaccine development has been a high priority for the medical community for many years, but to date, no effective HCMV vaccine has been approved.

[0019] Carcinogenic properties of HCMV

[0020] HCMV-encoded proteins exhibit various oncogenic functions (Geisler et al., 2019, ibid.). Upon entry into host cells, the mesentery proteins of HCMV viral particles such as pUL48 are released, thereby disabling both innate and cellular immune responses and promoting enhanced metabolic activity in host cells (Kumari et al., Cell Death & Differentiation, 2017, 8:e3078). These HCMV-encoded proteins enable cells to bypass the G1 phase to promote rapid cell division (Kumari et al., 2017, ibid.). By upregulating anti-apoptotic genes and downregulating pro-apoptotic genes, cells enter an enhanced survival state.

[0021] After viral DNA enters the cell nucleus, cellular RNA polymerases I and II (Pol I and II) are used to transcribe viral genes by binding to the major Immediate Early Promoter (MIEP) (Kostopoulou et al., *Oncotarget*, 2017, 8:96536-96552). The initially expressed gene is the Immediate Early (IE) gene. IE proteins derived from this gene act as transcription factors controlling the expression of early and late viral genes and direct host genes. These proteins are essential for establishing lytic infection and for viral reactivation during the latent period (Kumari et al., 2017, ibid.; Tamrakar et al., *Journal of Virology*, 2005, 79:15477-15493). Lysing HCMV infection leads to cell cycle dysregulation, and IE gene products interfere with key cytokines, including the retinoblastoma protein family (Rb), cyclins, p53, Wnt, phosphatidylinositol 3-kinase / Akt, human telomerase reverse transcriptase (hTERT), and NF-κB, to increase the immortality of infected cells (Moussawi et al., *Scientific Reports*, 2018, 8:12574). These pathways are typically activated in cancer cells. Activation of pro-mitochondrial signals delivered by proto-oncogenes such as Fos and Myc can be induced by IE proteins in HCMV-infected cells (Hagemeier et al., *Journal of Virology*, 1992, 66:4452-4456). Furthermore, MYB gene expression is induced in HCMV-infected cells, similar to the enhanced MYB gene expression in HPV-associated carcinomas (Moussawi et al., 2018, ibid.). In addition to cell division-promoting signals, HCMV infection causes chromosomal aberrations through the deterioration of DNA repair pathways, leading to genetic instability in infected cells (Straat et al., *Journal of the National Cancer Institute*, 2009, 101:488-497; Siew et al., *Journal of Biomedical Sciences*, 2009, 16:107). This drives the development of gene mutations.

[0022] Reports indicate that various HCMVs encoding G protein-coupled receptor (GPCR)-like proteins, including US27, US28, UL33, and UL78, exhibit important oncogenic functions (Heukers et al., *Oncogene*, 2018, 37:4110-4121). G protein activation metabolism and key oncogenic signaling pathways, such as the cAMP and PI3K signaling pathways, are crucial, with the latter being essential for the emergence of anchorage-independent growth and oncogenic transformation of epithelial cells (Moussawi et al., 2018, ibid.; Boroughs et al., *Nature Cell Biology*, 2015, 17:351-359). The early HCMV-2.7 gene transcript is a long non-coding (lnc) RNA that interacts directly with complex I of the respiratory chain in mitochondria. It prevents mitochondrial-induced cell death by inhibiting Fas-ligand interactions and by inhibiting granzyme B through binding to apoptosis protease 8, improving the oxidative capacity of infected cells, and maintaining energy production (Reeves et al., Science, 2007, 316:1345-1348).

[0023] HCMV also employs several mechanisms to manipulate innate and adaptive immune responses to reduce immune surveillance and increase its survival in its immune-active host, which may well explain an important immune evasion mechanism in HCMV infection of cancer cells. HCMV encodes multiple proteins that regulate NK cell recognition of infected cells (Fielding et al., PLOS Pathogens, 2014, 10:e1004058) and increases CD8+. + T cell tolerance to viral proteins. HCMV-encoded proteins can stimulate the development of immature DC phenotypes, which reduces CD4+. + Activation of T cell response (Wagner et al., Journal of Leukocyte Biology, 2008, 83:56-63), and additional reduction of CD8 + Elimination of infected cells by cytotoxic T cells.

[0024] HCMV therapeutic targets:

[0025] Currently, the only available antiviral therapy for HCMV relies on nucleoside analogs such as ganciclovir (GCV) and valganciclovir (VAL-GCV) (Rawlinson et al., Lancet Infect Dis, 2017, 17(6):e177-e188; James and Kimberlin, Curr Opin Pediatr, 2016, 28(1):81-85). These nucleoside analogs have several drawbacks, such as poor bioavailability, toxic side effects, and the risk of developing resistance. Current results indicate that two highly polymorphic HCMV genes, DNA polymerase (UL54) and viral phosphotransferase (UL97), play important roles in resistance to GCV (Komatsu et al., Antiviral Research, 2014, 101:12-25).

[0026] Furthermore, and importantly, existing antiviral agents can only treat lysed HCMV infection, but cannot eliminate latent virus. Eradicating or reducing the latent reservoir would help reduce the burden of HCMV-related disease in several patient populations.

[0027] Previously developed anti-HCMV drugs, such as ganciclovir (GCV), foscarnet (FOS), and cidofovir (CDV), all target the UL54 viral DNA polymerase. However, in the transplant setting, antiviral toxicity and HCMV antiviral resistance pose increasingly significant treatment challenges, thus creating an urgent need for novel anti-HCMV drugs with novel viral targets (Burrel et al., 2014, "Lack of influence of human cytomegalovirus (HCMV) susceptibility to current antiviral drugs on HCMV-encoded US28 chemokine receptor polymorphism", poster presentation at ECCMID 2014 in Barcelona).

[0028] Burrel et al., 2014 (ibid.) taught that the HCMV-encoded US28 protein constitutes a potential target for novel antiviral therapies due to its potential role in viral dissemination and persistence, as well as in smooth muscle cell migration and tumorigenesis.

[0029] HCMV US28 is a seven-transmembrane protein belonging to the class of G protein-coupled receptors (GCPRs). GCPRs constitute the largest family of proteins targeted by approved drugs (Sriram and Insel, *Molecular Pharmacology*, 2018, 93(4):251-258), and share a common architecture, each consisting of a single polypeptide with an extracellular N-terminus, an intracellular C-terminus, and seven hydrophobic transmembrane domains (TM1-TM7) linked by three extracellular loops (ECL1-3) (Alexander et al., *British Journal of Pharmacology*, 2019, 176, Supplement 1:S21-S141).

[0030] The full sequence of US28 encoded by HCMV strain DB (registration number KT959235) is provided in this application as SEQ ID NO:5, wherein:

[0031] The -N-terminal extracellular domain (also referred to herein as ECD1, as it is the first extracellular domain) is provided herein as SEQ ID NO:1 and corresponds to positions 1-37 of SEQ ID NO:5.

[0032] - The first extracellular loop (ECL1; although also referred to herein as ECD2, as it is the second extracellular domain) is provided herein as SEQ ID NO:2 and at positions 91-101 corresponding to SEQ ID NO:5.

[0033] - The second extracellular loop (ECL2; although also referred to herein as ECD3, as it is the third extracellular domain) is provided herein as SEQ ID NO:3 and corresponds to positions 167-183 of SEQ ID NO:5; and

[0034] - The third extracellular loop (ECL3; although also referred to herein as ECD4, as it is the fourth extracellular domain) is provided herein as SEQ ID NO:4 and at positions 250-273 corresponding to SEQ ID NO:5.

[0035] Burrel et al. (ibid.) assessed the polymorphism level of the US28 protein in clinical HCMV strains and concluded that the polymorphism level of US28 in clinical strains was higher than that of other previously reported HCMV-encoded proteins (such as UL97 phosphotransferase and UL44 processivity factor), although this polymorphism did not vary significantly with HCMV susceptibility or resistance to currently approved antiviral drugs (i.e., GCV, FOS, and CDV). Therefore, they supported the view that the HCMV-encoded US28 chemokine receptor could constitute a promising viral target for anti-HCMV drugs, especially in the case of HCMV resistance.

[0036] The authors of WO 2019 / 151865 employed a US28-focusing approach, as reported in the equivalent journal article De Groof et al., 2019, *Molecular Pharmaceutics*, 16:3145-3156. The authors reported generating a single heavy chain variable domain antibody (VHH), based on a specific VHH example, termed VUN100 (SEQ ID NO:60 of this application). This antibody is claimed to specifically detect US28 in glioblastoma (GBM) tissue and inhibit both ligand-dependent and constitutive US28 activity. The authors also reported that this antibody thus attenuated US28-dependent GBM growth in vitro and in vivo in an orthotopic xenograft model.

[0037] The diagram shows that VUN100 binds to discontinuous epitopes comprising multiple binding sites within the N-terminal extracellular region of US28 (the complete N-terminal extracellular region, also referred to herein as ECD1, corresponding to positions 1-37), and is further influenced by the presence of the third extracellular loop of US28 (ECL3, positions 250-273, also referred herein as ECD4), as discussed in Example 3 of WO 2019 / 151865 (page 36, columns 11-32) and Figure 2 of De Groof et al., 2019 (ibid.). De Groof (2019, ibid.) identified that removal of N-terminal amino acid positions 1-22 results in non-binding, and further identified that VUN100 does not bind to amino acid positions 11-15, but amino acid position 16 is required. Furthermore, WO 2019 / 151865... Figure 8Results in section D relating VUN100 to binding with different HCMV strains demonstrate binding differences among the VHL / E, Merlin, and TB40 / E strains of HCMV, with binding being particularly reduced in the TB40 / E (B1 type) strain, at only about half the binding level observed against the Merlin strain. The US28 encoded by the TB40 / E strain differs from that encoded by the Merlin and VHL / E strains at positions 8, 18, and 19 within the N-terminus (see Table 3 of this application), indicating that one or more of these positions (along with possible other amino acids in regions 1-10 and 16-22) also form part of the epitope bound by VUN100. Therefore, VUN100 most likely binds between amino acid positions 1-10 and 16-22 at the N-terminus. Furthermore, replacing the ECD4 region with the corresponding region of CCR5 prevents the binding of VUN100, which means that its binding requires a discontinuous epitope between N-terminal positions 1-22 (including at least position 16, and one or more of positions 8, 18 and / or 19) and an amino acid within ECD4.

[0038] As stated above, the polymorphism level of US28 in clinical viral strains is higher than that of other previously reported HCMV-encoded proteins (Burrel et al., ibid.), and numerous N-terminal polymorphisms of US28 have been reported (Goffard et al., 2006, ibid.; Arav-Boger et al., 2002, ibid.). As determined by the applicant, and as shown in Table 3 of this application, the N-terminal region of US28 bound by VUN100 is particularly sensitive to inter-strain polymorphism.

[0039] Therefore, the inventors considered the possibility that a high level of polymorphism in specific portions of the N-terminal region and the third extracellular loop (“ECD4”) of US28 bound by VUN100 might prevent the VUN100 VHH molecule from maintaining an anti-US28 binding signature consistent with that encoded by different HCMV viral strains. When considered in this context, as stated above, the binding of VUN100 to different HCMV viral strains (WO 2019 / 151865) Figure 8 D) Demonstrates the binding differences of HCMV among the VHL / E, Merlin, and TB40 / E strains, with particularly reduced binding in the TB40 / E (B1 type) strain, only about half the binding level observed against the Merlin strain. Furthermore, further characterization of VUN100 is reported in the preprint article by De Groof et al., 2020 (doi:https: / / doi.org / 10.1101 / 2020.05.12.071860), which is available online, with supplementary data... Figure 2 Results are provided for the percentage of IE expression induced in the nuclei of CD14+ monocytes bound by VUN100. All cells tested were from subjects who were seropositive for HCMV and confirmed to be latently infected with HCMV, but the HCMV virus strain infecting each donor was undetermined. The levels of IE expression induced by VUN100 bound to these HCMV-positive CD14+ cells from each of four different patients were substantially different, with reported percentages of 57%, 33%, 22%, and 4% for cells from donors 1–4, respectively (differences greater than 14-fold). This high level of response following VUN100 binding to confirmed HCMV-positive cells appears most likely to be attributed to infection of each of the donors with a different HCMV virus strain, and therefore strongly indicates that the binding capacity of VUN100 will vary significantly among different HCMV virus strains. The same figure also shows a high level of change in response (more than 7-fold difference) after binding of the bivalent form of VUN100 (referred to as VUN100b in De Groof et al., 2020, ibid., denoted by SEQ ID NO: 63 of this application) to HCMV-positive cells from donors 1–4 of the same group, again providing results indicative of strain-specific binding sensitivity. De Groof et al., 2021, Pharmacol Rev 73:828–846 also describes how successive passages of HCMV lead to the development of a resistant mutant with a truncated US28, which has a premature stop codon in extracellular loop 3, resulting in reduced surface expression of US28. Such resistance may adversely affect VUN100 because it depends on a partial epitope in the third extracellular loop.

[0040] Furthermore, it should be noted that analyses comparing the binding of VUN100 Ab to US28-expressing HEK293T membranes versus those to simulated transfected HEK293T membranes showed that 20% of simulated transfected cells were bound by VUN100, and the US28-expressing HEK293T membrane achieved only a relative specificity score of 4 (De Groof et al., 2019 (ibid.), in their supporting information, Figure S1.A, and Table 2 of this application). The apparent ability to distinguish US28-expressing cells from US28-negative cells (with a specificity score of only about 4, particularly considering the high off-target binding with simulated cells) is likely suboptimal, raising concerns about VUN100's ability to provide specific targeting to HCMV-infected cells while avoiding unacceptable off-target side effects in healthy cells. It also raises concerns about VUN100's applicability in assays (including diagnostic assays such as those used for immunohistochemistry (IHC)) to reliably identify US28-expressing cells, particularly HCMV-infected cells. In addition, in another publication, it has been confirmed that the efficacy of the US28-targeting nanobody needs to be validated in viral and potential in vivo environments (De Groof et al., 2021, ibid.).

[0041] There is a particular need for a binding molecule that provides a significantly greater ability than VUN100 to specifically bind to US28-expressing cells (especially HCMV-infected cells) and / or minimize off-target binding to cells that do not express US28 (especially uninfected HCMV cells) when used in vivo and / or in assays (including IHC).

[0042] In order to utilize US28 as a therapeutic target, it is important to address one or more of the most critical issues mentioned above, including the relatively high levels of non-specific binding activity reported against VUN100 molecules known in the art, the relatively high off-target binding activity observed in VUN100, and / or to provide US28 binding molecules that address issues of viral strain diversity, viral mutation, mutational drift, and the ability of viruses to hide from the immune system during viral latency.

[0043] Therefore, the objective of this invention is to provide binding molecules that can bind with high specificity (much lower than that to healthy human cells) to biological materials expressing US28 and / or positive for HCMV infection and / or minimize the absolute level of off-target binding to healthy human cells. For example, there is widespread interest in providing binding molecules to combat HCMV infection and related conditions, which deliver or guide cytotoxic effects to the cells to which the binding molecules bind, and one objective of this invention is to provide a manner that targets these effects in a way that minimizes or avoids unacceptable (e.g., therapeutically unacceptable) levels of off-target cytotoxicity in healthy human cells. In particular, one of the objectives of this invention is to provide a binding molecule that, in assessing the specificity of binding to US28 and / or HCMV-infected cells compared to US28-expressing and / or HCMV-positive biological materials (e.g., cells) compared to US28-non-expressing and HCMV-non-positive biological materials (e.g., equivalent cells), has a higher level of specificity for binding to US28 and / or HCMV-infected cells than VUN100 Ab of WO 2019 / 151865 and De Groof et al., 2019 (ibid.) and / or VUN100b divalent molecules of De Groof et al., 2020 (ibid.).

[0044] Another objective of the present invention is to provide a binding molecule for US28 that is specific for binding to biomaterials expressing US28 and / or positive for US28-expressing cells infected with HCMV compared to corresponding biomaterials not expressing US28 (such as healthy human cells), and / or exhibits a significantly lower absolute level of off-target binding to healthy human cells than the VUN100 Ab molecule described above.

[0045] Another objective of this invention is to provide a virus strain-agnostic binding molecule that is therefore ideally capable of targeting all or substantially all HCMV infections (regardless of the presence of HCMV virus strains or combinations of virus strains) and / or capable of providing sustained action during treatment of HCMV infection, regardless of the likelihood of the infected virus strain increasing one or more HCMV mutations in the treated subject. In particular, binding molecules targeting US28 exhibiting a greater degree of virus strain-agnostic binding compared to VUN100 Ab are of particular interest. Summary of the Invention

[0046] The present invention provides a binding molecule having highly specific binding to one or more (preferably all) of the US28 protein of human cytomegalovirus (HCMV), extremely low levels of nonspecific binding to healthy (uninfected) cells, and / or unknown binding ability to viral strains, as well as a nucleic acid molecule encoding said binding molecule.

[0047] The binding molecule of the present invention is designed to bind to a first epitope within a polypeptide consisting of the amino acid sequence of TDVLNQSKPVTL (SEQ ID NO: 177) within the N-terminus (also referred to herein as extracellular domain 1 (ECD1)) of the US28 protein of human cytomegalovirus (HCMV), and exhibits binding specificity to the first epitope. The applicant has surprisingly identified that, unlike many regions of the N-terminal region (ECD1) of the US28 protein of HCMV, the amino acid sequence of TDVLNQSKPVTL (SEQ ID NO: 177) is highly conserved among all known HCMV strains and, in addition, possesses suitable immunogenicity and is suitable as an antigen for generating anti-US28 antibodies having one or more of the following (if all): improved strain-agnostic binding properties, improved (i.e., relatively high) binding specificity, and / or improved (i.e., relatively low) off-target binding activity, for example, compared to the prior art monovalent and bivalent VUN100 antibodies discussed above.

[0048] The applicant also surprisingly identified that the ECD3 of the HCMV US28 protein is highly conserved across all known HCMV strains (exhibiting only a single-position polymorphism, as discussed below), and further possesses suitable immunogenicity and suitability as an antigen for generating anti-US28 antibodies having one or more of the following (if all): improved strain-agnostic binding properties, improved (i.e., relatively high) binding specificity, and / or improved (i.e., relatively low) off-target binding activity, for example, compared to the prior art monovalent and bivalent VUN100 antibodies discussed above. Therefore, optionally, the binding molecule of the present invention is also designed to bind a second epitope within the extracellular domain 3 (ECD3) of the HCMV US28 protein and exhibits binding specificity to the second epitope. The binding molecule having binding specificity to both the first and second epitopes may be in a multispecific form.

[0049] In another alternative, the binding molecule of the present invention having binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO:177 within ECD1 of the US28 protein of HCMV is a first binding molecule formulated with a second binding molecule having binding specificity to a second epitope within ECD3 of the US28 protein of HCMV, wherein the second epitope is preferably as further described herein.

[0050] The binding molecules of the present invention have been shown to possess excellent binding properties, including those described above and further as described herein. For example, surprisingly, the binding molecules of the present invention have also been shown to provide particularly advantageous binding specificity against invasive and / or metastatic HCMV-infected cancers (including breast cancer).

[0051] In some preferred embodiments, the binding molecule is selected from antibodies (including, for example, BiTE antibodies) and chimeric antigen receptors (CARs) or their functional variants, fragments, fusion proteins and / or conjugates, as well as nucleic acid molecules encoding them. The binding molecule may, for example, include or bind to a cytotoxic component or other effector component capable of influencing (e.g., inhibiting or killing) any cell to which the binding molecule binds. The binding molecule may, for example, include or bind to a component capable of recruiting other agents (e.g., other proteins, drugs, cells or any other selected substance) in such a way that the recruited agent has the ability to specifically target and influence (e.g., inhibit or kill) the cell to which the binding molecule binds; thus, a non-limiting example is the BiTE molecule, which has the ability to recruit T cells to act on the cells to which the BiTE binds. Cells expressing the binding molecule are also provided, including examples where the binding molecule is a CAR, and the cells may be CAR-expressing cells, including CAR-T cells, CAR-NK cells and CAR-M cells.

[0052] These and other disclosures of the invention are described in more detail below and with respect to the appended claims and drawings.

[0053] Therefore, a first aspect of the present invention provides a binding molecule comprising one or more polypeptide chains, said binding molecule having binding specificity for at least a first epitope within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO:177) within ECD1 of the US28 protein of human cytomegalovirus (HCMV).

[0054] Optionally, the binding molecule of the first aspect of the invention also has binding specificity for a second epitope within extracellular domain 3 (ECD3) of the US28 protein of HCMV (and / or wherein the binding molecule is a first binding molecule formulated with a second binding molecule having binding specificity for the second epitope within ECD3 of the US28 protein of HCMV). For example, the binding molecule of the first aspect of the invention may be a multispecific (e.g., bispecific or trispecific) binding molecule, the multispecific binding molecule comprising one or more regions having binding specificity for a first epitope within a polypeptide comprising the amino acid sequence of SEQ ID NO: 177 within ECD1, and further comprising one or more regions having binding specificity for a second epitope of the US28 protein encoded by HCMV within ECD3.

[0055] According to the present invention, ECD1, SEQ ID NO:177 and ECD3 of the US28 protein each comprise, consist substantially of or consist of the amino acid sequence present in, or substantially of, the US28 protein encoded by the HCMV virus strain at positions 1 to 37, 26 to 37 and 167 to 183 of the US28 protein encoded by the human cytomegalovirus (HCMV) DB virus strain as described in SEQ ID NO:5.

[0056] For example (but not limited to), the binding molecule of the first aspect of the invention may be selected from an antibody or a chimeric antigen receptor (CAR).

[0057] The binding molecule of the first aspect of the invention may, for example, have binding specificity to a first epitope that is entirely present in the amino acid sequence of SEQ ID NO:177, and / or optionally, the second epitope is entirely present in the ECD3 of the US28 protein of HCMV.

[0058] The binding molecule of the first aspect of the invention may, for example, have binding specificity for a first linear epitope within the amino acid sequence of SEQ ID NO:177 and / or optionally for a second linear epitope within ECD3 of the US28 protein.

[0059] The binding molecule of the first aspect of the invention may, for example, have a virus strain-unknown binding specificity to an epitope within the amino acid sequence of ECD1 and / or ECD3 of the US28 protein of HCMV. For example, the binding molecule may:

[0060] - The binding specificity is specific to the first epitope within the amino acid sequence of ECD1 of the US28 protein of HCMV, SEQ ID NO:177, wherein the binding specificity is unknown for two or more (e.g., all) HCMV viral strains, for example, for two or more variant viral strains with different sequences within the N-terminus, such as multiple HCMV viral strains exhibiting interstrain sequence variations (e.g., any one or more of positions 8, 15, 18, 19, 24, 25, including but not limited to the sequence variations listed in Table 3 of this application) at one or more positions in the region 1 to 25 of ECD1, for example, wherein the multiple viral strains are two, three, four, five, six, seven, eight, nine, or ten different viral strains selected from the group consisting of: DB, Toledo, Towne, VR1814, TB40 / E, Merlin, AD169, VHL / E, Davis, and BL; and / or

[0061] - The binding molecule has binding specificity for a second epitope within ECD3 of the US28 protein of HCMV, wherein the binding specificity is unknown to two or more (e.g., all) HCMV viral strains, for example, unknown to the 4D variant and the 4N variant (each as further described herein); and

[0062] - In any case, the HCMV strains selected from any two or more (such as all) of the following groups are unknown: DB, Towne, AF1, VHL / E, AD169, BL, DAVIS, JP, Merlin, PH, TB40 / E, Toledo, TR and VR1814 (FIX).

[0063] Therefore, the binding molecule of the first aspect of the invention may, for example, have binding specificity to a first epitope within the amino acid sequence of ECD1 of the US28 protein of HCMV, regardless of whether the ECD1 of the US28 protein contains mutations of known variants, provided that the first epitope contains the sequence of TDVLNQSKPVTL (SEQ ID NO:177) encoded by the following HCMV viral strains as found in ECD1 of US28: DB, Towne, AF1, VHL / E, AD169, BL, DAVIS, JP, Merlin, PH, TB40 / E, Toledo, TR, and VR1814 (FIX). The sequence of TDVLNQSKPVTL (SEQ ID NO:177) is completely conserved in all the listed clinical viral strains and, to the applicant's knowledge, is also conserved in all known HCMV viral strains.

[0064] Optionally, the binding molecule of the first aspect of the invention may, for example, have binding specificity to a second epitope within the ECD3 of the US28 protein of HCMV, regardless of whether the ECD3 of the US28 protein contains the sequence of the 4D or 4N variant:

[0065] -The 4D variant mentioned above contains TKK encoded by a first-group HCMV virus strain, as found in ECD3 of US28. D The sequences of NQCMTDYDYLEVS (SEQ ID NO:7) are: Towne, VR1814, TB40 / E, Merlin, JP, Ad169, AF1, VHL / E, BL, and DAVIS; and

[0066] The -4N variant contains TKK encoded by a second group of HCMV virus strains, such as those found in ECD3 of US28. NThe sequence of NQCMTDYDYLEVS (SEQ ID NO:6): Toledo, TR and DB virus strains.

[0067] By utilizing the scheme described herein, the applicant has consistently and iteratively generated a large number of antibodies with binding specificity to the first epitope of the ECD1 amino acid sequence of the US28 protein of HCMV in SEQ ID NO:177, and a large number of antibodies with binding specificity to the second epitope of the US28 protein of HCMV in ECD3, including antibodies referred to herein by the following names (the sequences of which are provided below):

[0068] Exemplary antibody against SEQ ID NO:177 US28-4-4H3C3, US28-4-7B1F3, US28-4-2F5B11, US28-4-4A11A11, US28-4-2G2B3, US28-4-5D6H11, US28-4-9G3B9, US28-4-5E8F7, US28-4-6G3D6, and US28-4-5E1E4; and

[0069] Exemplary antibodies against ECD3 US28-13-5G6-1D3, US28-13-1C10-1C10, US28-13-1H3-1A10, US28-14-2C2-1G4, US28-13-1C10-1G9 and US28-14-4E4-1E8.

[0070] In one embodiment, the binding molecule of the first aspect of the invention comprises one, two, three, four, five, or all six complementarity-determining regions (CDRs) corresponding to a first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO: 177, respectively, of any one, two, three, four, five, or six CDR sequences of antibody US28-4-4H3C3 (generally abbreviated herein as “4H3C3”), and / or any one or more functional variants of the CDR sequence of antibody 4H3C3, and optionally wherein the binding molecule is selected from antibodies and CARs.

[0071] Optionally, the combining molecule according to this embodiment may include:

[0072] (a) The variable heavy chain (V) of antibody 4H3C3 H One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO: 196, 197, and 198, respectively; and / or

[0073] (b) The variable light chain (V) of antibody 4H3C3 L One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO:199, 200, and 201, respectively.

[0074] Alternatively, in another option, the binding molecule according to this embodiment may include:

[0075] (a) at least one variable weight chain (V H A polypeptide that has binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO:177, wherein the V H The polypeptide comprises CDR 1, 2, and 3 sequences having sequences of SEQ ID NO: 196, 197, and 198, respectively, and optionally at least one of the variable heavy chains (V) H The polypeptide contains the sequence of SEQ ID NO:187, is substantially composed of, or is composed of; and / or

[0076] (b) at least one variable light chain (V L A polypeptide that has binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO:177, wherein the V L The polypeptide comprises CDR 1, 2, and 3 sequences having sequences of SEQ ID NO:199, 200, and 201, respectively, and optionally a variable light chain (V) therein. L The polypeptide contains, is substantially composed of, or is composed of the sequence of SEQ ID NO:189.

[0077] Refer to the sequence identification number (SEQ ID NO) described below to identify the following sequence of the 4H3C3 antibody in this article:

[0078]

[0079]

[0080] In some embodiments, the 4H3C3 binding molecule is humanized (referred to herein as the "4H3C3 humanized variant"), and optionally, the binding molecule may comprise:

[0081] (a) V as described in SEQ ID NO:196 H -CDR1;

[0082] (b) V as described in any of SEQ ID NO: 197, 293 and 294 H -CDR2;

[0083] (c) V as described in SEQ ID NO:198 H -CDR3;

[0084] (d) V as described in SEQ ID NO:199 or 295 L -CDR1;

[0085] (e) V as described in SEQ ID NO:200 or 222 L -CDR2; and / or

[0086] (f) V as described in SEQ ID NO:201 L -CDR3.

[0087] In some embodiments, the 4H3C3 binding molecule is humanized, and optionally includes:

[0088] (a) Variable heavy chains selected from the group consisting of SEQ ID NO:256-259; and / or

[0089] (b) Select a variable light chain from the group consisting of SEQ ID NO:260-263.

[0090] In another embodiment, the binding molecule of the first aspect of the invention comprises one, two, three, four, five, or all six CDRs corresponding to any one, two, three, four, five, or six of the CDR sequences of antibody US28-4-7B1F3 (generally abbreviated herein as "7B1F3") as defined respectively as SEQ ID NO: 219, 220, 221, 199, 222, and 223, having binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO: 177, and / or any one or more functional variants of the CDR sequence of antibody 7B1F3, and optionally wherein the binding molecule is selected from antibodies and CARs.

[0091] Optionally, the combining molecule according to this embodiment may include:

[0092] (a) V of antibody 7B1F3 H One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO: 219, 220, and 221, respectively; and / or

[0093] (b) V of antibody 7B1F3 L One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO:199, 222, and 223, respectively.

[0094] Alternatively, in another option, the binding molecule according to this embodiment may include:

[0095] (a) at least one V H A polypeptide that has binding specificity to a first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, wherein the V H The polypeptide comprises CDR1, 2, and 3 sequences having sequences of SEQ ID NO:219, 220, and 221, respectively, and optionally at least one of the V sequences. H The polypeptide contains, is substantially composed of, or is composed of the sequence of SEQ ID NO:211; and / or

[0096] (b) at least one V L A polypeptide that has binding specificity to a first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, wherein the V L The polypeptide comprises CDR1, 2, and 3 sequences having sequences of SEQ ID NO:199, 222, and 223, respectively, and optionally V. L The polypeptide contains, is substantially composed of, or is composed of the sequence SEQ ID NO:213.

[0097] Refer to the sequence identification number (SEQ ID NO) described below to identify the following sequence of the 7B1F3 antibody in this article:

[0098]

[0099] In some implementations, the 7B1F3 binding molecule is humanized (referred to herein as the "7B1F3 humanized variant"), and optionally, the binding molecule may comprise:

[0100] (a) V as described in SEQ ID NO:219 H -CDR1;

[0101] (b) V as described in any of SEQ ID NO: 220, 296 and 297 H -CDR2;

[0102] (c) V as described in SEQ ID NO:221 or 298 H -CDR3;

[0103] (d) V as described in SEQ ID NO:199 or 295 L -CDR1;

[0104] (e) V as described in SEQ ID NO:222 L-CDR2; and / or

[0105] (f) V as described in SEQ ID NO:223 L -CDR3.

[0106] In some embodiments, the 7B1F3-binding molecule is humanized, and optionally includes:

[0107] (a) A variable heavy chain selected from the group consisting of SEQ ID NO: 264-267, 270 or 271; and / or

[0108] (b) Select a variable light chain from the group consisting of SEQ ID NO:268,261,269 and263.

[0109] In some preferred embodiments, the variable heavy chain of the 7B1F3-binding molecule has been mutated to remove V. H - Glycosylation sites in the CDR3 domain. Preferably, V H -CDR3 is selected from SEQ ID NO:270 or 271.

[0110] In another embodiment, the binding molecule of the first aspect of the invention comprises one, two, three, four, five, or all six CDRs corresponding to any one, two, three, four, five, or six of the CDR sequences of antibody US28-4-2F5B11 (generally abbreviated herein as "2F5B11") as defined respectively as SEQ ID NO:242, 243, 244, 199, 245, and 246, having binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO:177, and / or any one or more functional variants of the CDR sequence of antibody 2F5B11, and optionally wherein the binding molecule is selected from antibodies and CARs.

[0111] Optionally, the combining molecule according to this embodiment may include:

[0112] (a) V of antibody 2F5B11 H One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO:242, 243, and 244, respectively; and / or

[0113] (b) V of antibody 2F5B11 L One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO:199, 245, and 246, respectively.

[0114] Alternatively, in another option, the binding molecule according to this embodiment may include:

[0115] (a) at least one V H A polypeptide that has binding specificity to a first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, wherein the V H The polypeptide comprises CDR1, 2, and 3 sequences having sequences of SEQ ID NO:242, 243, and 244, respectively, and optionally at least one of the V sequences. H The polypeptide contains, is substantially composed of, or is composed of the sequence of SEQ ID NO:233; and / or

[0116] (b) at least one V L A polypeptide that has binding specificity to a first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, wherein the V L The polypeptide comprises CDR1, 2, and 3 sequences having sequences of SEQ ID NO:199, 245, and 246, respectively, and optionally V. L The polypeptide contains, is substantially composed of, or is composed of the sequence SEQ ID NO:235.

[0117] Refer to the sequence identification number (SEQ ID NO) described below to identify the following sequence of the 2F5B11 antibody in this article:

[0118]

[0119]

[0120] In another embodiment, the binding molecule of the first aspect of the invention comprises one, two, three, four, five, or six CDRs corresponding to any one, two, three, four, five, or all six of the following common CDR sequences, having binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO:177 (wherein the substitutional amino acid at a specific position is indicated in parentheses, and * indicates the absence of an amino acid at that position):

[0121] (a)V H -CDR1 corresponds to (S / N)YW(M / I)H (SEQ ID NO:247);

[0122] (b)V H-CDR2 corresponds to Y(I / V)NP(S / R / N)T(G / A)Y(A / T)E(Y / F)NQKF(K / M)D(SEQ IDNO:248) or Y(I / V)NP(S / R / N)T(G / A)Y(A / T)E(Y / F)NQ(K / Q)(F / L)(K / M / Q)(D / G)(SEQ ID NO:299);

[0123] (c)V H -CDR3 corresponds to (L / I)(R / L)(F / N / S)(G / D)(S / * / R)(S / T)GFAY(SEQ ID NO:249) or (L / I)(R / L)(F / N / S / Q)(G / D)(S / * / R)(S / T)GFAY(SEQ ID NO:300);

[0124] (d)V L -CDR1 corresponds to KSSQSLLYSSNQKNYLA (SEQ ID NO:199) or (K / R)SSQSLLYSSNQKNYLA (SEQ ID NO:301);

[0125] (e)V L -CDR2 corresponds to WAST(W / R)E(S / Y) (SEQ ID NO:250); and / or

[0126] (f)V L -CDR3 corresponds to QQYYSFPLT (SEQ ID NO:201).

[0127] As defined above for any of antibodies 4H3C3, 7B1F3, and / or 2F5B11, V has binding specificity to the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO: 177. H -CDR1、V H -CDR2、V H -CDR3、V L -CDR1、V L -CDR2 and / or V L - Any one or more functional variants of the CDR3 sequence may optionally include those with the features described above for V. H -CDR1、V H -CDR2、V H -CDR3、V L -CDR1、V L -CDR2 and / or V L-CDR3 is a sequence of the corresponding common sequences described in SEQ ID NO:247, 248 or 299, 249 or 300, 199 or 301, 250 and 201 respectively.

[0128] Optionally, the binding molecule of the first aspect of the invention further comprises one, two, three, four, five or six complementarity-determining regions (CDRs) having binding specificity to a second epitope within the ECD3 of the US28 protein of HCMV corresponding to any one, two, three, four, five or six of the CDR sequences of antibody 13-5G6-1D3 (generally abbreviated as “1D3” herein), as defined respectively as SEQ ID NO:8, 9, 10, 14, 15 and 16, and / or any one or more functional variants of the CDR sequence of antibody 1D3, and optionally wherein the binding molecule is selected from antibodies and CARs.

[0129] For example, the binding molecule of this option according to the first aspect of the invention may further comprise (a) a variable heavy chain (V) of antibody 1D3 as defined in SEQ ID NO:8, 9 and 10 respectively. H (a) one, two, or all three sequences of CDR 1, 2, and 3; and / or (b) the variable light chain (V) of antibody 1D3 as defined in SEQ ID NO: 14, 15, and 16, respectively. L (CDR1, 2, and 3 sequences, one, two, or all three sequences)

[0130] Alternatively or concurrently, in this option, the binding molecule may further comprise: (a) at least one variable heavy chain (V H A polypeptide comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO:8, 9, and 10, respectively, and optionally at least one of them being a variable heavy chain (V H (a) The polypeptide contains the sequence of SEQ ID NO:12, is substantially composed of or consists of; and / or (b) at least one variable light chain (V L A polypeptide comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO:14, 15, and 16, respectively, and optionally a variable light chain (V... L The polypeptide contains, is substantially composed of, or is composed of the sequence of SEQ ID NO:18.

[0131] Refer to the sequence identification number (SEQ ID NO) described below to identify the following sequence of the US28-13-5G6-1D3 antibody in this article:

[0132]

[0133] In another option, the binding molecule of the first aspect of the invention further comprises one, two, three, four, five, or six CDRs having binding specificity to a second epitope within ECD3 of the US28 protein of HCMV corresponding to any one, two, three, four, five, or all six of the CDR sequences of antibody 13-1C10-1C10 (generally abbreviated as “1C10” herein), as defined respectively as SEQ ID NO: 112, 113, 114, 117, 83, and 118, and / or any one or more functional variants of the CDR sequence of antibody 1C10, and optionally wherein the binding molecule is selected from antibodies and CARs.

[0134] For example, the binding molecule of this option according to the first aspect of the invention may further comprise (a) the V of antibody 13-1C10-1C10 as defined as SEQ ID NO: 112, 113 and 114 respectively. H One, two, or all three sequences of CDR 1, 2, and 3; and / or (b) the V of antibody 13-1C10-1C10 as defined in SEQ ID NO: 117, 83, and 118, respectively. L One, two, or all three sequences of CDR 1, 2, and 3.

[0135] Alternatively or concurrently, in this option, the binding molecule according to this embodiment may further include: (a) at least one V H A polypeptide comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO: 112, 113, and 114, respectively, and optionally at least one of them, V H The polypeptide contains the sequence of SEQ ID NO:104, is substantially composed of or consists of; and / or (b) at least one V L A polypeptide comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO: 117, 83, and 118, respectively, and optionally V L The polypeptide contains, is substantially composed of, or is composed of the sequence SEQ ID NO:108.

[0136] Referring to the sequence identification number (SEQ ID NO) described below, identify the following sequence of the US28-13-1C10-1C10 antibody in this article:

[0137]

[0138] In another option, the binding molecule of the first aspect of the invention further comprises one, two, three, four, five, or all six CDRs having binding specificity to a second epitope within ECD3 of the US28 protein of HCMV corresponding to any one, two, three, four, five, or all six of the CDR sequences of antibody 13-1H3-1A10 (generally abbreviated herein as “1A10”), as defined respectively as SEQ ID NO: 112, 113, 114, 117, 83, and 118, and / or any one or more functional variants of the CDR sequences of antibody 1A10, and optionally wherein the binding molecule is selected from antibodies and CARs.

[0139] For example, the binding molecule of this option according to the first aspect of the invention may further comprise (a) the V of antibody 13-1H3-1A10 as defined as SEQ ID NO:112, 113 and 114 respectively. H One, two, or all three sequences of CDR 1, 2, and 3; and / or (b) the V of antibody 13-1H3-1A10 as defined in SEQ ID NO: 117, 83, and 118, respectively. L One, two, or all three sequences of CDR 1, 2, and 3.

[0140] Alternatively or concurrently, in this option, the binding molecule according to this embodiment may further include: (a) at least one V H A polypeptide comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO: 112, 113, and 114, respectively, and optionally at least one of them, V H The polypeptide contains the sequence of SEQ ID NO:122, is substantially composed of or consists of; and / or (b) at least one V L A polypeptide comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO: 117, 83, and 118, respectively, and optionally V L The polypeptide contains, is substantially composed of, or is composed of the sequence SEQ ID NO:126.

[0141] Referring to the sequence identification number (SEQ ID NO) described below, identify the following sequence of the US28-13-1H3-1A10 antibody in this article:

[0142]

[0143] In another option, the binding molecule of the first aspect of the invention further comprises one, two, three, four, five, or six CDRs having binding specificity to a second epitope within ECD3 of the US28 protein of HCMV corresponding to any one, two, three, four, five, or all six of the CDR sequences of antibody 13-1C10-1G9 (generally abbreviated as “1G9” herein), as defined in SEQ ID NO: 76, 77, 78, 82, 83, and 84, and / or any one or more functional variants of the CDR sequences of antibody 1G9, and optionally wherein the binding molecule is selected from antibodies and CARs.

[0144] For example, the binding molecule of this option according to the first aspect of the invention may further comprise (a) the V of antibody 13-1C10-1G9 as defined in SEQ ID NO:76, 77 and 78 respectively. H One, two, or all three sequences of CDR 1, 2, and 3; and / or (b) the V of antibody 13-1C10-1G9 as defined in SEQ ID NO:82, 83, and 84, respectively. L One, two, or all three sequences of CDR 1, 2, and 3.

[0145] Alternatively or concurrently, in this option, the binding molecule according to this embodiment may further include: (a) at least one V H A polypeptide comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO:76, 77, and 78, respectively, and optionally at least one of them, V H The polypeptide contains the sequence of SEQ ID NO:68, is substantially composed of or consists of; and / or (b) at least one V L A polypeptide comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO:82, 83, and 84, respectively, and optionally V L The polypeptide contains, is substantially composed of, or is composed of the sequence SEQ ID NO:72.

[0146] Referring to the sequence identification number (SEQ ID NO) described below, identify the following sequence of the US28-13-1C10-1G9 antibody in this article:

[0147]

[0148] In another option, the binding molecule of the first aspect of the invention further comprises one, two, three, four, five, or six CDRs having binding specificity to a second epitope within ECD3 of the US28 protein of HCMV corresponding to any one, two, three, four, five, or all six of the CDR sequences of antibody 14-4E4-1E8 (generally abbreviated as “1E8” herein), as defined in SEQ ID NO: 76, 95, 96, 82, 99, and 100, and / or any one or more functional variants of the CDR sequences of antibody 1E8, and optionally wherein the binding molecule is selected from antibodies and CARs.

[0149] For example, the binding molecule of this option according to the first aspect of the invention may further comprise (a) the V of antibody 14-4E4-1E8 as defined in SEQ ID NO:76, 95 and 96 respectively. H One, two, or all three sequences of CDR 1, 2, and 3; and / or (b) the V of antibody 14-4E4-1E8 as defined in SEQ ID NO:82, 99, and 100, respectively. L One, two, or all three sequences of CDR 1, 2, and 3.

[0150] Alternatively or concurrently, in this option, the binding molecule according to this embodiment may further include: (a) at least one V H A polypeptide comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO:76, 95, and 96, respectively, and optionally at least one of them, V H The polypeptide contains the sequence of SEQ ID NO:88, is substantially composed of or consists of; and / or (b) at least one V L A polypeptide comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO:82, 99, and 100, respectively, and optionally V L The polypeptide contains, is substantially composed of, or is composed of the sequence SEQ ID NO:92.

[0151] Refer to the sequence identification number (SEQ ID NO) described below to identify the following sequence of the antibody US28-14-4E4-1E8 in this article:

[0152]

[0153] In another option, the binding molecule of the first aspect of the invention further comprises one, two, three, four, five, or six CDRs having binding specificity to a second epitope within ECD3 of the US28 protein of HCMV, corresponding to any one, two, three, four, five, or all six of the following common CDR sequences (wherein the substitutional amino acid at a specific position is indicated in parentheses, and * indicates the absence of an amino acid at that position):

[0154] (a)V H -CDR1 corresponds to S(Y / H)A(M / L)S (SEQ ID NO:167);

[0155] (b)V H -CDR2 corresponds to SISS(G / R)G(S / R)TYYPDSVKG (SEQ ID NO:168);

[0156] (c)V H -CDR3 corresponds to GG(S / T)(T / R / H)(M / H / Y)(I / S)(T / Y)(T / G)(G / N)(L / *)GF(A / D)(Y / F) (SEQ ID NO: 169);

[0157] (d)V L -CDR1 corresponds to S(A / V)SSSVSYMH (SEQ ID NO:170);

[0158] (e)V L -CDR2 corresponds to D(T / S)SKLAS (SEQ ID NO:171); and / or

[0159] (f)V L -CDR3 corresponds to QQW(S / T / *)SN(* / N)PP(I / L)T(SEQ ID NO:172).

[0160] In another option, the binding molecule of the first aspect of the invention further comprises one, two, three, four, five, or six CDRs having binding specificity to a second epitope within ECD3 of the US28 protein of HCMV, corresponding to any one, two, three, four, five, or all six of the following common CDR sequences (wherein the substitutional amino acid at a specific position is indicated in parentheses, and * indicates the absence of an amino acid at that position):

[0161] (a)V H -CDR1 corresponds to S(Y / H)A(M / L)S (SEQ ID NO:167);

[0162] (b)V H-CDR2 corresponds to SISS(G / R)GRTYYPDSVKG (SEQ ID NO:174);

[0163] (c)V H -CDR3 corresponds to GG(S / T)(T / R / H)(M / H / Y)(I / S)(T / Y)(T / G)(G / N)GF(A / D)(Y / F) (SEQ ID NO: 175);

[0164] (d)V L -CDR1 corresponds to S(A / V)SSSVSYMH (SEQ ID NO:170);

[0165] (e)V L -CDR2 corresponds to D(T / S)SKLAS (SEQ ID NO:171); and / or

[0166] (f)V L -CDR3 corresponds to QQW(T / *)SN(* / N)PPIT(SEQ ID NO:176).

[0167] As defined above, V has binding specificity to the second epitope within ECD3 of the US28 protein of HCMV, as defined by any of the antibodies US28-13-5G6-1D3, 13-1C10-1C10, 13-1H3-1A10, 13-1C10-1G9, and 14-4E4-1E8. H -CDR1、V H -CDR2、V H -CDR3、V L -CDR1、V L -CDR2 and / or V L - Any one or more functional variants of the CDR3 sequence may optionally include those having, as described above in the two preceding paragraphs, respectively, for V. H -CDR1、V H -CDR2、V H -CDR3、V L -CDR1、V L -CDR2 and / or V L -CDR3 refers to the sequence of the corresponding common sequence.

[0168] The sequence corresponding to the above SEQ ID NO is given in the part entitled "Sequence" of this application, which follows the embodiments of this application.

[0169] In some embodiments, the binding molecules according to the first aspect of the invention may be selected from the group consisting of:

[0170] (a) Bivalent antibodies, such as IgG-scFv antibodies (e.g., wherein the first binding domain is intact IgG and the second binding domain is scFv, said scFv being attached to the first binding domain at the N-terminus of the light chain of said IgG and / or at the C-terminus of the light chain and / or at the N-terminus of the heavy chain and / or at the C-terminus of the heavy chain, or vice versa), including but not limited to bivalent antibodies having binding specificity to the first epitope within a polypeptide consisting of the amino acid sequence of TDVLNQSKPVTL (SEQ ID NO:177) and binding specificity to the second epitope within extracellular domain 3 (ECD3) of the US28 protein of HCMV, for example, wherein said first epitope and / or second epitope are further defined as in this application;

[0171] (b) Monovalent antibodies, such as Or "knob-in-hole" bispecific antibodies (e.g., scFv-KIH, scFv-KIH) r BiTE-KIH or BiTE-KIH r );

[0172] (c)scFv2-Fc antibody;

[0173] (d) Bispecific antibodies, such as bispecific T-cell conjugate (BiTE) antibodies;

[0174] (e) Dual variable domain (DVD)-Ig antibody;

[0175] (f) Antibodies based on biaffinity retargeting (DART) (e.g., DART2-Fc or DART);

[0176] (g) A trispecific antibody, such as a DNL-Fab3 antibody or a trispecific antibody, having binding specificity for a first epitope within a polypeptide consisting of the amino acid sequence of TDVLNQSKPVTL (SEQ ID NO: 177), and binding specificity for a second epitope within extracellular domain 3 (ECD3) of the US28 protein of HCMV, for example, wherein the first and / or second epitopes are as defined in this application, and binding specificity for a third epitope (such as an epitope presented by an immune cell), optionally wherein the trispecific antibody is a trispecific immune cell conjugate antibody, such as a trispecific T cell conjugate (TiTE), and optionally wherein the TiTE antibody contains a CD3 binding domain;

[0177] (h)scFv-HSA-scFv antibody;

[0178] (i) Single-domain antibodies;

[0179] (j) Heavy chain IgG only (hcIgG), such as camel IgG (e.g., VHH antibody) and shark immunoglobulin neoantigen receptor (IgNAR), and their single-chain antibodies; and

[0180] (k) A chimeric antigen receptor (CAR) comprising an extracellular domain constituting, substantially composed of, or composed of a binding molecule according to a first aspect of the invention, such as an extracellular domain comprising any one or a combination of options (a) to (h) of this list.

[0181] Alternatively or concurrently, the binding molecules according to the first aspect of the invention may be selected from the group consisting of:

[0182] (i) a bispecific immune cell conjugate antibody, such as a bispecific T cell conjugate (BiTE), wherein optionally the BiTE antibody comprises a CD3 binding domain; or

[0183] (ii) a monoclonal antibody, optionally a recombinant monoclonal antibody, such as a monoclonal antibody recombined from CHO cells. A first aspect of the invention also provides a functional fragment of a binding molecule as defined above, wherein the functional fragment:

[0184] (a) An antigen-binding fragment comprising, or consisting of, a variant, fusion, or derivative thereof of, the binding molecule according to any one of the preceding claims, wherein the antigen-binding fragment comprising, a variant, fusion, or derivative thereof is selected from the group consisting of: Fv fragments (such as single-chain Fv fragments (scFv) or disulfide-bound Fv fragments), Fab-like fragments (such as Fab fragments, Fab' fragments, or F(ab)2 fragments) and single-domain antibodies (dAbs, including single and dual forms, such as dAb-linker-dAbs and nanobodies);

[0185] (b) providing one or more of the binding features of the binding molecule as defined herein in the first aspect of the invention;

[0186] (c) A CDR sequence comprising a binding molecule of the first aspect of the invention as defined herein; and / or

[0187] (d) V comprising a binding molecule as defined herein as a first aspect of the invention. H and / or V L sequence.

[0188] The fusion of the binding molecule of the first aspect of the invention is also provided herein. For example, a binding molecule or a functional fragment of the binding molecule as defined above is provided, wherein the binding molecule or the functional fragment thereof comprises a fusion polypeptide sequence comprising a first amino acid sequence fused to a second amino acid sequence, wherein the first amino acid sequence comprises or is composed of at least one polypeptide chain of the binding molecule or the functional fragment thereof, and the second amino acid sequence is a fusion chaperone.

[0189] In some embodiments, the binding molecule of the first aspect of the invention is a chimeric antigen receptor (CAR) or is contained within such a chimeric antigen receptor. Therefore, the first aspect of the invention also provides a CAR comprising:

[0190] (i) an extracellular domain, wherein the extracellular domain comprises or consists of: a binding molecule of the first aspect of the invention as defined herein or a functional segment of the binding molecule as defined herein;

[0191] (ii) Transmembrane domains; and

[0192] (iii) Intracellular domains;

[0193] The extracellular domain of the CAR is specifically binding to a first epitope within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) within ECD1 of the US28 protein of human cytomegalovirus (HCMV), and optionally also to a second epitope within ECD3.

[0194] The ECD1, SEQ ID NO:177 and ECD3 of the US28 protein each contain an amino acid sequence present in the US28 protein, the positions of which correspond to positions 1 to 37, 26 and 37 and 167 to 183 of the US28 protein encoded by human cytomegalovirus (HCMV) as described in SEQ ID NO:5.

[0195] Optionally, in the CAR:

[0196] (a) The extracellular domain of the CAR has binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO:177) that is entirely present in the ECD1 of the US28 protein of HCMV, and / or binding specificity to a second epitope that is entirely present in the ECD3.

[0197] (b) The extracellular domain of the CAR has binding specificity to a first linear epitope within the polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) within ECD1 of the US28 protein, and / or binding specificity to a second linear epitope within ECD3.

[0198] (c) The extracellular domain of CAR is located within the ECD1 region of the US28 protein of HCMV, and is composed of TDVLNQSKPVTL (SEQ ID NO). The first epitope within the polypeptide consisting of the amino acid sequence NO:177 has a binding specificity unknown to HCMV strains, for example, an epitope within ECD1 of the HCMV US28 protein with a binding specificity unknown to two or more (e.g., all) HCMV strains selected from the following groups: DB, Towne, AD169, DAVIS, BL, JP, Merlin, PH, TB40 / E, Toledo, TR, VHL / E, and VR1814 (FIX), and / or a second epitope within ECD3 of the HCMV US28 protein with a binding specificity unknown to HCMV strains, for example, an epitope within ECD3 of the HCMV US28 protein with a binding specificity unknown to two or more (e.g., all) HCMV strains selected from the following groups: DB, Towne, AD169, DAVIS, BL, JP, Merlin, PH, TB40 / E, Toledo, TR, VHL / E, and VR1814 (FIX);

[0199] (d) The extracellular domain of the CAR is specific for the first epitope within the polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) of the ECD1 region of the US28 protein of multiple HCMV strains, regardless of whether the multiple HCMV strains exhibit interstrain sequence variations at one or more positions in the region of ECD1 from position 1 to 25 (such as any one or more of positions 8, 15, 18, 19, 24, 25, including but not limited to the sequence variations listed in Table 3 of this application), for example, said multiple strains being two, three, four, five, six, seven, eight, nine, or ten different strains selected from the group consisting of: DB, Toledo, Towne, VR1814, TB40 / E, Merlin, AD169, VHL / E, Davis, and BL; and / or

[0200] (e) The extracellular domain of CAR is specific for the second epitope within the ECD3 of the HCMV US28 protein, regardless of whether the ECD3 of the US28 protein contains the following sequence:

[0201] - Such as TKKDNQCMTDYDYLEVS (SEQ ID NO:7) found in ECD3 of US28, which is encoded by most HCMV viral strains, or

[0202] - Such as TKKNNQCMTDYDYLEVS (SEQ ID NO:6) found in ECD3 of US28, which is encoded by a small number of HCMV virus strains.

[0203] In some embodiments, in the CAR according to the first aspect of the invention:

[0204] (a) The extracellular domain of the CAR has binding specificity to the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, and contains one, two, three, four, five or six complementarity-determining regions (CDRs) corresponding to any one, two, three, four, five or all six CDR sequences of antibody 4H3C3 as defined in SEQ ID NO:196, 197, 198, 199, 200 and 201, and / or functional variants of any one or more sequences of the CDR sequence of antibody 4H3C3 (such as humanized variants of 4H3C3);

[0205] (b) The extracellular domain of the CAR has binding specificity to the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, and comprises:

[0206] (i) The variable heavy chain (V) of antibody 4H3C3 H One, two, or all three sequences of CDR 1, 2, and 3, as defined by SEQ ID NO: 196, 197, and 198, or as defined by its 4H3C3 humanized variant; and / or

[0207] (ii) The variable light chain (V) of antibody 4H3C3 L One, two, or all three sequences of CDR 1, 2, and 3, as defined by SEQ ID NO: 199, 200, and 201, or as defined by its 4H3C3 humanized variant; and / or

[0208] (c) The extracellular domain of the CAR has binding specificity to the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, and comprises:

[0209] (i) at least one variable weight chain (V H The polypeptide sequence comprises CDR 1, 2, and 3 sequences having sequences of SEQ ID No: 196, 197, and 198 (or their 4H3C3 humanized variants), respectively, and optionally wherein at least one of the variable heavy chains (VH The polypeptide sequence contains, is substantially composed of, or is composed of the sequence of SEQ ID NO:187 (or its 4H3C3 humanized variant); and / or

[0210] (ii) at least one variable light chain (V L ) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences having SEQ ID NO:199, 200, and 201 (or their 4H3C3 humanized variants), respectively, and optionally wherein the variable light chain (V L The polypeptide contains the sequence of SEQ ID NO:189 (or its 4H3C3 humanized variant), or is substantially composed of or consists of the sequence of SEQ ID NO:189.

[0211] In another embodiment, in the CAR according to the first aspect of the invention:

[0212] (a) The extracellular domain of the CAR has binding specificity to the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, and contains one, two, three, four, five or six complementarity-determining regions (CDRs) corresponding to any one, two, three, four, five or all six CDR sequences of antibody 7B1F3 as defined in SEQ ID NO:219, 220, 221, 199, 222 and 223, and / or functional variants of any one or more sequences of the CDR sequence of antibody 7B1F3 (such as humanized variants of 7B1F3);

[0213] (b) The extracellular domain of the CAR has binding specificity to the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, and comprises:

[0214] (i) The variable heavy chain (V) of antibody 7B1F3 H One, two, or all three sequences of CDR 1, 2, and 3, as defined by SEQ ID NO: 219, 220, and 221, or as defined by its 7B1F3 humanized variant; and / or

[0215] (ii) The variable light chain (V) of antibody 7B1F3 L One, two, or all three sequences of CDR 1, 2, and 3, as defined by SEQ ID NO: 199, 222, and 223, or as defined by its 7B1F3 humanized variant; and / or

[0216] (c) The extracellular domain of the CAR has binding specificity to the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, and comprises:

[0217] (i) at least one variable weight chain (V H ) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences having SEQ ID No: 219, 220, and 221 (or their 7B1F3 humanized variants), and optionally wherein at least one of the variable heavy chains (V H The polypeptide sequence contains, is substantially composed of, or is composed of the sequence of SEQ ID NO:211 (or its 7B1F3 humanized variant); and / or

[0218] (ii) at least one variable light chain (V L ) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO:199, 222, and 223 (or their 7B1F3 humanized variants), respectively, and optionally wherein the variable light chain (V L The polypeptide contains the sequence of SEQ ID NO:213 (or its 7B1F3 humanized variant), or is substantially composed of or consists of the sequence of SEQ ID NO:213.

[0219] In another embodiment, in the CAR according to the first aspect of the invention:

[0220] (a) The extracellular domain of the CAR has binding specificity to the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, and contains one, two, three, four, five or six complementarity-determining regions (CDRs) that correspond to any one, two, three, four, five or all six of the CDR sequences of antibody 2F5B11 as defined in SEQ ID NO:242, 243, 244, 199, 245 and 246, and / or functional variants of any one or more sequences of the CDR sequences of antibody 2F5B11;

[0221] (b) The extracellular domain of the CAR has binding specificity to the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, and comprises:

[0222] (i) The variable heavy chain (V) of antibody 2F5B11 H One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO:242, 243, and 244, respectively; and / or

[0223] (ii) The variable light chain (V) of antibody 2F5B11 L One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO: 199, 245, and 246, respectively; and / or

[0224] (c) The extracellular domain of the CAR has binding specificity to the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:177, and comprises:

[0225] (i) at least one variable weight chain (V H ) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID No: 242, 243, and 244, respectively, and optionally wherein at least one of the variable heavy chains (V H The polypeptide sequence comprises, or is substantially composed of, the sequence of SEQ ID NO:233; and / or

[0226] (ii) at least one variable light chain (V L ) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO:199, 245, and 246, respectively, and optionally wherein the variable light chain (V L The polypeptide contains, or is substantially composed of, the sequence of SEQ ID NO:235.

[0227] In some options, in the CAR according to the first aspect of the invention:

[0228] (a) The extracellular domain of the CAR further has binding specificity to a second epitope within ECD3 of the US28 protein of HCMV and contains one, two, three, four, five or six complementarity-determining regions (CDRs) corresponding to any one, two, three, four, five or all six CDR sequences of antibody 1D3 as defined in SEQ ID NO:8, 9, 10, 14, 15 and 16, and / or functional variants of any one or more sequences of the CDR sequences of antibody 1D3;

[0229] (b) The extracellular domain of the CAR further exhibits binding specificity to the second epitope within ECD3 of the US28 protein of HCMV, and includes:

[0230] (i) The variable heavy chain (V) of antibody 1D3 H One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO:8, 9, and 10, respectively; and / or

[0231] (ii) The variable light chain (V) of antibody 1D3 L One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO: 14, 15, and 16, respectively; and / or

[0232] (c) The extracellular domain of the CAR further exhibits binding specificity to the second epitope within ECD3 of the US28 protein of HCMV, and comprises: (i) at least one variable heavy chain (V H ) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID No: 8, 9, and 10, respectively, and optionally at least one of them being a variable heavy chain (V H (ii) a polypeptide sequence comprising, substantially comprising, or consisting of the sequence of SEQ ID NO:12; and / or at least one variable light chain (V L A polypeptide sequence comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO: 14, 15, and 16, respectively, and optionally, a variable light chain V. L The polypeptide contains, is substantially composed of, or is composed of the sequence of SEQ ID NO:18.

[0233] In some other options, in the CAR according to the first aspect of the invention:

[0234] (a) The extracellular domain of the CAR further has binding specificity to the second epitope within ECD3 of the US28 protein of HCMV and contains one, two, three, four, five or six complementarity-determining regions (CDRs) that correspond to any one, two, three, four, five or all six of the CDR sequences of antibody 1C10 as defined in SEQ ID NO: 112, 113, 114, 117, 83 and 118, and / or functional variants of any one or more sequences of the CDR sequences of antibody 1C10;

[0235] (b) The extracellular domain of the CAR further exhibits binding specificity to the second epitope within ECD3 of the US28 protein of HCMV, and includes:

[0236] (i) The variable heavy chain (V) of antibody 1C10 H One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO: 112, 113, and 114, respectively; and / or

[0237] (ii) The variable light chain (V) of antibody 1C10 L One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO: 117, 83, and 118, respectively; and / or

[0238] (c) The extracellular domain of the CAR further exhibits binding specificity to the second epitope within ECD3 of the US28 protein of HCMV, and includes:

[0239] (i) at least one variable weight chain (V H ) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID No: 112, 113, and 114, respectively, and optionally wherein at least one of the variable heavy chains (V H The polypeptide sequence comprises, or is substantially composed of, the sequence of SEQ ID NO: 104; and / or

[0240] (ii) at least one variable light chain (V L ) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO: 117, 83, and 118, respectively, and optionally wherein the variable light chain (V L The polypeptide contains, or is substantially composed of, the sequence of SEQ ID NO:108.

[0241] In some other options, in the CAR according to the first aspect of the invention:

[0242] (a) The extracellular domain of the CAR further has binding specificity to the second epitope within ECD3 of the US28 protein of HCMV and contains one, two, three, four, five or six complementarity-determining regions (CDRs) that correspond to any one, two, three, four, five or all six of the CDR sequences of antibody 1A10 as defined in SEQ ID NO: 112, 113, 114, 117, 83 and 118, and / or functional variants of any one or more sequences of the CDR sequences of antibody 1A10;

[0243] (b) The extracellular domain of the CAR further exhibits binding specificity to the second epitope within ECD3 of the US28 protein of HCMV, and includes:

[0244] (i) The variable heavy chain (V) of antibody 1A10 H One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO: 112, 113, and 114, respectively; and / or

[0245] (ii) The variable light chain (V) of antibody 1A10 L One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO: 117, 83, and 118, respectively; and / or

[0246] (c) The extracellular domain of the CAR further exhibits binding specificity to the second epitope within ECD3 of the US28 protein of HCMV, and includes:

[0247] (i) at least one variable weight chain (VH ) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID No: 112, 113, and 114, respectively, and optionally wherein at least one of the variable heavy chains (V H The polypeptide sequence comprises, or is substantially composed of, the sequence of SEQ ID NO: 122; and / or

[0248] (ii) at least one variable light chain (V L ) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO: 117, 83, and 118, respectively, and optionally wherein the variable light chain (V L The polypeptide contains, or is substantially composed of, the sequence of SEQ ID NO:126.

[0249] In some other options, in the CAR according to the first aspect of the invention:

[0250] (a) The extracellular domain of the CAR further has binding specificity to the second epitope within ECD3 of the US28 protein of HCMV and contains one, two, three, four, five or six complementarity-determining regions (CDRs) that correspond to any one, two, three, four, five or all six of the CDR sequences of antibody 1G9 as defined in SEQ ID NO:76, 77, 78, 82, 83 and 84, and / or functional variants of any one or more sequences of the CDR sequences of antibody 1G9;

[0251] (b) The extracellular domain of the CAR further exhibits binding specificity to the second epitope within ECD3 of the US28 protein of HCMV, and includes:

[0252] (i) The variable heavy chain (V) of antibody 1G9 H One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO:76, 77, and 78, respectively; and / or

[0253] (ii) The variable light chain (V) of antibody 1G9 L One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO: 82, 83, and 84, respectively; and / or

[0254] (c) The extracellular domain of the CAR further exhibits binding specificity to the second epitope within ECD3 of the US28 protein of HCMV, and includes:

[0255] (i) at least one variable weight chain (V H) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID No: 76, 77, and 78, respectively, and optionally wherein at least one of the variable heavy chains (V H The polypeptide sequence comprises, or is substantially composed of, the sequence of SEQ ID NO:68; and / or

[0256] (ii) at least one variable light chain (V L ) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO:82, 83, and 84, respectively, and optionally wherein the variable light chain (V L The polypeptide contains, or is substantially composed of, the sequence of SEQ ID NO:72.

[0257] In some other options, in the CAR according to the first aspect of the invention:

[0258] (a) The extracellular domain of the CAR further has binding specificity to the second epitope within ECD3 of the US28 protein of HCMV and contains one, two, three, four, five or six complementarity-determining regions (CDRs) that correspond to any one, two, three, four, five or all six of the CDR sequences of antibody 1E8 as defined in SEQ ID NO:76, 95, 96, 82, 99 and 100, and / or functional variants of any one or more sequences of the CDR sequences of antibody 1E8;

[0259] (b) The extracellular domain of the CAR further exhibits binding specificity to the second epitope within ECD3 of the US28 protein of HCMV, and includes:

[0260] (i) The variable heavy chain (V) of antibody 1E8 H One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO:76, 95, and 96, respectively; and / or

[0261] (ii) The variable light chain (V) of antibody 1E8 L One, two, or all three sequences of CDR 1, 2, and 3, as defined in SEQ ID NO:82, 99, and 100, respectively; and / or

[0262] (c) The extracellular domain of the CAR further exhibits binding specificity to the second epitope within ECD3 of the US28 protein of HCMV, and includes:

[0263] (i) at least one variable weight chain (V HThe polypeptide sequence comprises CDR 1, 2, and 3 sequences having sequences of SEQ ID No: 76, 95, and 96, respectively, and optionally wherein at least one of the variable heavy chains (V) is described. H The polypeptide sequence comprises, or is substantially composed of, the sequence of SEQ ID NO:88; and / or

[0264] (ii) at least one variable light chain (V L ) polypeptide sequences comprising CDR 1, 2, and 3 sequences having sequences of SEQ ID NO:82, 99, and 100, respectively, and optionally wherein the variable light chain (V L The polypeptide contains, or is substantially composed of, the sequence of SEQ ID NO:92.

[0265] Optionally, in this CAR, the extracellular domain is an antibody, such as a single-chain variable fragment (scFv).

[0266] The transmembrane domain of the CAR according to the first aspect of the invention may, for example, include a protein transmembrane domain, such as the transmembrane domain of a transmembrane receptor protein, and optionally the transmembrane domain includes a transmembrane domain of a protein selected from: the α, β or ζ chain of a T cell receptor, CD28, CD3ε, CD8, CD45 and CD4.

[0267] The extracellular domain of the CAR according to the first aspect of the invention may be connected to the transmembrane domain, for example, via a hinge region.

[0268] The intracellular domain of the CAR according to a first aspect of the invention may, for example, include an intracellular signal transduction domain, wherein: (a) the intracellular signal transduction domain includes one or more immune receptor tyrosine-based activation motifs (ITAMs); and / or (b) the intracellular signal transduction domain includes signal transduction domains of CD3ζ, Fc receptor γ, Fc receptor β, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, and CD66d.

[0269] The intracellular domain of the CAR according to a first aspect of the invention may, for example, include one or more co-stimulatory domains, such as: (a) wherein the one or more co-stimulatory domains include one or more functional signal transduction domains derived from proteins selected from CD28, 41BB, OX40, ICOS, CD27, and DAP10; (b) wherein the intracellular domain incorporates a co-stimulatory domain adjacent to the intracellular signal transduction domain; (c) wherein the intracellular domain includes two or more co-stimulatory domains, such as two tandem co-stimulatory domains; and / or (d) wherein the intracellular domain incorporates a single cytokine signal.

[0270] The CAR according to the first aspect of the invention may, for example, additionally include a leader sequence.

[0271] A second aspect of the invention provides a nucleic acid molecule or a combination of multiple different nucleic acid molecules, wherein the nucleic acid molecule comprises, or the combination of multiple different nucleic acid molecules comprises, one or more nucleic acid sequences, which individually or in combination encode a binding molecule of the first aspect of the invention, such as an antibody or CAR according to the first aspect of the invention.

[0272] A third aspect of the invention provides a vector comprising (or a combination of multiple different vectors comprising) a nucleic acid molecule according to a second aspect of the invention or a combination of multiple different nucleic acid molecules according to a second aspect of the invention. The vector or vectors of the third aspect of the invention may, for example, be selected from: retroviral vectors, plasmids, lentiviral vectors, and adenoviral vectors.

[0273] Optionally, the nucleic acid molecule or combination of multiple different nucleic acid molecules according to the second aspect of the invention and / or the vector according to the third aspect of the invention contain one or more additional sequences, wherein the additional sequences or each additional sequence encodes one or more optional markers.

[0274] A fourth aspect of the invention provides a cell or cell population (optionally homogeneous or heterogeneous) comprising a nucleic acid molecule or combination of multiple different nucleic acid molecules according to a second aspect of the invention and / or a vector according to a third aspect of the invention, optionally wherein the cell expresses one or more binding molecules (such as one or more antibodies and / or one or more CARs) according to a first aspect of the invention, the one or more binding molecules and / or CARs being encoded by a nucleic acid molecule or combination of multiple different nucleic acid molecules according to a second aspect of the invention or a vector according to a third aspect of the invention. The cell may optionally be selected from isolated cells, isolated cells, and in vitro cells.

[0275] A cell according to a fourth aspect of the invention may, for example, comprise: (a) a nucleic acid molecule or a combination of multiple different nucleic acid molecules according to a second aspect of the invention, wherein the encoded binding molecule is an antibody according to a first aspect of the invention, a functional fragment of the antibody, or an antibody having a functional fragment of the binding molecule comprising a fusion polypeptide sequence; and / or (b) a vector according to a third aspect of the invention, wherein the vector comprises a nucleic acid molecule or a combination of multiple different nucleic acid molecules as defined in option (a) of this paragraph.

[0276] The cell according to a fourth aspect of the invention may, for example, comprise: (a) a nucleic acid molecule or a combination of several different nucleic acid molecules according to a second aspect of the invention, wherein the encoded binding molecule is a CAR according to a first aspect of the invention; and / or (b) a vector according to a third aspect of the invention, wherein the vector comprises a nucleic acid molecule or a combination of several different nucleic acid molecules as defined in part (a) of this paragraph. Without limitation, the cell may, for example, be selected from: T cells, natural killer (NK) cells, and macrophages. Thus, the cell may optionally be a CAR-T cell, a CAR-NK cell, or a CAR macrophage, and optionally, when the cell is a CAR-T cell, the T cell may be selected, for example, from: CD8. + T cells, CD4+ T cells, effector T cells, helper T cells, memory T cells, cytotoxic T lymphocytes (CTLs), EBV-specific T cell receptors (TCRs), or γδ-T cell subtypes.

[0277] A fourth aspect of the invention also provides a cell comprising a binding molecule according to a first aspect of the invention and / or a nucleic acid encoding the binding molecule, optionally wherein the nucleic acid is a nucleic acid or a vector as defined by a second or third aspect of the invention, respectively. For example, the binding molecule may be an antibody according to a first aspect of the invention, a functional fragment of the antibody according to a first aspect of the invention, or an antibody having a functional fragment of the binding molecule comprising a fusion polypeptide sequence according to a first aspect of the invention, optionally wherein the antibody is a monoclonal antibody, and further, for example, wherein the cell is a mammalian cell recombinantly expressing a monoclonal antibody, such as a CHO cell.

[0278] A fourth aspect of the invention also provides a cell comprising a CAR according to a first aspect of the invention and / or a nucleic acid encoding the CAR, optionally wherein the nucleic acid is a nucleic acid or vector as defined by a second or third aspect of the invention, respectively. Without limitation, the cell may be selected, for example, from T cells, natural killer (NK) cells, and macrophages. Thus, the cell may be optionally a CAR-T cell, a CAR-NK cell, or a CAR macrophage, and optionally, when the cell is a CAR-T cell, the T cell may be selected, for example, from CD8. + T cells, CD4+ T cells, effector T cells, helper T cells, memory T cells, cytotoxic T lymphocytes (CTLs), EBV-specific T cell receptors (TCRs), or γδ-T cell subtypes.

[0279] A fifth aspect of the invention provides a method for generating cells, more particularly recombinant cells, or populations of such cells (optionally homogeneous or heterogeneous cell populations), comprising introducing a nucleic acid molecule or a combination of multiple different nucleic acid molecules according to a second aspect of the invention and / or a vector according to a third aspect of the invention into the cells.

[0280] The method may optionally further include the step of selecting cells according to a fifth aspect of the invention; for example, selecting said cells from a heterogeneous cell population, thereby producing an enriched and / or homogeneous cell population. This selection step may include selecting one or more optional markers present in a nucleic acid molecule or a combination of multiple different nucleic acid molecules according to a second aspect of the invention, and / or the presence of a carrier according to a third aspect of the invention.

[0281] A sixth aspect of the invention provides a method for generating a binding molecule according to a first aspect of the invention, such as an antibody or CAR according to a first aspect of the invention, the method comprising: expressing a nucleic acid molecule or a combination of multiple different nucleic acid molecules according to a second aspect of the invention in cells, more particularly, recombinant cells or populations of such cells (optionally, homogeneous or heterogeneous cell populations), and / or a vector according to a third aspect of the invention. Optionally, the method of the sixth aspect of the invention may further comprise the step of isolating the thus generated binding molecule from the cells; for example, wherein the binding molecule is an antibody according to a first aspect of the invention, a functional fragment of the antibody, or an antibody having a functional fragment of the binding molecule comprising a fusion polypeptide sequence according to a first aspect of the invention. The cells may optionally be selected from isolated cells, isolated cells, and in vitro cells.

[0282] A seventh aspect of the invention provides a separated binding molecule obtained by or through the method of the sixth aspect of the invention, optionally wherein the separated binding molecule is further formulated for administration to a subject.

[0283] An eighth aspect of the invention provides a conjugate comprising a portion that binds to a binding molecule as defined in the first aspect of the invention, or a portion that binds to a functional fragment of the binding molecule. Without limitation, the portion may be, for example, a therapeutic, preventative, diagnostic, prognostic, or therapeutically diagnostic portion. In some embodiments, the portion is a drug (e.g., wherein the conjugate is an antibody-drug conjugate (“ADC”)) and / or a radioactive portion (e.g., wherein the conjugate is suitable for radioimmunotherapy (“RIT”)).

[0284] A ninth aspect of the present invention provides a method for producing a conjugate according to an eighth aspect of the present invention, the method comprising the following steps:

[0285] (a) Providing a binding molecule or a functional fragment of the binding molecule as defined in the first aspect of the invention; and

[0286] (b) To bind part of the binding molecule or a functional fragment of the binding molecule.

[0287] The method of the ninth aspect of the invention may further include the step of separating the conjugate thus generated. The separated conjugate may therefore be present in a separated form, for example, in a composition in which at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or substantially 100% (in molar ratio) of the binding molecule or a functional fragment of the binding molecule is present in conjugate form. Alternatively or additionally, the separated form of the conjugate may be a composition in which at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or substantially 100% (in molar ratio) of the portion is present in conjugate form. The ninth aspect of the invention further provides a separated conjugate or a composition comprising the separated conjugate.

[0288] In certain preferred embodiments of the conjugate of the eighth aspect of the invention or the method of the ninth aspect of the invention, the binding molecule is an antibody according to the first aspect of the invention, a functional fragment of the antibody, or an antibody having a functional fragment of the binding molecule comprising a fusion polypeptide sequence according to the first aspect of the invention.

[0289] The tenth aspect of the invention provides a separated conjugate obtained by or through the method of the ninth aspect of the invention, optionally wherein the separated conjugate is further formulated for administration to a subject.

[0290] The eleventh aspect of the present invention provides a method for combating HCMV or HCMV-related diseases or conditions, the method comprising administering to a subject or ex vivo cellular material or in vitro cellular material any one or more of the following agents:

[0291] i. The binding molecule according to the first aspect of the invention,

[0292] ii. The functional fragment of the binding molecule according to the first aspect of the invention,

[0293] iii. The separated bound molecules according to the seventh aspect of the invention,

[0294] iv. According to the second aspect of the invention, a nucleic acid molecule or a combination of multiple different nucleic acid molecules,

[0295] v. The carrier according to the third aspect of the invention,

[0296] vi. Cells according to the fourth aspect of the invention,

[0297] vii. The conjugate according to the eighth aspect of the invention, and

[0298] viii. The separated conjugate according to the tenth aspect of the invention.

[0299] In other words, the eleventh aspect of the present invention provides one or more of the reagents for combating HCMV-related diseases or conditions in subjects or in vitro or ex vivo cellular material.

[0300] Furthermore, the eleventh aspect of the present invention provides the use of one or more of the reagents in the manufacture of a medicament for combating HCMV-related diseases or conditions in a subject or in vitro or ex vivo cellular material.

[0301] According to the eleventh aspect of the invention, the HCMV-related disease or condition to be combated may be HCMV infection or associated with HCMV infection. In one embodiment, HCMV infection may be a monoclonal infection. Optionally, in an alternative embodiment, HCMV infection comprises multi-strain HCMV infection, wherein multi-strain HCMV infection comprises infection with more than one different HCMV viral strain, for example, two or more HCMV viral strains encoding different US28 protein sequences. The two or more viral strains may encode the US28 protein, which differs in one or more extracellular regions, such as the N-terminal (ECD1) region, the first extracellular loop (ECD2) region, the second extracellular loop (ECD3) region, and / or the third extracellular loop (ECD4) region.

[0302] In one embodiment of interest, two or more HCMV strains in a multi-strain HCMV infection each encode a US28 protein that differs from one another at least at one or more positions in the N-terminal (ECD1) region; for example, they may differ at positions 1, 2, 3, 4, 5, 6, 8, 9, 10 or more amino acids in the N-terminal (ECD1) region. For example, the two or more HCMV strains in a multi-strain HCMV infection may exhibit interstrain sequence variations at one or more positions in the region of ECD1 from position 1 to 25 (such as any one or more of positions 8, 15, 18, 19, 24, 25, including but not limited to the sequence variations listed in Table 3 of this application), for example, wherein the multi-strain infection comprises at least two, three, four, five, six, seven, eight, nine or ten different strains selected from the group consisting of: DB, Toledo, Towne, VR1814, TB40 / E, Merlin, AD169, VHL / E, Davis, and BL.

[0303] Alternatively, in another embodiment of interest, two or more HCMV virus strains in a multi-strain HCMV infection each encode a US28 protein that is distinct from each other at one or more locations in the second extracellular (ECD3) region. For example, one or more HCMV virus strains in a multi-strain HCMV infection may encode a US28 protein that encodes a 4N variant of ECD3, and one or more other HCMV virus strains in a multi-strain HCMV infection may encode a US28 protein that encodes a 4D variant of ECD3.

[0304] According to the eleventh aspect of the invention, the HCMV-related disease or condition to be combated may be a latent HCMV infection (e.g., a single or multiple latent HCMV infection) or associated with a latent HCMV infection (optionally, a multiple latent HCMV infection).

[0305] According to the eleventh aspect of the invention, the HCMV-related disease or condition to be combated may be a lysed HCMV infection (optionally a multi-strain lysed HCMV infection) or associated with a lysed HCMV infection (optionally a multi-strain lysed HCMV infection).

[0306] According to the eleventh aspect of the present invention, the disease or condition associated with HCMV to be combated may be a congenital HCMV infection (e.g., monoclonal or polyclonal infection), such as latent congenital monoclonal or polyclonal HCMV infection or lytic congenital monoclonal or polyclonal HCMV infection.

[0307] According to the eleventh aspect of the invention, the HCMV-related disease or condition to be combated may be cancer, such as HCMV-infected cancer (optionally monoculture or polyculture HCMV-infected cancer), or latent HCMV-infected cancer (optionally monoculture or polyculture latent HCMV-infected cancer).

[0308] According to the eleventh aspect of the invention, the HCMV-associated disease or condition to be combated can be epithelial carcinoma; optionally, the epithelial carcinoma is breast cancer; for example, the breast cancer is triple-negative breast cancer (TNBC) or HER2-positive breast cancer. HER2-positive breast cancer can be, for example, HER2+HR- (where HR- refers to hormone receptor-negative, specifically estrogen receptor-negative (ER-) and progesterone receptor-negative (PR-) status); or HER2+ER+PR-; or HER2+ER-PR+; or as a triple-positive form of breast cancer, “TPBC”, of HER2+ER+PR+. It should be noted that HER2+HR- is a specific invasive form of breast cancer and is of great interest for the diagnosis and treatment according to the invention. This form of epithelial carcinoma can optionally be HCMV-infected epithelial carcinoma of monoclonal or polyclonal forms, such as epithelial carcinoma of latent HCMV infection (optionally monoclonal or polyclonal latent HCMV-infected cancer).

[0309] According to the eleventh aspect of the invention, the HCMV-related disease or condition to be combated may be a metastatic and / or invasive form of cancer. The metastatic and / or invasive form of cancer may optionally be a metastatic and / or invasive cancer of monoclonal or polyclonal HCMV infection, such as a metastatic and / or invasive cancer of latent HCMV infection (optionally monoclonal or polyclonal latent HCMV infection cancer).

[0310] In some embodiments, the HCMV-related disease or condition to be combated according to the eleventh aspect of the invention may be glioblastoma. In other embodiments described herein, the disease or condition is not glioblastoma and / or the subject to be treated does not have and / or has not been diagnosed with glioblastoma.

[0311] In some embodiments, the subject to be treated (or ex vivo or in vitro cellular material) according to the eleventh aspect of the present invention may have and / or have been diagnosed with or have HCMV-infected cancer cells, such as latent HCMV-infected cancer cells.

[0312] In some embodiments, the subject to be treated according to the eleventh aspect of the invention may be, or is intended to be, a recipient of cellular material (such as cell product donation). The cell product may, for example, comprise, consist substantially of, or be composed of ex vivo living cellular material selected from: one or more types of ex vivo cells; one or more types of ex vivo cell cultures; one or more types of ex vivo tissues; one or more types of ex vivo tissue cultures; one or more types of ex vivo organs; and / or one or more types of ex vivo organ cultures. Optionally, the cell product may be derived directly or indirectly from a living donor.

[0313] In some embodiments, the subject to be treated according to the eleventh aspect of the invention may be, or is intended to be, a donor of cellular material, such as a donor of cell products. The cell products may comprise, substantially comprise, or consist of any one or more cells, tissues, or organs derived from the donor.

[0314] In some embodiments, the ex vivo or in vitro cellular material to be processed according to the eleventh aspect of the invention may be an ex vivo cell product. The ex vivo cell product may, for example, comprise, consist substantially of, or consist of ex vivo living cell material selected from: one or more types of ex vivo cells; one or more types of ex vivo cell cultures; one or more types of ex vivo tissues; one or more types of ex vivo tissue cultures; one or more types of ex vivo organs; and / or one or more types of ex vivo organ cultures. Optionally, the cell product may be derived directly or indirectly from a living donor.

[0315] In one embodiment, the one or more reagents to be used according to the eleventh aspect of the invention may, for example, be selected from (or include one or more reagents selected from the following):

[0316] i. Therapeutic antibodies as defined by the first aspect of the present invention,

[0317] ii. The functional fragment of the therapeutic antibody as defined by the first aspect of the invention,

[0318] iii. A therapeutic antibody comprising a fusion polypeptide sequence as defined in the first aspect of the invention; and

[0319] iv. A functional fragment of the therapeutic antibody comprising a fusion polypeptide sequence as defined by the first aspect of the invention.

[0320] For example, one or more reagents used according to the eleventh aspect of the invention may be (or include one or more reagents selected from the following) bispecific antibodies as defined by the first aspect of the invention. Without limitation, this may be a bispecific immune cell conjugate antibody. An exemplary embodiment is a bispecific T-cell conjugate (BiTE) antibody, optionally wherein, in addition to containing the region of the binding molecule of the first aspect of the invention having binding specificity to the ECD1 region of the US28 protein, the BiTE antibody further comprises a T-cell adaptor domain, such as a CD3 binding domain.

[0321] In another embodiment, one or more reagents used according to the eleventh aspect of the invention may be (or include one or more reagents selected from the following) a trispecific antibody as defined in the first aspect of the invention. An exemplary embodiment is a trispecific antibody wherein, in addition to containing the region of the binding molecule of the first aspect of the invention (which has binding specificity for a first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO:177 within the ECD1 region of the US28 protein), the antibody further comprises a T-cell binding domain (such as a CD3 binding domain) and an ECD3 binding domain, as described herein with respect to the ECD3 binding molecule.

[0322] In another embodiment, one or more reagents to be used according to the eleventh aspect of the invention may be, for example, (or include) conjugates according to the eighth aspect and / or the tenth aspect of the invention, such as conjugates as antibody-drug conjugates (“ADC”), or conjugates containing a radioactive portion, such as conjugates suitable for radioimmunotherapy (“RIT”).

[0323] In some embodiments, the ADC comprises an antimitotic payload (e.g., a tubulin inhibitor, such as maytansine). In some embodiments, the ADC comprises a payload that acts as a DNA disruptor (e.g., a topoisomerase inhibitor, such as SN38). In some embodiments, the ADC comprises a payload that acts as a transcription inhibitor (e.g., an RNA Pol II inhibitor, such as muscarine). In some embodiments, the ADC comprises a payload selected from the group consisting of: maytansine compounds (e.g., maytansine, DM1, DM3, and DM4); aurestatin payloads (e.g., dolalastatin 10, MMAE, MMAF, and PF-06380101); tubulolysins (e.g., tubulolysin A, tubulolysin B, tubulolysin C, tubulolysin G, and tubulolysin I); eribulin; and paclitaxel derivatives (e.g., docetaxel and paclitaxel). DNA damaging agents (such as spirosporins; anthraxycin-based dimers, including pyrrolobenzodiazepine (PBD) dimer, indobenzobenzodiazepine (IGN) dimer, and pyrrolobenzodiazepine (PDD); docalamycin-based payloads; anthracycline antibiotics doxorubicin, ladelrubicin, and PNU-159682; and camptothecin-based molecules, including camptothecin, ethatec, and SN-38 (7-ethyl-10-hydroxycamptothecin)).

[0324] In another embodiment, the one or more reagents to be used according to the eleventh aspect of the invention may, for example, be (or include) cells (or cell populations, such as homogeneous cell populations), wherein the cells or cell populations contain a CAR according to the fourth aspect of the invention. The cells or cell populations are typically isolated and / or formulated for administration to a subject. The cells or cell populations may, for example, contain a CAR according to the first aspect of the invention and / or nucleic acid encoding the CAR, optionally wherein the nucleic acid is a nucleic acid or vector as defined by the second or third aspect of the invention, respectively. The cells or cell populations may, for example, be cells according to the fourth aspect of the invention. Without limitation, the one or more cells may, for example, be selected from: T cells, natural killer (NK) cells, and macrophages. Thus, the cells may optionally be CAR-T cells, CAR-NK cells, or CAR macrophages, and optionally, when the cells are CAR-T cells, the T cells may be selected, for example, from: CD8 cells. + T cells, CD4+ T cells, effector T cells, helper T cells, memory T cells, cytotoxic T lymphocytes (CTLs), EBV-specific T cell receptors (TCRs), or γδ-T cell subtypes.

[0325] Optionally, according to the eleventh aspect of the invention, another substance, such as another therapeutic, preventive, diagnostic, prognostic or therapeutic diagnostic substance (such as the ECD3 binding molecule described herein), may be administered to the subject, and optionally, this other substance may be administered separately, sequentially or simultaneously with each of one or more reagents.

[0326] Therefore, the eleventh aspect of the present invention also provides a method for treating a subject in need, which is performed by administering a therapeutic, preventive, diagnostic, prognostic, or therapeutic diagnostic substance to the subject, wherein the subject is also treated separately, sequentially (e.g., before or after), or simultaneously with any one of one or more reagents.

[0327] In the simultaneous treatment implementation scheme, one or more agents subsequently used according to the eleventh aspect of the invention may be formulated and / or administered in combination with therapeutic, preventive, diagnostic, prognostic, or therapeutic diagnostic substances; or may be formulated separately but administered simultaneously as two separate formulations.

[0328] For example, in one implementation, the disease or condition to be treated may be a form of cancer (such as one or more forms of cancer as disclosed above), and other therapeutic, preventive, diagnostic, prognostic, or therapeutic diagnostic substances may be targeted at the cancer.

[0329] A twelfth aspect of the present invention provides a reagent for a pharmaceutical preparation, wherein the reagent is selected from:

[0330] i. The binding molecule according to the first aspect of the invention,

[0331] ii. The functional fragment of the binding molecule as defined in the first aspect of the invention,

[0332] iii. The separated bound molecules according to the seventh aspect of the invention,

[0333] iv. According to the second aspect of the invention, a nucleic acid molecule or a combination of multiple different nucleic acid molecules,

[0334] v. The carrier according to the third aspect of the invention,

[0335] vi. Cells according to the fourth aspect of the invention,

[0336] vii. The conjugate according to the eighth aspect of the invention, and

[0337] viii. The separated conjugate according to the tenth aspect of the invention.

[0338] With respect to the eleventh aspect of the present invention, the reagent may be, for example, a reagent as defined above.

[0339] The thirteenth aspect of the present invention provides a peptide or polypeptide comprising, substantially comprising, or comprising the sequence TDVLNQSKPVTL (SEQ ID NO: 177), or comprising, or comprising an immunogenic fragment of SEQ ID NO: 177. The peptide or polypeptide is not the US28 protein. Preferably, the peptide or polypeptide contains only the US28-derived sequence of SEQ ID NO: 177 or the sequence of an immunogenic fragment of SEQ ID NO: 177, and / or the peptide or polypeptide does not contain any sequence of 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 consecutive amino acids that is identical to a sequence of consecutive amino acids of the same length found in the US28 protein, except for the region containing the sequence of SEQ ID NO: 177.

[0340] A fourteenth aspect of the present invention provides a peptide or polypeptide comprising, substantially composed of, or composed of, the sequences TKKNNQCMTDYDYLEVS (SEQ ID NO: 6) and / or TKKDNQCMTDYDYLEVS (SEQ ID NO: 7), or comprising the immunogenic fragments of SEQ ID NO: 6 and / or 7. The peptide or polypeptide is not the US28 protein. Optionally, the peptide or polypeptide further comprises the sequence of SEQ ID NO: 177 or the sequence of the immunogenic fragment of SEQ ID NO: 177. Preferably, only the US28-derived sequence in the peptide or polypeptide is the sequence of SEQ ID NO: 6 and / or 7 or the sequence of the immunogenic fragment of SEQ ID NO: 6 and / or 7, and optionally also the sequence of SEQ ID NO: 177 or the sequence of the immunogenic fragment of SEQ ID NO: 177.

[0341] According to the thirteenth or fourteenth aspect of the invention, an immunogenic fragment comprising the reference sequence SEQ ID NO:177, a peptide or polypeptide substantially composed of or composed of the reference sequence comprises less than the full sequence of the reference sequence, and preferably comprises at least 3, 4, 5, 6, 7, 8, 9, 10 or 11 consecutive amino acids of the reference sequence SEQ ID NO:177.

[0342] According to the fourteenth aspect of the invention, the immunogenic fragments of the reference sequence SEQ ID NO:6 and / or 7 each contain less than the full sequence of the reference sequence, and preferably contain at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 consecutive amino acids of the reference sequence.

[0343] In one embodiment, the immunogenic fragment of the peptide or polypeptide of the thirteenth and / or fourteenth aspects of the present invention comprises, is substantially composed of, or is composed of the following: a sequence common to SEQ ID NO:6 and SEQ ID NO:7 and present within the said sequence.

[0344] The thirteenth and fourteenth aspects of the present invention also provide peptides or polypeptides comprising, consisting of, or substantially consisting of the following:

[0345] (i) An immunogenic fragment or variant of the reference sequence TDVLNQSKPVTL (SEQ ID NO: 177), which comprises a sequence of epitopes in SEQ ID NO: 177 that bind to any of the antibodies 4H3C3, 7B1F3, and / or 2F5B11 as described herein (which also includes scFv, which comprises V of 4H3C3, 7B1F3, and / or 2F5B11 as defined in SEQ ID No: 187, 211, and 233, respectively). H sequence V H The polypeptide sequence, and V having 4H3C3, 7B1F3 and / or 2F5B11 as defined as in SEQ ID Nos: 189, 213 and 235 respectively. L sequence V L (Polypeptide sequence); preferably, the peptide or polypeptide is specifically bound by 4H3C3, 7B1F3 and / or 2F5B11.

[0346] (ii) Immunogenic fragments or variants selected from reference sequences of TKKNNQCMTDYDYLEVS (SEQ ID NO:6) and / or TKKDNQCMTDYD YLEVS (SEQ ID NO:7), wherein the immunogenic fragment or variant comprises a sequence of an epitope within ECD3 of US28 that binds to any of the antibodies 1D3, 1C10, 1A10, 1G9 and / or 1E8 as described herein (including scFv, which comprises V of 1D3, 1C10, 1A10, 1G9 and / or 1E8 as defined in SEQ ID NO:12, 104, 122, 68 and 88, respectively). H sequence V H The polypeptide sequence, and V such as those comprising 1D3, 1C10, 1A10, 1G9 and / or 1E8 as defined as SEQ ID No: 18, 108, 126, 72 and 92 respectively. L sequence V L (Polypeptide sequence). Preferably, the peptide or polypeptide is specifically bound by 1D3, 1C10, 1A10, 1G9 and / or 1E8.

[0347] The fifteenth aspect of the invention provides a combination of at least two (e.g., three) different peptides and / or polypeptides, comprising a first peptide or polypeptide and a second peptide or polypeptide (and optionally at least one third peptide or polypeptide), wherein:

[0348] (a) The first peptide or polypeptide comprises or is substantially composed of the sequence TDVLNQSKPVTL (SEQ ID NO: 177) or an immunogenic fragment thereof (such as the immunogenic fragment defined in the thirteenth aspect of the invention); and

[0349] (b) The second peptide or polypeptide comprises or is substantially composed of the sequence TKKNNQCMTDYDYLEVS (SEQ ID NO:6) or an immunogenic fragment thereof (such as the immunogenic fragment defined by the fourteenth aspect of the invention), provided that the immunogenic fragment contains at least the 4N amino acids of SEQ ID NO:6; or

[0350] (c) The second peptide or polypeptide comprises or is substantially composed of the sequence TKKDNQCMTDYDYLEVS (SEQ ID NO:7) or an immunogenic fragment thereof (such as the immunogenic fragment defined by the fourteenth aspect of the invention), provided that the immunogenic fragment contains at least the 4D amino acids of SEQ ID NO:7; and

[0351] Optionally, the combination may contain a third peptide, and if the second peptide or peptide is defined as in option (b), the third peptide or peptide corresponds to option (c), or if the second peptide or peptide is defined as in option (c), the third peptide or peptide corresponds to option (b).

[0352] The sixteenth aspect of the present invention provides a fusion protein comprising, substantially comprising, or comprising: a first amino acid sequence fused directly or via one or more linker amino acid sequences to a second amino acid sequence, wherein the first amino acid sequence is a peptide or polypeptide sequence as defined in the thirteenth or fourteenth aspect of the present invention; and the second amino acid sequence is a fusion chaperone.

[0353] Optionally, the fusion partner is a carrier protein, such as a carrier protein selected to provide a fusion protein suitable for immunization against the first amino acid sequence and for generating antibodies. For example, the carrier protein may be selected from: keyhole cyanin (KLH), human serum albumin (HSA), bovine serum albumin (BSA), ovalbumin (OVA), tetanus toxoid (TT), diphtheria toxoid (DT), cross-reactive material (CRM) of genetically modified diphtheria toxoid, meningococcal outer membrane protein complex (OMPC), and Haemophilus influenzae protein D (HiD).

[0354] The seventeenth aspect of the invention provides a combination of at least two (e.g., three) different fusion proteins, said fusion proteins comprising a first fusion protein and a second fusion protein (and optionally, at least a third different fusion protein), wherein:

[0355] (a) The first fusion protein according to the sixteenth aspect of the invention comprises a first amino acid sequence as the first fusion protein, the sequence comprising, substantially comprising, or comprising of the following: the sequence TDVLNQSKPVTL (SEQ ID NO: 177) or an immunogenic fragment or variant thereof; and

[0356] (b) The second fusion protein according to the sixteenth aspect of the invention comprises a first amino acid sequence as the first fusion protein, the sequence comprising, substantially consisting of, or consisting of: sequence TKKNNQCMTDYDYLEVS (SEQ ID NO:6) or an immunogenic fragment or variant thereof, provided that said immunogenic fragment or variant comprises the 4N amino acid of SEQ ID NO:6; or

[0357] (c) The second fusion protein according to the sixteenth aspect of the invention comprises a first amino acid sequence as the second fusion protein, the sequence comprising, substantially comprising, or comprising of: the sequence TKKDNQCMTDYDYLEVS (SEQ ID NO:7) or an immunogenic fragment or variant thereof, provided that the immunogenic fragment or variant comprises the 4D amino acid of SEQ ID NO:7; and

[0358] Optionally, the combination may include a third different fusion protein, and if the second fusion protein is as defined in option (b), then the third fusion protein corresponds to option (c), or if the second fusion protein is as defined in option (c), then the third fusion protein corresponds to option (b).

[0359] The eighteenth aspect of the invention provides a conjugate comprising a portion that binds to a peptide or polypeptide as defined in any one or both of the thirteenth and fourteenth aspects of the invention, or a portion that binds to a fusion protein as defined in the sixteenth aspect of the invention.

[0360] A portion of the conjugate may directly bind to a peptide or polypeptide as defined in any one or both of the thirteenth and fourteenth aspects of the invention, or to a fusion protein as defined in the sixteenth aspect of the invention. Alternatively, a portion of the conjugate may indirectly bind to a peptide or polypeptide as defined in any one or both of the thirteenth and fourteenth aspects of the invention, or to a fusion protein as defined in the sixteenth aspect of the invention, as via a linker.

[0361] Optionally, this portion may be a carrier, such as a carrier protein, selected from the following: keyhole hemocyanin (KLH), human serum albumin (HSA), bovine serum albumin (BSA), ovalbumin (OVA), tetanus toxoid (TT), diphtheria toxoid (DT), cross-reactive material (CRM) of genetically modified diphtheria toxoid, meningococcal outer membrane protein complex (OMPC), and Haemophilus influenzae protein D (HiD).

[0362] The nineteenth aspect of the invention provides a combination of at least two (e.g., three) different conjugates, wherein the combination comprises:

[0363] (a) A first conjugate according to the eighteenth aspect of the invention, wherein the first conjugate comprises, is substantially composed of, or is composed of a portion conjugated to a peptide or polypeptide, wherein the peptide or polypeptide comprises, is substantially composed of, or is composed of the sequence TDVLNQSKPVTL (SEQ ID NO: 177) or an immunogenic fragment or variant thereof; and

[0364] (b) A second conjugate according to the eighteenth aspect of the invention, wherein the second conjugate comprises, is substantially composed of, or is composed of a portion conjugated to a peptide or polypeptide, wherein the peptide or polypeptide comprises, is substantially composed of, or is composed of the sequence TKKNNQCMTDYDYLEVS (SEQ ID NO:6) or an immunogenic fragment or variant thereof, provided that the immunogenic fragment or variant comprises the 4N amino acid of SEQ ID NO:6; or

[0365] (c) A second conjugate according to the eighteenth aspect of the invention, wherein the second conjugate comprises, is substantially composed of, or is composed of a portion conjugated to a peptide or polypeptide, wherein the peptide or polypeptide comprises, is substantially composed of, or is composed of the sequence TKKDNQCMTDYDYLEVS (SEQ ID NO:7) or an immunogenic fragment or variant thereof, provided that the immunogenic fragment or variant comprises the 4D amino acid of SEQ ID NO:7; and

[0366] Optionally, the combination may include a third different conjugate, and if the second conjugate is as defined in option (b), the third conjugate corresponds to option (c), or if the second conjugate is as defined in option (c), the third conjugate corresponds to option (b).

[0367] The twentieth aspect of the present invention provides a method for producing a conjugate according to the nineteenth aspect of the present invention, the method comprising the following steps:

[0368] (a) Providing a peptide or polypeptide as defined in any one or both of the thirteenth and / or fourteenth aspects of the present invention, a combination thereof as defined in the fifteenth aspect of the present invention, or a fusion protein as defined in the sixteenth aspect of the present invention; and

[0369] (b) Combine part with it.

[0370] The twenty-first aspect of the present invention provides a method for producing combinations of at least two (e.g., three) different conjugates as defined in the nineteenth aspect of the present invention.

[0371] In one embodiment, the method includes the following steps: (a) providing or producing a first conjugate as defined by the method according to the twentieth aspect of the invention; (b) providing or producing a second conjugate as defined by the eighteenth aspect of the invention (wherein the first conjugate is different from the second conjugate) by the method according to the twentieth aspect of the invention; (c) optionally providing or producing a third conjugate as defined by the eighteenth aspect of the invention (wherein the first conjugate, the second conjugate, and the third conjugate are different) by the method according to the twentieth aspect of the invention; and (d) combining the first conjugate, the second conjugate, and optionally the third conjugate, thereby forming a combination according to the nineteenth aspect of the invention.

[0372] In another embodiment, the method includes the steps of: (a) providing a combination of at least two (e.g., three) different peptides and / or polypeptides according to the fifteenth aspect of the invention, or a combination of at least two (e.g., three) different fusion proteins according to the seventeenth aspect of the invention; and (b) conjugating a portion to a combination of at least two (e.g., three) different peptides and / or polypeptides according to the fifteenth aspect of the invention, or conjugating a portion to a combination of at least two (e.g., three) different fusion proteins according to the seventeenth aspect of the invention, thereby forming a combination according to the nineteenth aspect of the invention.

[0373] The method of the twentieth or twenty-first aspect of the invention may optionally include the step of separating the conjugates or combinations of conjugates thus generated.

[0374] The twenty-second aspect of the invention provides isolated conjugates or combinations thereof obtained or obtainable by any of the methods of the twenty or twenty-first aspect of the invention, optionally wherein the isolated conjugates are further formulated for administration to a subject.

[0375] The twenty-third aspect of the invention provides a nucleic acid molecule or a combination of multiple different nucleic acid molecules, wherein the nucleic acid molecule comprises, or the combination of multiple different nucleic acid molecules comprises, one or more nucleic acid sequences individually or in combination, encoding, one or more peptides and / or polypeptides, combinations of at least two (e.g., three) different peptides and / or polypeptides according to the thirteenth and / or fourteenth aspects of the invention, fusion proteins according to the fifteenth aspect of the invention, and combinations of at least two (e.g., three) different fusion proteins according to the sixteenth aspect of the invention and / or combinations of at least two (e.g., three) different fusion proteins according to the seventeenth aspect of the invention.

[0376] The nucleic acid molecules or individual nucleic acid molecules according to the twenty-third aspect of the present invention may, for example, be independently selected from DNA or RNA molecules. The nucleic acid molecules or individual nucleic acid molecules according to the twenty-third aspect of the present invention may, for example, be independently selected from single-stranded or double-stranded nucleic acid molecules.

[0377] A twenty-fourth aspect of the invention provides a vector comprising a nucleic acid molecule or a combination of multiple different nucleic acid molecules according to a twenty-third aspect of the invention. Any vector may be used, although (but not limited to) the vector optionally selected from: retroviral vectors, plasmids, lentiviral vectors, and adenovirus vectors.

[0378] A twenty-fifth aspect of the invention provides a cell comprising a nucleic acid molecule or a combination of multiple different nucleic acid molecules according to a twenty-third aspect of the invention, or a vector according to a twenty-fourth aspect of the invention. Optionally, the cell expresses one or more peptides or polypeptides selected from any one or both of the thirteenth and / or fourteenth aspects of the invention, a combination of at least two (e.g., three) different peptides and / or polypeptides according to the fifteenth aspect of the invention, a fusion protein according to the sixteenth aspect of the invention, and / or a combination of at least two (e.g., three) different fusion proteins according to the seventeenth aspect of the invention.

[0379] The twenty-sixth aspect of the invention provides a cell exposed to and / or containing one or more peptides or polypeptides selected from any one or both of the thirteenth and / or fourteenth aspects of the invention, combinations of at least two (e.g., three) different peptides and / or polypeptides according to the fifteenth aspect of the invention, fusion proteins according to the sixteenth aspect of the invention and / or combinations of at least two (e.g., three) different fusion proteins according to the seventeenth aspect of the invention, conjugates according to the eighteenth aspect of the invention, combinations of at least two (e.g., three) different conjugates according to the nineteenth aspect of the invention, nucleic acid molecules or combinations of multiple different nucleic acid molecules according to the twenty-third aspect of the invention, and / or carriers according to the twenty-fourth aspect of the invention.

[0380] The twenty-seventh aspect of the invention provides a method for isolating and / or enriching cells containing a T-cell receptor (TCR) that is specific to a first epitope (and optionally a second epitope in ECD3) of a polypeptide comprising the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) in ECD1 of US28 (e.g., naturally occurring T cells, or recombinant cells expressing a CAR according to the first aspect of the invention, such as CAR T cells, CAR NK cells, and / or CAR macrophages), wherein the method comprises the step of isolating and / or enriching cells having binding specificity to the sequence of SEQ ID No: 177 or its immunogenic fragment, and optionally also having binding specificity to one or both of the sequences of SEQ ID NO: 6 and / or 7 or their immunogenic fragments, using one or more reagents.

[0381] One or more of the reagents are or selected from the group consisting of: peptides or polypeptides of any one or both of the thirteenth and / or fourteenth aspects of the invention, combinations of at least two (e.g., three) different peptides and / or polypeptides according to the fifteenth aspect of the invention, fusion proteins according to the sixteenth aspect of the invention and / or combinations of at least two (e.g., three) different fusion proteins according to the seventeenth aspect of the invention, conjugates according to the eighteenth aspect of the invention and / or combinations of at least two (e.g., three) different conjugates according to the nineteenth aspect of the invention.

[0382] In one embodiment of the method of the twenty-seventh aspect of the present invention, the sequence may be formulated as an MHC tetramer, for example for antigen-specific CD8. + Class I MHC tetramers for T cell detection, and CD4 for antigen-specific detection + T cell detection uses class II MHC tetramers or fluorophore-labeled tetramers for flow cytometry or fluorescence microscopy. Optionally, T cells can be selected from: CD8 + T cells, CD4+ T cells, effector T cells, helper T cells, memory T cells, cytotoxic T lymphocytes (CTLs), EBV-specific T cell receptors (TCRs), or γδ-T cell subtypes.

[0383] The twenty-eighth aspect of the present invention provides an MHC tetramer comprising a peptide or polypeptide of any one or both of the thirteenth and / or fourteenth aspects of the present invention, or a combination of at least two (e.g., three) different peptides and / or polypeptides according to the fifteenth aspect of the present invention, optionally wherein the peptide or each peptide comprises or corresponds to an immunogenic fragment of SEQ ID NO:177, SEQ ID NO:6 and / or SEQ ID NO:7, or any one or both, for example wherein the MHC tetramer is for antigen-specific CD8 +Class I MHC tetramers for T cell detection, and CD4 for antigen-specific detection + Type II MHC tetramers for T cell detection, and fluorophore-labeled tetramers for flow cytometry or fluorescence microscopy. MHC tetramers can be further used to isolate and / or enrich cells containing a T cell receptor (TCR) specific to the first epitope within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO:177) of ECD1 and / or ECD3 of US28, such as T cells selected from the following groups: CD8 + T cells, CD4 + T cells, effector T cells, helper T cells, memory T cells, cytotoxic T lymphocytes (CTLs), EBV-specific T cell receptors (TCRs) or γδ-T cell subtypes and / or recombinant cells expressing CAR according to the first aspect of the invention, such as CAR T cells, CAR NK cells and / or CAR macrophages.

[0384] A twenty-ninth aspect of the present invention provides a vaccine composition suitable for vaccination against, reducing the risk of, preventing or combating diseases or conditions associated with human cytomegalovirus (HCMV). The vaccine may be an active or passive vaccine. An active vaccine according to the twenty-ninth aspect of the present invention can trigger an immune response against a first epitope within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) located within ECD1 of the US28 protein of HCMV. Optionally, the active vaccine also triggers and / or provides an immune response against a second epitope located within ECD3 of the US28 protein of HCMV. A passive vaccine according to the twenty-ninth aspect of the present invention can be a composition providing an immune response against a first epitope located within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) located within ECD1 of the US28 protein of HCMV. Optionally, the passive vaccine also provides an immune response against a second epitope located within ECD3 of the US28 protein of HCMV. As discussed above in the context of other aspects of the invention, ECD1, SEQ ID NO:177 and ECD3 of the US28 protein comprise, are substantially composed of or consist of the amino acid sequences present in, or are composed of in, the US28 protein encoded by the HCMV virus strain at positions corresponding to positions 1 to 37, 26 to 37 and 167 to 183 of the US28 protein encoded by the human cytomegalovirus (HCMV) DB virus strain as described in SEQ ID NO:5.

[0385] In some embodiments, the vaccine composition of the twenty-ninth aspect of the present invention is designed to trigger and / or provide an immune response for:

[0386] (a) One or more epitopes in a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO:177) that is entirely present in ECD1 of the US28 protein of HCMV, and / or one or more epitopes that are entirely present in ECD3 of the US28 protein of HCMV.

[0387] (b) One or more linear epitopes within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO:177) within ECD1 of the US28 protein of HCMV, and / or one or more linear epitopes present in ECD3 of the US28 protein of HCMV.

[0388] (c) One or more epitopes within ECD3 of the US28 protein of HCMV, which are one or more epitopes present in the same form in both the 4D variant and the 4N variant of HCMV, wherein the 4D variant of HCMV encodes the US28 protein of ECD3 containing the sequence TKKDNQCMTDYDYLEVS (SEQ ID NO:7), and wherein the 4N variant of HCMV encodes the US28 protein of ECD3 containing the sequence TKKNNQCMTDYDYLEVS (SEQ ID NO:6);

[0389] (d) Where the immune response triggered or provided by the vaccine is unknown to multiple HCMV virus strains exhibiting interstrain sequence variations (such as any one or more of positions 8, 15, 18, 19, 24, 25, including but not limited to the sequence variations listed in Table 3 of this application) at one or more locations in the regions 1 to 25 of ECD1, for example, wherein said multiple virus strains are at least two, three, four, five, six, seven, eight, nine, or ten different virus strains selected from the group consisting of: DB, Toledo, Towne, VR1814, TB40 / E, Merlin, AD169, VHL / E, Davis, and BL; and / or

[0390] (e) wherein the immune response triggered or provided by the vaccine is an HCMV strain for which the 4D variant and 4N variant are unknown, and triggers and / or provides an immune response against one or more of the 4D variant HCMV strains selected from Towne, VR1814, TB40 / E, Merlin, JP, Ad169, VHL / E, BL, AF1 and DAVIS, and also against one or more of the 4N variant HCMV strains selected from Toledo, TR and DB.

[0391] The vaccine composition may be a passive vaccine, and / or optionally include: (a) one or more binding molecules according to a first aspect of the invention, (b) a functional fragment of the one or more binding molecules as defined by a first aspect of the invention, (c) one or more isolated binding molecules according to a seventh aspect of the invention, (d) one or more nucleic acid molecules or a combination of multiple different nucleic acid molecules according to a second aspect of the invention, (e) one or more carriers according to a third aspect of the invention, (f) one or more cells according to a fourth aspect of the invention, (g) one or more conjugates according to an eighth aspect of the invention, and / or (h) one or more isolated conjugates according to a tenth aspect of the invention.

[0392] Alternatively, the vaccine composition may be an active vaccine, and / or optionally include:

[0393] (a) One or more peptides or polypeptides of any one or both of the thirteenth and / or fourteenth aspects of the present invention, a combination of at least two (e.g., three) different peptides and / or polypeptides of the fifteenth aspect of the present invention, a fusion protein of the sixteenth aspect of the present invention, a combination of at least two (e.g., three) different fusion proteins of the seventeenth aspect of the present invention, a conjugate of the eighteenth aspect of the present invention, and / or a combination of at least two (e.g., three) different conjugates of the nineteenth aspect of the present invention.

[0394] (b) One or more nucleic acid molecules or combinations of multiple different nucleic acid molecules according to the twenty-third aspect of the present invention and / or a vector according to the twenty-fourth aspect of the present invention; and / or

[0395] (c) Cells, such as antigen-presenting cells (e.g., dendritic cells), or a homogeneous or heterogeneous population of said cells, wherein said cells or each of said cells has one or more of the following: peptides or polypeptides of any one or both of the thirteenth and / or fourteenth aspects of the invention, combinations of at least two (e.g., three) different peptides and / or polypeptides according to the fifteenth aspect of the invention, fusion proteins according to the sixteenth aspect of the invention, combinations of at least two (e.g., three) different fusion proteins according to the seventeenth aspect of the invention, conjugates according to the eighteenth aspect of the invention, combinations of at least two (e.g., three) different conjugates according to the nineteenth aspect of the invention, one or more nucleic acid molecules or combinations of multiple different nucleic acid molecules according to the twenty-third aspect of the invention, and / or carriers according to the twenty-fourth aspect of the invention.

[0396] The thirtieth aspect of the present invention provides a method for vaccinating against a disease or condition related to HCMV, reducing the risk of such disease or condition, preventing such disease or condition, and / or combating such disease or condition, the method comprising administering a vaccine according to the twenty-ninth aspect of the present invention to a subject.

[0397] The thirtieth aspect of the invention provides a vaccine according to the twenty-ninth aspect of the invention, which is used to vaccinate a subject against an HCMV-related disease or condition, reduce the risk of the disease or condition, prevent the disease or condition, and / or combat the disease or condition.

[0398] The thirtieth aspect of the invention provides the use of a vaccine according to the twenty-ninth aspect of the invention for manufacturing a medicine for use in vaccinating against, reducing the risk of, preventing and / or combating a disease or condition associated with HCMV.

[0399] The disease or condition associated with HCMV may be, for example, the HCMV-related disease or condition disclosed above in the eleventh aspect of the invention. Optionally, the disease or condition is a latent HCMV infection, or a disease or condition associated with a latent HCMV infection.

[0400] In some implementations, methods for vaccinating against, reducing the risk of, preventing or combating HCMV-related diseases or conditions may include administering the vaccine to the subject only once.

[0401] In other embodiments, methods for vaccinating against, reducing the risk of, preventing, and / or combating HCMV-related diseases or conditions may include administering the vaccine to the subject two or more times. For example, in embodiments where the vaccine is an active vaccine, it may be suitable to administer an initial dose and subsequent booster doses to the subject separately.

[0402] The thirty-first aspect of the present invention provides a method for assessing one or more biological conditions and / or biological characteristics of a subject and / or ex vivo biological material, wherein the method comprises: (a) contacting the subject and / or ex vivo biological material with a binding molecule, for example as defined by the first aspect of the present invention, or a conjugate, for example as defined by the eighth or tenth aspect of the present invention; and (b) assessing the subject and / or ex vivo biological material based on direct and / or indirect measurements of the binding of the binding molecule or conjugate to the subject and / or ex vivo biological material.

[0403] In some embodiments, the assessment (which may include diagnosis) of one or more biological conditions and / or biological characteristics of a subject and / or ex vivo biological material is performed by in situ hybridization (ISH) specifically detecting one or more nucleic acid sequences encoded by HCMV, most preferably wherein the ISH does not detect nucleic acid sequences encoded by healthy (i.e., uninfected by HCMV) subjects and / or healthy ex vivo biological materials. By way of non-limiting examples, the ISH may use nucleic acid sequences as discussed in the embodiments of this application. In some embodiments, the biological condition is cancer and / or the biological characteristic is related to cancer. In some embodiments, the cancer is selected from one or more cancers specified herein, optionally wherein the cancer is not glioblastoma. In some embodiments, the cancer is selected from: breast cancer (e.g., HER2+ breast cancer or triple-negative breast cancer), astrocytoma, glioblastoma, adrenocortical carcinoma, renal cell carcinoma, cardiac sarcoma, liver cancer, and angiomyolipoma; optionally wherein the cancer is not glioblastoma.

[0404] In some embodiments, the assessment (which may include diagnosis) of one or more biological conditions and / or biological characteristics of a subject and / or ex vivo biological material is performed by immunohistochemistry (IHC) specifically detecting one or more protein sequences encoded by HCMV, most preferably wherein the IHC does not detect protein sequences encoded by healthy (i.e., uninfected by HCMV) subjects and / or healthy ex vivo biological materials. In some embodiments, IHC uses binding molecules that allow specific detection of one or more protein sequences expressed only by latent HCMV infection or only on its surface. In some embodiments, IHC uses binding molecules that allow specific detection of one or more protein sequences expressed only by lysed HCMV infection or only on its surface. In some embodiments, IHC uses binding molecules that allow specific detection of one or more protein sequences expressed by both lysed and latent HCMV infection, such as those expressed on their surface. In some embodiments, IHC may be performed (e.g., using biological tissue with unpermeable cells) to allow detection only of proteins expressed on the cell surface. In other embodiments, IHC may be performed (e.g., using biological tissue with permeable cells) to allow detection of intracellular proteins. As a non-limiting example, IHC can use antibody-based molecularly specific detection of one or more protein sequences encoded by HCMV as discussed in the embodiments of this application, and / or use one or more of the binding molecules of the present invention. In some embodiments, the biological condition is cancer and / or the biological feature is cancer-related. In some embodiments, the cancer is selected from one or more cancers specified herein, optionally wherein the cancer is not glioblastoma. In some embodiments, the cancer is selected from: breast cancer (e.g., HER2+ breast cancer or triple-negative breast cancer), astrocytoma, glioblastoma, adrenocortical carcinoma, renal cell carcinoma, cardiac sarcoma, liver cancer, and angiomyolipoma; optionally wherein the cancer is not glioblastoma.

[0405] Subjects and / or live ex vivo biological materials that have been diagnosed as positive for HCMV infection by the thirty-second aspect of the present invention may be exemplary subjects and / or materials that can be processed according to other aspects of the present invention as described herein.

[0406] The thirty-second aspect of the present invention provides a method for combating HCMV infection (such as latent HCMV infection and / or lysed HCMV infection and / or multi-strain HCMV infection) in living ex vivo biological material, the method comprising contacting the living ex vivo biological material with one or more reagents selected from the group consisting of:

[0407] i. The binding molecule according to the first aspect of the invention,

[0408] ii. The functional fragment of the binding molecule as defined in the first aspect of the invention,

[0409] iii. The separated bound molecules according to the seventh aspect of the invention,

[0410] iv. According to the second aspect of the invention, a nucleic acid molecule or a combination of multiple different nucleic acid molecules,

[0411] v. The carrier according to the third aspect of the invention,

[0412] vi. According to the fifth aspect of the invention,

[0413] vii. The conjugate according to the eighth aspect of the invention, and

[0414] viii. The separated conjugate according to the tenth aspect of the invention.

[0415] The thirty-second aspect of the invention also provides living ex vivo biological materials obtained or obtainable by the methods of this aspect.

[0416] In one embodiment of the method and / or the living ex vivo biological material obtained or obtainable therefrom in the thirty-second aspect of the invention, the ex vivo living biological material comprises, is substantially composed of, or is composed of the following living ex vivo biological materials: one or more types of ex vivo cells; one or more types of ex vivo cell cultures; one or more types of ex vivo tissues; one or more types of ex vivo tissue cultures; one or more types of ex vivo organoids; one or more types of ex vivo organoid cultures; one or more types of ex vivo organs; and / or one or more types of ex vivo organ cultures.

[0417] The thirty-third aspect of the present invention provides a method for treating a subject in need, comprising administering to the subject an ex vivo living biological material as defined in the thirty-second aspect of the present invention.

[0418] For example, this method can be used for transplanting ex vivo living biological materials, such as organ or tissue transplants. This method can be used to prevent HCMV transmission and infection in transplant recipients, or to reduce the risk of HCMV infection-related diseases or conditions.

[0419] The thirty-fourth aspect of the present invention provides a method for screening binding molecules that have binding specificity and / or binding affinity for a first epitope within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) within ECD1 of the US28 protein of human cytomegalovirus (HCMV), the method comprising:

[0420] (a) Providing one or more peptides or polypeptides, said one or more peptides or polypeptides comprising, or substantially comprising, the sequence TDVLNQSKPVTL (SEQ ID NO: 177) or an immunogenic fragment thereof, or being substantially composed of or consisting of the sequence TDVLNQSKPVTL.

[0421] Preferably, the US28-derived sequence present in one or more of the peptides or polypeptides is SEQ ID NO:177 or its immunogenic fragment (such as the fragment that binds to antibodies 4H3C3, 7B1F3 and / or 2F5B11);

[0422] (b) Provide one or more candidate binding molecules;

[0423] (c) Determining the binding specificity and / or binding affinity of one or more candidate binding molecules for the one or more peptides, thereby selecting one or more binding molecules that have binding specificity to the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO: 177; and

[0424] Optionally, the method further includes screening for the binding specificity of the binding molecule to an epitope within the extracellular domain 3 (ECD3) of the US28 protein of human cytomegalovirus (HCMV) by means of additional method steps (which may be performed before or after steps (a)-(c)), said additional method steps including:

[0425] (i) Provide one or more peptides or polypeptides corresponding to the amino acid sequence present in ECD3 of the US28 protein.

[0426] Preferably, the US28-derived sequence present in one or more of the peptides is SEQ ID NO:6 and / or 7 or its immunogenic fragment (such as the fragment that binds to antibodies 1D3, 1C10, 1A10, 1G9 and / or 1E8).

[0427] (ii) Provide one or more candidate binding molecules, optionally wherein steps (a)-(c) are performed prior to steps (i)-(iii), and wherein the candidate binding molecule used in step (ii) is the product of step (c);

[0428] (iii) Determine the binding specificity and / or binding affinity of one or more candidate binding molecules to one or more peptides or polypeptides corresponding to the amino acid sequence present in ECD3 of the US28 protein, optionally wherein steps (a)-(c) are performed after steps (i)-(iii), and wherein the candidate binding molecule of step (b) is the product of step (iii) of this claim.

[0429] The thirty-fifth aspect of the invention provides a method for producing a composition comprising multiple copies of a binding molecule, the method comprising causing a selected candidate binding molecule to be replicated, the candidate binding molecule having been selected by the method according to the thirty-fourth aspect of the invention.

[0430] The thirty-sixth aspect of the invention provides a method for evaluating selected candidate binding molecules, which have been selected by the method of the thirty-fourth aspect of the invention and / or generated by the method of the thirty-fifth aspect of the invention, the method comprising identifying a structure within the selected candidate binding molecule that provides binding characteristics of the candidate binding molecule (in particular, binding specificity and / or binding affinity to a first epitope within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) within ECD1 of the US28 protein of human cytomegalovirus (HCMV), and optionally binding specificity and / or binding affinity to a second epitope within ECD3), for example by identifying the CDR sequence or each CDR sequence in the selected candidate binding molecule as an antibody or CAR.

[0431] The thirty-seventh aspect of the invention provides a method for producing a composition comprising multiple copies of a binding molecule having binding specificity and / or binding affinity (and optionally binding specificity and / or binding affinity) to a first epitope within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) within ECD1 of the US28 protein of human cytomegalovirus (HCMV) and, optionally, binding specificity and / or binding affinity to a second epitope within ECD3, wherein, according to the method of the thirty-sixth aspect of the invention, the binding molecule comprises a structure (e.g., a CDR sequence) or each of such structures identified within selected candidate binding molecules as providing their binding characteristics, the method comprising replicating the binding molecule.

[0432] The thirty-seventh aspect of the invention further provides a composition of bound molecules obtained through the same aspect. Attached Figure Description

[0433] Figure 1Western blot analysis was used to verify US28 protein expression in transformed CHO-US28-A1 cells using anti-HIS Ab. From left to right, first column: ladder band; second column: protein extract from CHO control cells; third column: protein extract from CHO-US28-A1 cells; and fourth column: 6HIS positive control. The C-terminal portion of the US28-A1 construct transfected into CHO-US28-A1 cells contains a 6HIS tag. When compared to the ladder band, a specific band was marked at approximately 41 kDa with staining using an anti-HIS antibody bound to the 6HIS tag, which is equivalent to the previously reported size of the HCMV US28 protein. This band, circled in the image, did not appear in control CHO cells, thus verifying that US28 is expressed in transfected CHO-US28-A1 cells but not in control CHO cells. The 6HIS positive control was positive, indicating that the 6HIS Ab bound to its target as expected.

[0434] Figure 2 Flow cytometry analysis showed the surface binding of the US28-13-5G6-1D3 antibody clone on CHO-US28-A1 cells. From left to right: blank control, second antibody control, and the US28-13-5G6-1D3 Ab clone bound to the surface of CHO-US28-A1 cells. US28-13-5G6-1D3 Ab bound to 53.4% ​​of CHO-US28-A1 cells, while the blank control and second antibody control showed weak binding: 0.11% and 1.63%, respectively.

[0435] Figure 3 The positive surface binding of clone US28-13-5G6-1D3 on CHO-US28-A1 cells was further verified by serial dilution in FACS analysis. From left to right, clone US28-13-5G6-1D3 Ab was diluted 1:20, 1:50, and 1:200 (w / v) to bind to the surface of CHO-US28-A1 cells.

[0436] Figure 4 The binding of clone US28-13-5G6-1D3 to the positive surface of CHO-US28-A1 cells was compared with that to US28-negative CHO control cells. Clonal US28-13-5G6-1D3 Ab at a dilution of 1:50 (w / v) bound to the surface of US28-positive CHO-US28-A1 cells 15 times more than to US28-negative CHO cells.

[0437] Figure 5The original ELISA analysis showed equal qualitative binding of the US28-13-5G6-1D3 antibody clones to Bio-Peptide-1 (US28 ECD3 genotype 4N) and Bio-Peptide-2 (US28 ECD3 genotype 4D). Since no other mutations were observed in ECD3, these results suggest that the binding of the US28-13-5G6-1D3 Ab to its target is unknown in HCMV strains.

[0438] Figure 6 Qualitative ELISA analysis demonstrated the binding of the recombinant antibody product US28-13-5G6-1D3 rAb to bioactive peptides 1 and 2. These results showed strong and equal binding of the generated antibody to both genetic variants of US28 ECD3, confirming that the recombinant antibody binds well to its target and maintains the unknown binding characteristics of the HCMV virus strain.

[0439] Figure 7 The surface binding of 13-5G6-1D3 rAb on CHO-US28-A1 cells and their respective control CHO cells was verified using FACS analysis. Bars representing CHO cell results were stained dark gray, while bars representing CHO-US28-A1 cell results were stained light gray. From left to right, the first bar shows measurements of a blank control without antibodies against CHO-US28-A1 and CHO cells, respectively; the second bar shows surface binding of anti-mouse IgG-Alexa 488 second Ab alone on both cell types; the third bar shows surface binding of 13-5G6-1D3 rAb diluted 1:10 (w / v) on both cell types; the fourth bar shows surface binding of 13-5G6-1D3 rAb diluted 1:50 (w / v) only on CHO-US28-A1 cells; and the fifth bar shows surface binding of 13-5G6-1D3 rAb diluted 1:100 (w / v) only on CHO-US28-A1 cells. The y-axis shows binding as a percentage of cells. Based on these results, the optimal staining dilution of 13-5G6-1D3 rAb is 1:50 w / v (from the third bar on the left). The binding of 13-5G6-1D3 rAb diluted 1:10 (w / v) to the surface of CHO cells was measured only, and the binding was 0.77% after removing the control (blank and anti-mouse IgG-Alexa488). These results are consistent with previous results obtained using antibodies derived from the 13-5G6-1D3 clone and demonstrate a high specific surface area binding of 13-5G6-1D3 rAb on CHO-US28-A1 cells, exceeding that of normal CHO cells by >21 times.

[0440] Figure 8 FACS analysis showed that US28-13-5G6-1D3 rAb bound to the surface of an HCMV Ad169-infected MRC-5 cell population, but not to simulated cells. A. Top row shows the surface binding of US28-13-5G6-1D3 rAb on simulated cells relative to HCMV Ad169-infected MRC-5 cells, demonstrating highly specific binding on HCMV-infected cells. B. To verify the binding of 13-5G6-1D3 rAb to the surface of an HCMV-infected cell population, another group of HCMV Ad169-infected cells and simulated cells were permeabilized and stained with the commercially available antibody MAB810X against the HCMV major immediate early (IE) antigen, an intracellular protein known to be expressed early during lysed HCMV infection. The MAB810X antibody stained the same HCMV-infected MRC-5 cell population as the US28-13-5G6-1D3 rAb, and no uninfected cells were observed with either antibody staining, confirming that the surface binding exhibited by the US28-13-5G6-1D3 rAb is specific for HCMV Ad169-infected cells.

[0441] Figure 9 The non-specific binding of US28-13-5G6-1D3 rAb was tested by using a mouse IgG isotype control instead of the primary antibody, followed by incubation with goat anti-mouse IgG-Alexa 488. Results showed that, by using US28-13-5G6-1D3 rAb, staining of HCMV-infected MRC-5 cells shifted compared to the isotype control, while staining of uninfected cells (simulated) was similar to the IgG isotype control. Taken together, these results demonstrate that US28-13-5G6-1D3 rAb specifically binds (approximately 16-fold more) to the surface of lysed HCMV-infected cells compared to uninfected cells.

[0442] Figure 10The binding of US28-13-5G6-1D3 rAb to primary PBMCs from three HCMV seropositive subjects was investigated using the same flow cytometry protocol as in previous studies. The bars in the figure show the relative surface binding of US28-13-5G6-1D3 rAb on PBMCs from their respective donors. Results show surface binding of US28-13-5G6-1D3 rAb on 18.37%, 3.57%, and 5.25% of total PBMCs from the three subjects, respectively. The relative proportions of PBMCs from the same subjects expressing certain different cell surface markers are listed below the bars; the total exceeds 100% because some of the same cells express more than one of these cell surface markers (however, these were not measured during the same experiments as US28-13-5G6-1D3 rAb binding). Of the PBMCs studied, only CD11+, CD14+, and CD16+ positive cells were HCMV carriers, and these surface markers partially overlapped in different mononuclear cells. The population of latently infected HCMV mononuclear cells typically comprises about 15% of total PBMCs (although considerable variability can exist among subjects). Therefore, the surface binding of US28-13-5G6-1D3 rAb observed in donors 1, 2, and 3 to 18.37%, 3.57%, and 5.25% of total PBMCs, respectively, confirms binding to a considerable proportion of PBMCs that may be HCMV carriers. These results are independent of PBMC subtype but indicate that US28-13-5G6-1D3 rAb can bind to the surface of latently HCMV-infected cells.

[0443] Figure 11 The binding of commercially available US28 polyclonal Ab to CHO-US28-A1 cells was tested and compared with the binding of US28-13-5G6-1D3rAb to the same cells. A. The US28-13-5G6-1D3 antibody bound to the surface of more than 50% of CHO-US28-A1 cells (from the first column on the left), while the commercially available US28 Ab bound to only 10% of the cells (from the second column on the left). B. We then tested the commercially available US28 Ab on HCMV Ad169-infected MRC-5 cells, where it showed specific binding to the HCMV-infected population. However, compared with the IgG isotype control, the commercially available US28 polyclonal Ab also stained uninfected mimic cells approximately twice as much, indicating nonspecific binding to the surface of uninfected MRC-5 cells. When the signal from the IgG isotype was subtracted, the binding specificity of the commercially available US28 Ab to HCMV Ad169-positive MRC-5 cells was only 1.7 compared to US28-negative mimic MRC-5 cells.

[0444] Figure 12The binding of US28-13-5G6-1D3 diluted 1:400 (w / v) to HCMV-infected human tissue was investigated using immunohistochemical analysis (IHC). A. Staining HCMV-infected lung tissue with US28-13-5G6-1D3 rAb confirmed the specificity for HCMV-infected alveolar and endothelial cells. Arrows (in the non-colored version of this figure) mark the cytoplasmic staining of US28-13-5G6-1D3 rAb on typical HCMV-infected alveolar cells with characteristic giant cell effect in an HCMV-positive control slide. B. 13-5G6-1D3 shows positive US28 staining on macrophages, but alveolar cells in normal lung tissue are negatively stained. C. The same macrophages show positive HCMV DNA in the same lung biopsy section, while no HCMV DNA signal is present in normal alveolar cells, consistent with US28 staining in the same sample. D. Staining HCMV-infected lung tissue with MAB810R antibody confirms specificity for HCMV-infected alveoli and endothelial cells. Arrows (in the non-color version of this figure) indicate MAB810R antibody nuclear staining on typical HCMV-infected cells exhibiting characteristic giant cell effects in an HCMV-positive control slide. E. IE staining of alveolar HCMV-positive macrophages in normal lung tissue is negative. Normal alveolar cells also show negative staining. F. Using IgG as a negative control antibody and showing negative staining of the same lung tissue. See also the non-color version. Figure 12 The color version.

[0445] Figure 13 HCMV US28 expression was investigated in a breast cancer cohort using immunohistochemistry (IHC) and in situ hybridization (ISH). A. In a triple-negative breast cancer (TNBC) sample, US28-13-5G6-1D3 rAb showed strong cytoplasmic staining (3+) of cancer cells (marked with arrows in the non-colored version of this figure). Most tumor cells in this sample were positive for US28-13-5G6-1D3 rAb (brown). B. The same sample shows some spot-positive cytoplasmic staining for anti-IEMAB810R antibody in a few cells throughout the sample. C. ISH analysis shows multiple HCMV DNA signals in many nuclei of the same tumor cells, typical of many triple-negative and HER2-positive tumors in our material. Arrows indicate some positive HCMV DNA signals in the figure. No HCMV DNA was observed in the cytoplasm of the cells. D. Negative control IgG Ab showed negative staining. Figure 13 The color version is provided on the page following the non-color version.

[0446] Figure 14A. Adenocarcinoma metastases from HER2-positive breast cancer show positive intermediate cytoplasmic staining (2+) for US28-13-5G6-1D3 rAb (brown) in all tumor cells. B. Most cancer cells in the same sample are negative for MAB810R staining. For MAB810R Ab, only one or two cells in the entire sample have spot-positive cytoplasmic staining (not shown in the figure). C. ISH analysis shows numerous positive nuclear HCMV DNA signals in the same tumor cells. Arrows indicate such positive HCMV DNA signals. HCMV DNA was not observed in the cytoplasm of the tumor cells. D. The negative control anti-IgG Ab staining of the same sample is negative. Also provided... Figure 14 The color version.

[0447] Figure 15 US28 staining and HCMV ISH were negative in many normal adjacent tumor (NAT) breast tissues, as illustrated in the figure for sample BR1008b_J6. A. US28-13-5G6-1D3 rAb shows negative IHC staining in normal breast tissue. B. MAB810R antibody also shows negative staining in the same sample. C. No nuclear or cytoplasmic HCMV DNA signal was observed in the same sample by ISH. D. IgG staining was also negative. These results indicate that antibodies consistently show negative staining against normal glandular breast tissue without signs of HCMV infection. Notably, the HCMV-negative sample BR1008b_J6 was placed on the same TMA slide as samples BR1008b_D5 and BR1008b_H6, which showed strong positive staining for US28-13-5G6-1D3 antibody and positive nuclear signal for HCMV DNA ISH. Therefore, the samples were exposed to the exact same staining conditions and antibody / DNA probe concentrations. Positive staining observed with US28-13-5G6-1D3rAb was assessed to be specific for HCMV-infected cells in both breast cancer and normal tissues. Also provided... Figure 15 The color version.

[0448] Figure 16A. IHC staining of primary breast cancer samples with US28-13-5G6-1D3 rAb was specific and positive in approximately 73% of the 41 primary breast tumor samples studied. 100% of the tumors that were US28-positive were also positive for HCMV DNA signaling, with multiple signals in the nuclei of 12 out of 41 tumors. All 10 normal adjacent tissue controls (n=10) were negative for US28 staining in the cytoplasm of breast epithelial cells (0), and 7 out of 10 were also negative for ISH signaling. B. Positive staining with US28-13-5G6-1D3 rAb was observed in approximately 94% of the 30 breast cancer metastases studied and was specific for metastatic cells. All TNBC (n=7) and HER2-positive (n=11) metastases were positive for US28-13-5G6-1D3 staining, and the only negative samples (n=2) were hormone receptor-positive cancers. ISH analysis revealed positive nuclear HCMV DNA in 100% of metastatic tumors. 43% of metastatic tissues showed multiple nuclear DNA signals in tumor cells. These samples were exclusively TNBC or HER2+ subtypes, with two exceptions showing a low HR+ status. ISH results are not shown in the figure.

[0449] Figure 17 Human glioblastoma tissue was studied using US28-13-5G6-1D3 rAb and MAB810R antibody via IHC and ISH analysis for HCMV DNA. A. Grade IV glioblastoma brain tumors show moderate staining (brown) of US28 in tumor cells. B. MAB810R antibody staining did not show IE expression in the same cancer cells. However, positive cytoplasmic staining with MAB810R was observed in approximately 90% of glioblastoma samples. Staining was present in several cells in each positive sample, unlike breast cancer samples. However, glial cell staining was weaker than with US28-13-5G6-1D3 rAb. C. Brain tissue NAT was negative for 13-5G6-1D3 staining. D. ISH analysis showed positive nuclear HCMV DNA signaling in the same tumor cells. Arrows indicate these signals. E. The same grade IV glioblastoma sample was negative for IgG antibody staining. F. ISH analysis was negative for the same brain tissue NAT sample. In the non-color versions of these figures, positive glial cells are indicated by arrows. Figure 17 The color version is provided on the page following the non-color version.

[0450] Figure 18US28-13-5G6-1D3 staining was performed on a cohort of human brain cancers containing grade 1-3 astrocytomas, grade 4 glioblastomas, and NAT tissue. All grade 1 astrocytomas (n=4) were negative (0). In grades 2-3 astrocytomas, 6 were negative (0), 37 had positive cytoplasmic staining (1+), and 2 had moderately positive cytoplasmic staining (2+). All grade 4 glioblastomas (n=19) showed positive cytoplasmic staining (1+) for US28-13-5G6-1D3 rAb, with 3 being moderately positive (2+). ISH analysis confirmed the presence of nuclear HCMV DNA in tumor cells of all tumor samples. Only 3 of the 10 NAT samples were positive for HCMV DNA.

[0451] Figure 19 A. Flow cytometry analysis of the 28-13-5G6-1D3-PE antibody on various primary human cells was performed to exclude general off-target binding to the surfaces of these cell types. The following cell lines were studied: primary human adrenocortical cells, primary human renal epithelial cells, primary human cardiac microvascular endothelial cells, primary human liver epithelial cells, and primary human venous smooth muscle cells. The US28-targeting antibody 13-5G6-1D3 showed extremely weak surface binding, with binding well below <1% to all these cell types, indicating no off-target surface binding of 13-5G6-1D3 to these cell types. These results support our observations of laboratory cells showing low binding to the surfaces of normal US28-negative cells. B. Since original primary human cardiac cells were unavailable, immunohistochemistry was used to study the staining of human cardiac tissue samples for 13-5G6-1D3. The example in the figure shows negative 13-5G6-1D3 staining of myocardial tissue, similar to staining with a negative IgG antibody control. ISH analysis did not show any indication of latent HCMV infection in human myocardium. If HCMV infection is present in the human heart, it is always a productive infection type. The positive control, located on the same TMA plate as the heart sample, is positive: 13-5G6-1D3 shows positive staining for malignant pheochromocytoma. The ISH control also shows typical HCMV DNA staining in the nuclei of tumor cells in the same biopsy section, indicating latent HCMV infection in this tumor type. Positive 13-5G6-1D3 and HCMV ISH results are marked with arrows in the figure. Also provided... Figure 19 The color version.

[0452] Figure 20A number of pancreatic tissue samples were studied to rule out the general off-target binding of 28-13-5G6-1D3 to this tissue type. The top row shows normal pancreatic tissue negatively stained with 13-5G6-1D3, MAB810R, and IgG control antibodies. A negative HCMV ISH result indicates the absence of viral HCMV DNA in the normal pancreatic tissue sample. The bottom row shows a pancreatic tissue sample from another patient with positive 13-5G6-1D3 and MAB810R staining and negative IgG control antibody staining (negative control). HCMV ISH analysis also showed a positive result, indicating the presence of cytoplasmic HCMV DNA aggregates in the same sample. Therefore, the same sample was positive for both HCMV proteins US28 and IE and HCMV DNA, but negative for the negative control IgG, indicating specific antibody binding. As expected, US28 protein staining was cytoplasmic, as is expected since IE protein is a nucleoprotein primarily located in the cell nucleus. Because the virus is packaged in the cytoplasm, HCMV ISH showed large cytoplasmic viral DNA aggregates, indicating productive HCMV infection. These results indicate that the antibody US28-13-5G6-1D3 does not bind off-target to pancreatic tissue, and that the presence of HCMV infection in morphologically normal pancreatic tissue is productive, contrasting with tumors that appear to have latent characteristics. [Further details are also provided.] Figure 20 The color version.

[0453] Figure 21A. The absolute binding levels of a set of antibodies, comparing the binding properties of VUN100 (monovalent or bivalent) to US28-13-5G6-1D3 as disclosed in the art to control CHO cells, CHO cells expressing US28 encoded by different HCMV virus strains (DB and TB40 / E), and CHO cells expressing modified US28 containing all known US28 mutations (“mutant virus strains”). B. The binding specificity of the same set of antibodies to CHO cells expressing different forms of US28 compared to control CHO cells, expressed as the fold increase in binding to US28-expressing cells compared to control CHO cells. C. The effect of strain differences on the absolute binding levels of the same set of antibodies, shown as the percentage change in absolute binding levels between binding to CHO cells expressing US28 encoded by HCMV virus strains DB and TB40 / E, where a smaller percentage change indicates a greater degree of strain-unknown binding. D. Retention rate of binding specificity of the same group of antibodies between CHO cells expressing the US28 form encoded by HCMV strains DB and TB40 / E, where a near 100% retention rate of binding specificity indicates strain-agnostic binding specificity, while more significant differences (as shown by the two VUN100 antibody samples) indicate binding specificity variations dependent on the US28-encoding strain (i.e., lack of strain-agnostic binding specificity). E. Percentage of antibody binding to CHO cells expressing different forms of US28 (e.g., encoded by DB, TB40 / E, and mutant forms) when normalized to the observed binding levels for each US28 form with 1D3, where the percentage change in binding for a given antibody to different CHO forms indicates reduced strain-agnostic binding activity compared to 1D3-mFc antibodies and shows binding more dependent on the US28-encoding strain (i.e., lack of strain-agnostic binding compared to 1D3-mFc antibodies).

[0454] Figure 22 The percentage of off-target binding of the various ECD3 binding molecules (A) or various SEQ ID NO:177 binding molecules (B) of the present invention compared to VUN100, as assessed by binding to control CHO cells.

[0455] Figure 23The fold change in binding specificity of exemplary ECD3 binding molecules to US28-expressing CHO cells compared to control CHO cells, relative to the specificity level of VUN100 in the same analysis. A. The binding specificity of 1D3 was improved compared to VUN100 (n=3). B. The binding specificity of 1C10 was improved compared to VUN100 (n=3). C. The binding specificity of 1A10 was improved compared to VUN100 (n=3). D. The binding specificity of 1G4 was improved compared to VUN100 (n=3). E. The binding specificity of 1E8 was improved compared to VUN100 (n=1).

[0456] Figure 24 The fold change in binding specificity of the exemplary SEQ ID NO:177 binding molecule that binds to US28-expressing CHO cells compared to control CHO cells, relative to the specificity level of VUN100 in the same analysis.

[0457] Figure 25 The binding of N-terminal antibodies to HCMV-infected lung tissue and HCMV-negative myometrium was investigated by IHC. A. The previously illustrated US28-13-5G6-1D3 rAb was used as a positive control and showed optimal IHC staining at a 1:3200 (w / v) dilution in these studies. B. US28-4-2F5B11 rAb (1:1600 dilution (w / v)) showed positive staining on HCMV-infected cells and negative staining against HCMV-negative myometrium. C. US28-4-4F3C3 rAb (1:800 dilution (w / v)) showed HCMV-specific staining in infected lung tissue and negative staining against HCMV-negative myometrium. D. US28-4-7B1F3 rAb (1:6400 dilution (w / v)) showed positive and HCMV-specific staining in HCMV-positive lung tissue but not in myometrium. E. Mouse lung tissue with staining IgG was used as a negative control antibody. Staining of HCMV-infected lung tissue with the illustrated ECD1-binding molecule confirmed specificity for HCMV-infected alveolar cells, as no staining was observed in myometrial cells and fibroblasts in the corresponding HCMV-negative myometrial control. Similar to the US28-13-5G6-1D3 rAb, the ECD1-binding molecule stained typical HCMV-infected cells with a characteristic macrocell effect, exhibiting strong cytoplasmic or membrane staining in these cells, as the US28 protein is known to be located in the cytoplasm and cell membrane, and showed positive staining for some tissue macrophages known to be carriers of latent or reactivated HCMV.

[0458] Figure 26The Z-score distribution of sample hum7B1F3 (0.1 μg / ml) on the natural HuProt array shows the top 50 hits.

[0459] Figure 27 Z-score distribution of sample mouse 7B1F3 (0.1 μg / ml) on native HuProt array, showing the top 50 hits.

[0460] Figure 28 Z-score distribution of sample hum7B1F3 (0.1 μg / ml) on the native HuProt array, highest hit and selected additional hits in the HuProt array.

[0461] Figure 29 Z-score distribution of sample mouse 7B1F3 (0.1 μg / ml) on native HuProt array, highest hit and selected additional hits in HuProt array.

[0462] Figure 30 Structural analysis of .7B1F3. VH is located on the left and contains the indicated CDR-H1, CDR-H2, and CDR-H3; and VL is located on the right and contains the indicated CDR-L1, CDR-L2, and CDR-L3. The responsibility for N-glycosylation sequences is indicated by grid circles.

[0463] Figure 31 A comparison of the binding between parental mouse 7B1F3 (“7B1F3”) and humanized 7B1F3 (“hum7B1F3”).

[0464] Figure 32 Comparison of the binding between parental mouse 7B1F3 (“7B1F3”) and humanized, deglycosylated 7B1F3 (“hum7B1F3”) at a dose of 0.5 μg / mL.

[0465] Figure 33 The variations in the relative binding of the three exemplary ECD1 binding molecules of the present invention (antibodies 2F5B11, 4H3C3, and 7B1F3) and the prior art bivalent antibody VUN100 to US28 derived from different HCMV virus strains (VHL / E, DB, TB40 / E, and Merlin) are described. As further discussed in Example 8, data for each antibody clone were evaluated for binding to the US28 protein encoded by the HCMV VHL / E virus strain.

[0466] Figure 34 Typical analysis timeline of Example 9.

[0467] Figure 35Heatmap of tumor cell death: E-max (IC50 max) / E-control (IC50 control) in each 3D PDX tumor model.

[0468] Figure 36 Tumor size results (1 μM astrococcus was a positive control).

[0469] Figure 37 IC50 curve for tumor size.

[0470] Figure 38 An exemplary configuration of a bispecific antibody using the 7B1F3 binding domain. Detailed Implementation

[0471] This invention relates to reagents and related therapeutic, preventive and diagnostic methods that target one or more specific regions of the US28 protein encoded by human cytomegalovirus (HCMV), including but not limited to HCMV-infected cancer and other conditions associated with latent or lysed HCMV infection.

[0472] The HCMV US28 protein exhibits excellent potential to target HCMV infection (including latent reservoirs) because:

[0473] (1) Some portions of the US28 protein are expressed on the cell surface during lysis and latent HCMV infection (Elder et al., iScience, 2019, 12:13-26).

[0474] (2) US28 is a GCPR, whose migration to the plasma membrane allows for both direct targeting by binding molecules and its use as a payload transporter via endocytosis, which can be constitutive or ligand-bound. GCPRs collectively constitute the largest family of proteins targeted by approved drugs (Sriram and Insel, Molecular Pharmacology, 2018, 93(4):251-258); and

[0475] (3) Compared to many approved drugs that target GCPR encoded by human DNA, HCMV US28 is entirely encoded by viral DNA, thus employing a highly specific drug target that is exclusively located in infected HCMV cells but not in healthy human cells.

[0476] A. US28 binding molecules

[0477] When considering the design of binding molecules targeting US28, the inventors noted that the N-terminal domain, the ligand-binding portion of the US28 protein, extends physically from the plasma membrane and is therefore most likely to be exposed to host antibody production, immune responses, and genetic selection pressures (Mozzi et al., 2020, ibid.). Consistently, it is also a region known to contain high interstrain variability and mutations (Arav-Boger et al., 2002, ibid.). Less conserved sites (particularly those consistently identified by the inventors as being located within amino acid positions 1 to 25 of the N-terminal region) are also more prone to generating novel mutations that can alter responses to treatments targeting these regions over time (Komatsu et al., Antiviral Research, 2014, 101:12-25). Numerous such N-terminal polymorphisms are known in identified HCMV strains within regions containing amino acid positions 1 to 25, as summarized in Table 3 of this application. Therefore, new mutations in the HCMV gene are likely to arise at such less conserved sites, which are precisely determined by variations between different viral strains. Most structural antibodies are most likely to be generated targeting the N-terminal portion of the US28 protein (De Groof et al., Molecular Pharm, 2019, 16(7):3145-3156), and thus could be similar to the case of naturally occurring antibodies in humans (Elder et al., 2019, ibid.).

[0478] To date, three types of high-risk oncogenic HCMV strains have been identified. Recently, the clinical HCMV isolates DB (KT95923) and BL (MW980585) were identified to promote oncogenic molecular pathways, establish anchor-independent growth in vitro, and produce tumorigenicity in mouse models; therefore, they have been designated as high-risk oncogenic strains (Kumar et al., 2018 and Ahmad et al., 2021). Additionally, Soroanu et al. sequenced the C-terminal portion of the US28 gene in 10 HCMV-positive glioblastoma tumors. Comparison of the results (presented in the original NIHMS323374-supplement-1.pdf) shows that all these strains are similar to the HCMV VHL / E clinical isolate (L20501.1). The high-risk oncogenic strains DB, BL, and VHL / E all exhibit different mutations in the US28 gene, particularly in the N-terminal portion (Table 3). The N-terminal portion differs from the DB virus strain at positions E18D; A19E; F25L (VHL / E) and A19D, T21A, F25L (BL). Therefore, amino acid positions 18, 19, 21, and 25 are all mutated in these high-risk oncogenic virus strains; and other virus strains are also known to have mutations at positions 8 and / or 15 (Table 3).

[0479] Because high levels of polymorphism have been reported in the N-terminal region, and prior to this invention, this region of US28 appeared to be a potentially suboptimal target for designing anti-US28 antibodies and other anti-US28 binding molecules, especially since binding activity against US28 may substantially depend on the presence of an HCMV viral strain having an N-terminus that matches the binding activity. Furthermore, since it is evident that genetic drift can occur during HCMV infection, such drift may concentrate in highly polymorphic regions, allowing HCMV infection to evolve during infection to avoid binding sensitivity to anti-US28 antibodies and other anti-US28 binding molecules targeting such N-terminal sequences.

[0480] In fact, as discussed in the background section of this application, the previously described anti-N-terminal VHH antibody, referred to as VUN100, exhibits binding to a discontinuous epitope containing multiple binding sites within the N-terminal extracellular region of US28, and is further influenced by the presence of the third extracellular loop of US28 (also referred to herein as ECD4), as in Example 3 of WO 2019 / 151865 (page 36, lines 11-32) and De Groof et al. 2019 (ibid.). Figure 2 As discussed in the illustration.

[0481] It is worth noting that WO 2019 / 151865 Figure 8 Results in D relating VUN100 to binding with different HCMV strains showed differences in binding among the VHL / E, Merlin, and TB40 / E strains of HCMV, with binding being particularly reduced in the TB40 / E (B1 type) strain, only about half the binding level observed against the Merlin strain. Furthermore, further characterization of VUN100 is reported in a preprint article available online by De Groof et al., 2020 (doi:https: / / doi.org / 10.1101 / 2020.05.12.071860), with supplementary data... Figure 2Results are provided for the percentage of IE expression induced in the nuclei of CD14+ monocytes bound by VUN100. All cells tested were from subjects who were seropositive for HCMV and confirmed to be latently infected with HCMV, but the HCMV virus strain infecting each donor was undetermined. The levels of IE expression induced by VUN100 bound to these HCMV-positive CD14+ cells from each of four different patients were substantially different, with reported percentages of 57%, 33%, 22%, and 4% for cells from donors 1–4, respectively (differences greater than 14-fold). This high level of response following VUN100 binding to confirmed HCMV-positive cells appears most likely to be attributed to infection of each of the donors with a different HCMV virus strain, and therefore strongly indicates that the binding capacity of VUN100 will vary significantly among different HCMV virus strains. The same figure also shows a high level of change in response (more than 7-fold difference) after binding of the bivalent form of VUN100 (referred to as VUN100b in De Groof et al., 2020, ibid., denoted by SEQ ID NO:63 of this application) to HCMV-positive cells from donors 1–4 of the same group, again providing results indicative of strain-specific binding sensitivity. De Groof et al., 2021, Pharmacological Reviews 73:828–846 also describes how successive passages of HCMV lead to the development of a resistant mutant with a truncated US28, which has a premature stop codon in extracellular loop 3, resulting in reduced surface expression of US28. Such resistance may adversely affect VUN100 because it depends on a partial epitope in the third extracellular loop.

[0482] Despite its highly variable sequence, the inventors considered the existence of a specific region of the N-terminal portion (ECD1) of the US28 protein that could be a suitable target for antibodies that are highly specific to US28 and whose viral strain is unknown.

[0483] The inventors also determined that ECD2 and ECD3 of US28 are highly conserved among different HCMV viral strains; ECD2 does not have any known mutations, while analysis of known sequences of ECD3 from many different HCMV viral strains revealed only one known mutation. Among the known high-risk oncogenic viral strains, the DB strain is ECD3N170N (also referred to herein as the "4N" variant form because position 170 of the US28 protein corresponds to position 4 of ECD3), while the BL and VHL / E strains represent the N170D (also referred to herein as the "4D") variant (Table 3). The inventors identified multiple polymorphic sites in the DNA sequence encoding US28 ECD4 DNA, only one of which produces the more common amino acid change (R267K). Notably, the high-risk oncogenic BL viral strain contains both the ECD4 variant V250L and R267K (Table 3).

[0484] Surprisingly, this study confirmed that the conserved portions of the ECD2 and ECD4 proteins are not suitable immunogens in mice. The applicant has developed a novel method to identify highly specific, strain-agnostic binding molecules against a specific region of ECD1 targeting HCMV US28, corresponding to positions 26 to 37 and containing the sequence TDVLNQSKPVTL (SEQ ID NO: 177). The inventors' analysis determined that this sequence is significantly conserved across all known HCMV strains. Furthermore, highly specific, strain-agnostic binding molecules against the ECD3 region targeting HCMV US28 were also identified. As reported in the embodiments of this application, numerous monoclonal antibodies exhibited good and specific binding to peptides representing this conserved epitope within ECD1 in US28-overexpressing US28-CHO-A1 cells and HCMV-infected human lung tissue. In addition, the ECD3 monoclonal antibody exhibits good binding and specific binding on: two gene variants of the US28 ECD3 peptide, US28-CHO-A1 cells overexpressing US28, MRC-5 cells infected with HCMV Ad169, primary PBMCs from individuals with positive HCMV serological reactions, HCMV-infected human lung tissue, and several types of invasive human tumors, such as esophageal cancer, gastric cancer, rectal cancer, liver cancer, lung cancer, pancreatic cancer, cervical cancer, malignant pheochromocytoma and locally advanced colon cancer, breast cancer and its metastases, and glioblastoma grade 4.

[0485] Therefore, the applicant has provided highly specific ECD1 binding molecules targeting the US28 protein encoded by HCMV, which have the potential to provide HCMV strain-agnostic binding (and / or can be modified according to the teachings of this application to further include a highly specific and HCMV strain-agnostic ECD3 binding domain), particularly including but not limited to antibodies and chimeric antigen receptors (“CARs”) and their uses, such as for diagnostic, prophylactic, and therapeutic uses and methods related to HCMV. HCMV vaccines and other reagents suitable for generating said binding molecules are also provided.

[0486] A first aspect of the present invention provides a binding molecule comprising one or more polypeptide chains, said binding molecule having binding specificity for a first epitope within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) within ECD1 of the US28 protein of human cytomegalovirus (HCMV), and optionally wherein said binding molecule also has binding specificity for a second epitope within extracellular domain 3 (ECD3) of the US28 protein of HCMV (and / or wherein said binding molecule is a first binding molecule formulated with a second binding molecule having binding specificity for the second epitope within ECD3 of the US28 protein of HCMV), wherein ECD1, SEQ ID NO: 177 and ECD3 of the US28 protein comprise amino acid sequences present in the US28 protein, the positions of which correspond to positions 1 to 37, 26 to 37 and 167 to 183 of the US28 protein encoded by human cytomegalovirus (HCMV) as described in SEQ ID NO: 5, respectively. As further discussed below, non-limiting but particularly preferred embodiments of the binding molecules according to the first aspect of the invention include antibodies and chimeric antigen receptors (CARs).

[0487] Epitope:

[0488] As described above, the binding molecule according to the first aspect of the invention has binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) within ECD1 of the US28 protein of human cytomegalovirus (HCMV), and optionally the binding molecule also has binding specificity to a second epitope within extracellular domain 3 (ECD3) of the US28 protein of HCMV (and / or the binding molecule is a first binding molecule formulated with a second binding molecule having binding specificity to the second epitope within ECD3 of the US28 protein of HCMV), wherein ECD1, SEQ ID NO: 177 and ECD3 of the US28 protein comprise amino acid sequences present in the US28 protein, the positions of which correspond to positions 1 to 37, 26 to 37 and 167 to 183 of the US28 protein encoded by human cytomegalovirus (HCMV) as described in SEQ ID NO: 5, respectively.

[0489] The first epitope of the binding molecule of the first aspect of the invention, which is specific to its binding, may, for example, preferably be entirely present in the polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) within the ECD1 of the US28 protein of HCMV. An optional second epitope of the binding molecule of the first aspect of the invention, which is specific to its binding, may, for example, preferably be entirely present in the ECD3 of the US28 protein of HCMV.

[0490] The first and second epitopes, or each epitope, may be linear epitopes within a polypeptide (preferably entirely within the polypeptide) of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) within ECD1 and / or ECD3 of the US28 protein, for example. Alternatively, the first and second epitopes, or each epitope, may be discontinuous and / or conformational epitopes within a polypeptide (preferably entirely within the polypeptide) of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) within ECD1 and / or ECD3 of the US28 protein.

[0491] The first epitope may, for example, comprise or consist of 12 or fewer amino acids of the sequence of SEQ ID NO:177, such as 11, 10, 9, 8, 7, 6, 5, 4, 3 or fewer amino acids of the sequence of SEQ ID NO:177, which may optionally be consecutive amino acids of the sequence of SEQ ID NO:177 within ECD1 of US28.

[0492] The optional second epitope may, for example, contain or consist of 17 or fewer amino acids of the ECD3 of the US28 protein of HCMV, such as 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 or fewer amino acids of the ECD3 of the US28 protein of HCMV, which may optionally be consecutive amino acids in the ECD3 of US28.

[0493] The amino acid sequences present in the US28 protein at positions 1 to 37 (ECD1) and / or positions 167 to 183 (ECD3) of the US28 protein encoded by human cytomegalovirus (HCMV) as described in SEQ ID NO:5 are not necessarily identical to the sequences found in that region of SEQ ID NO:5, because the ECD1 and / or ECD3 sequences of US28 may differ between different HCMV strains. Therefore, in this document, the term “corresponding to” refers to the amino acids found in the region having the corresponding positions of the US28 protein encoded by any HCMV-associated viral strain (i.e., in: (i) the first extracellular loop, also interchangeably referred to as the ECD1 region and the N-terminus; and / or (ii) the second extracellular loop, also referred to as the ECD3 region).

[0494] Following sequence analysis of the US28 protein from numerous different clinical and laboratory HCMV strains, the applicant has identified a conserved region in the N-terminus (ECD1) of US28 corresponding to SEQ ID NO:177, present in all known HCMV strains, and a single polymorphism in the ECD3 encoding US28 by HCMV, thus providing a favorable ECD1 sequence and two alternative ECD3 sequences. The two alternative ECD3 sequences are referred to herein as the 4D variant and the 4N variant.

[0495] The favorable ECD1 sequence of US28 as defined in SEQ ID NO:177 is clearly conserved in all known HCMV virus strains, including but not limited to HCMV strains DB, Towne, AD169, BL, DAVIS, JP, Merlin, PH, TB40 / E, Toledo, TR, VHL / E, and VR1814(FIX).

[0496] 4D variants refer to sequence variations present in the ECD3 of US28, such as those encoded by Group 1 HCMV strains, and are considered relatively common; as identified by BLAST searches, approximately 90% of US28 sequences encoded by different HCMV strains exhibit 4D variant sequences. 4D variants are characterized by the inclusion of the TKK sequence in the ECD3 of US28. DNQCMTDYDYLEVS (SEQ ID NO: 7; where position 4 is underlined and is D). Exemplary HCMV strains of the first group with the 4D variant of US28 include Towne, VR1814, TB40 / E, VHL / E, Merlin, JP, Ad169, AF1, BL, and DAVIS strains.

[0497] The 4N variant refers to an alternative sequence variation present in the ECD3 of US28, encoded by group II HCMV strains, and exhibits a less common form. The 4D variant is characterized by the inclusion of the sequence TKK in the ECD3 of US28. N NQCMTDYDYLEVS (SEQ ID NO:6; where position 4 is underlined, representing N). Exemplary HCMV strains of the second group having the 4N variant of US28 include the Toledo, TR, and DB strains. These and other HCMV strains exhibiting the 4N variant sequence in ECD3 of US28 are shown in Table 1.

[0498] The first epitope of the binding molecule of the first aspect of the present invention (such as the HMCV virus strain-unknown binding molecule of the first aspect of the present invention) that has binding specificity is an epitope present in the sequence TDVLNQSKPVTL (SEQ ID NO: 177). In other words, the epitope in ECD1 of US28 that has binding specificity to the binding molecule of the first aspect of the present invention preferably excludes amino acids at positions 1 to 25 of the N-terminal region of US28.

[0499] In another option, where the first epitope is a discontinuous and / or conformational epitope within (preferably entirely within) the sequence TDVLNQSKPVTL (SEQ ID NO:177), the discontinuous epitope may include any 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acids of the sequence SEQ ID NO:177.

[0500] The linear, discontinuous, or conformational first epitope in the sequence TDVLNQSKPVTL (SEQ ID NO:177) can exclude one or more amino acids in the sequence corresponding to TDVLNQSKPVTL that contain SEQ ID NO:177 from position 1 to position 11.

[0501] Alternatively, one or more amino acids of TDVLNQSKPVTL may be excluded from linear, discontinuous, or conformational first epitopes bound by the binding molecule of the present invention (such as the HMCV virus strain unknown binding molecule of the first aspect of the present invention).

[0502] For example, the linear, discontinuous, or conformational epitopes in SEQ ID NO:177 may be alternatively or alternatively excluded in position 1. The linear, discontinuous, or conformational epitopes in SEQ ID NO:177 may be alternatively or alternatively excluded in position 2. The linear, discontinuous, or conformational epitopes in SEQ ID NO:177 may be alternatively or alternatively excluded in position 3. The linear, discontinuous, or conformational epitopes in SEQ ID NO:177 may be alternatively or alternatively excluded in position 4. The linear, discontinuous, or conformational epitopes in SEQ ID NO:177 may be alternatively or alternatively excluded in position 5. The linear, discontinuous, or conformational epitopes in SEQ ID NO:177 may be alternatively or alternatively excluded in position 6. The linear, discontinuous, or conformational epitopes in SEQ ID NO:177 may be alternatively or alternatively excluded in position 7. The linear, discontinuous, or conformational epitopes in SEQ ID NO:177 may be alternatively or alternatively excluded in position 8. Linear, discontinuous, or conformational epitopes within SEQ ID NO:177 may be excluded at position 9, either alternatively or separately. Linear, discontinuous, or conformational epitopes within SEQ ID NO:177 may be excluded at position 10, either alternatively or separately. Linear, discontinuous, or conformational epitopes within SEQ ID NO:177 may be excluded at position 11, either alternatively or separately. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded at position 12, either alternatively or separately.

[0503] The first epitope of the binding molecule of the first aspect of the invention (such as the HMCV virus strain unknown binding molecule of the first aspect of the invention) that has binding specificity is preferably an epitope common to and present in more than 90% of known HCMV clinical and / or laboratory virus strains (including at least all HCMV virus strains disclosed in this application), for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or substantially 100% (e.g., between 90% and 100%, between 91% and 100%, between 92% and 100%, between 93% and 100%, between 95% and 100%, between 96% and 100%, between 97% and 100%, between 98% and 100%, between 99% and 100%) of HCMV clinical and / or laboratory virus strains (including at least all HCMV virus strains disclosed in this application).

[0504] In a preferred embodiment, the amino acid in the first epitope of the binding molecule of the first aspect of the invention, which has binding specificity to it, may comprise an amino acid in an epitope within ECD1 bound to any one or more of the antibodies 4H3C3, 7B1F3, and / or 2F5B11 as described herein (which also includes scFv, which comprises V of 4H3C3, 7B1F3, and / or 2F5B11 as defined respectively as SEQ ID NO: 187, 211, 233). H sequence V H The polypeptide sequence, and V having 4H3C3, 7B1F3 and / or 2F5B11 as defined as in SEQ ID NO:189, 213 and 235 respectively. L sequence V L The polypeptide sequence is either identical to the amino acid sequence or differs from the epitope by no more than 5, 4, 3, 2, or 1 amino acid.

[0505] The binding molecule of the first aspect of the invention (such as the HMCV virus strain-agnostic binding molecule of the first aspect of the invention) optionally also has a second epitope with further binding specificity thereto, preferably an epitope common to and present in the sequences TKKNNQCMTDYDYLEVS (SEQ ID NO: 6, corresponding to the 4N variant of ECD3 of US28) and TKKDNQCMTDYDYLEVS (SEQ ID NO: 7, corresponding to the 4D variant of ECD3). In other words, the epitope within ECD3 of US28 with binding specificity of the binding molecule of the first aspect of the invention preferably excludes the fourth amino acid residue of each of SEQ ID No: 6 and 7, which corresponds to N in the 4N variant and D in the 4D variant.

[0506] In the case of a linear ECD3 epitope, then optionally, the epitope shared by the 4N variant and the 4D variant and excluding the fourth amino acid residue of the variant may include all 13 amino acids of the sequence NQCMTDYDYLEVS or any 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 or fewer amino acids thereof, which may optionally be consecutive amino acids of the sequence.

[0507] In another option, where the second epitope is a discontinuous and / or conformational epitope within (preferably entirely within) the ECD3 of the US28 protein, the discontinuous epitope may comprise any 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acids of the 4N variant ECD3 sequence of TKKNNQCMTDYDYLEVS and / or the 4D variant ECD3 sequence of TKKDNQCMTDYDYLEVS.

[0508] A linear discontinuity or conformational second epitope within ECD3 can exclude one or more amino acids of ECD3 in US28, which are contained in TKK corresponding to the 4N variant. N TKK in NQCMTDYDYLEVS and 4D variants D The first to the 17th positions within the sequence of NQCMTDYDYLEVS.

[0509] In a preferred embodiment, the second epitope of the linear discontinuity or conformation within ECD3 preferably excludes the fourth position (N / D), which is known to be different between different HCMV virus strains.

[0510] Alternatively, one or more amino acids of ECD3 in US28 may be excluded from linear, discontinuous, or conformational second epitopes that are optionally bound by the binding molecules of the present invention (such as the HMCV virus strain-unknown binding molecule of the first aspect of the present invention).

[0511] For example, linear, discontinuous, or conformational epitopes within ECD3 may be excluded, either alternatively or by alternative, at position 1. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded, either alternatively or by alternative, at position 2. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded, either alternatively or by alternative, at position 3. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded, either alternatively or by alternative, at position 5. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded, either alternatively or by alternative, at position 6. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded, either alternatively or by alternative, at position 7. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded, either alternatively or by alternative, at position 8. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded, either alternatively or by alternative, at position 9. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded, either alternatively or by alternative, at position 10. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded, either alternatively or by alternative, at position 11. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded at position 12, either alternatively or alternatively. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded at position 13, either alternatively or alternatively. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded at position 14, either alternatively or alternatively. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded at position 15, either alternatively or alternatively. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded at position 16, either alternatively or alternatively. Linear, discontinuous, or conformational epitopes within ECD3 may be excluded at position 17, either alternatively or alternatively.

[0512] The binding molecule of the first aspect of the invention (such as the HMCV virus strain unknown binding molecule of the first aspect of the invention) optionally also has a second epitope that is binding specific to more than 90% of known HCMV clinical and / or laboratory virus strains (including at least all HCMV virus strains disclosed in this application) and is present therein, for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or substantially 100% (e.g., between 90% and 100%, between 91% and 100%, between 92% and 100%, between 93% and 100%, between 95% and 100%, between 96% and 100%, between 97% and 100%, between 98% and 100%, between 99% and 100%) of HCMV clinical and / or laboratory virus strains (including at least all HCMV virus strains disclosed in this application).

[0513] In a preferred embodiment, the amino acid in the second epitope of the binding molecule of the first aspect of the invention optionally having binding specificity thereto may comprise or be identical to an amino acid in an epitope within ECD3 bound by: any one or more of the following antibodies described herein: US28-13-5G6-1D3, 13-1C10-1C10, 13-1H3-1A10, 13-1C10-1G9, 14-4E4-1E8 (generally abbreviated herein as “1D3”, “1C10”, “1A10”, “1G9”, and “1E8”, respectively) (which also includes scFv, which comprises a V of 1D3, 1C10, 1A10, 1G9, and / or 1E8 as defined as SEQ ID NO: 12, 104, 122, 68, and 88, respectively). H sequence V H The polypeptide sequence and V having 1D3, 1C10, 1A10, 1G9 and / or 1E8 as defined in SEQ ID NO:18, 108, 126, 72 and 92, respectively. L sequence V L (Polypeptide sequence), or differing from the epitope by no more than 5, 4, 3, 2 or 1 amino acid.

[0514] Combination characteristics:

[0515] As reported in the embodiments of this application, by using the methods described herein, a variety of monoclonal antibodies have been generated against a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO:177) within ECD1 of US28, and have demonstrated good and specific binding of peptides representing conserved epitopes within ECD1 on US28-overexpressing US28-CHO-A1 cells and HCMV-infected human lung tissue.

[0516] In addition, several monoclonal antibodies against ECD3 of US28 were generated using the methods described herein and demonstrated good and specific binding to both genetic variants of the US28 ECD3 peptide and US28-overexpressing US28-CHO-A1 cells. Some exemplary antibodies from these antibodies were further tested and demonstrated excellent binding properties to: HCMV Ad169-infected MRC-5 cells, primary PBMCs from HCMV serologically positive subjects, HCMV-infected human lung tissue, and several types of invasive human tumors, such as esophageal cancer, gastric cancer, rectal cancer, liver cancer, lung cancer, pancreatic cancer, cervical cancer, malignant pheochromocytoma and locally advanced colon cancer, breast cancer and its metastases, and glioblastoma grade 4.

[0517] These monoclonal antibodies are exemplary embodiments of ECD1 and ECD3 binding molecules that can be combined in multiple specific forms according to the present invention.

[0518] According to a first aspect of the invention, various analyses that can be used to evaluate the properties of binding molecules are described herein. In these analyses, a “reference binding molecule” is designated as a control, which refers to a specific reference binding molecule confirmed herein for ECD1 or ECD3. When a binding molecule according to the first aspect of the invention is able to bind to an epitope within a polypeptide of ECD1 consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177), the reference binding molecule will be an ECD1 reference binding molecule, such as 4H3C3, 7B1F3, 2F5B11, 4A11A11, 2G2B3, 5D6H11, 9G3B9, 5E8F7, 6G3D6, and / or 5E1E4. When a binding molecule according to the first aspect of the invention is also able to bind to an epitope within ECD3, the reference binding molecule will be an ECD3 reference binding molecule used to evaluate ECD3 binding, such as 1D3, 1C10, 1A10, 1G4, and / or 1E8. Therefore, multispecific binding molecules can have an ECD1 binding domain evaluated against an ECD1 reference binding molecule and an ECD3 binding domain evaluated against an ECD3 reference binding molecule.

[0519] More specifically, for ECD1, antibodies 4H3C3, 7B1F3, and / or 2F5B11 as described herein (including scFv, which contains V having 4H3C3, 7B1F3, and / or 2F5B11 as defined in SEQ ID NO:187, 211, and 233, respectively) H sequence V H The polypeptide sequence and V having 4H3C3, 7B1F3 and / or 2F5B11 as defined in SEQ ID NO: 189, 213 and 235, respectively.L sequence V L The polypeptide sequence is a preferred exemplary binding molecule according to the present invention, although other binding molecules have been generated and the scope of the first aspect of the invention is not limited to 4H3C3, 7B1F3 and / or 2F5B11, nor is it limited to binding molecules derived therefrom (such as other binding molecules sharing a CDR of 4H3C3, 7B1F3 and / or 2F5B11), although these may represent various preferred embodiments. However, antibodies to 4H3C3, 7B1F3 and / or 2F5B11 (which also include scFv, which contains V having 4H3C3, 7B1F3 and / or 2F5B11 as defined as SEQ ID NO: 187, 211 and 233 respectively) are also possible. H sequence V H The polypeptide sequence and V having 4H3C3, 7B1F3 and / or 2F5B11 as defined in SEQ ID NO: 189, 213, 235, respectively. L sequence V L The polypeptide sequence can provide a useful benchmark for characterizing the binding properties of other binding molecules according to the first aspect of the invention.

[0520] Furthermore, for ECD3, antibodies 1D3, 1C10, 1A10, 1G9, and / or 1E8 as described herein (including scFv, which contains V having 1D3, 1C10, 1A10, 1G9, and / or 1E8 as defined in SEQ ID Nos: 12, 104, 122, 68, and 88, respectively) are also available. H sequence V H The polypeptide sequence and V having 1D3, 1C10, 1A10, 1G9 and / or 1E8 as defined in SEQ ID Nos: 18, 108, 126, 72 and 92, respectively. L sequence V L The polypeptide sequence is a preferred exemplary binding molecule according to the present invention, although other binding molecules have been generated and the scope of the first aspect of the invention is not limited to 1D3, 1C10, 1A10, 1G9 and / or 1E8, nor is it limited to binding molecules derived therefrom (such as other binding molecules sharing a CDR of 1D3, 1C10, 1A10, 1G9 and / or 1E8), although these may represent various preferred embodiments. However, antibodies to 1D3, 1C10, 1A10, 1G9 and / or 1E8 (wherein they also include scFv, which comprises V having 1D3, 1C10, 1A10, 1G9 and / or 1E8 as defined as SEQ ID NO: 12, 104, 122, 68 and 88 respectively) are also possible. H sequence V HThe polypeptide sequence and V having 1D3, 1C10, 1A10, 1G9 and / or 1E8 as defined in SEQ ID NO:18, 108, 126, 72 and 92, respectively. L sequence V L (The polypeptide sequence) can provide a useful benchmark for characterizing the binding properties of other binding molecules according to the first aspect of the invention, the binding properties further including specificity for ECD3.

[0521] For example, when tested under the same conditions as 4H3C3, 7B1F3, 2F5B11, 4A11A11, 2G2B3, 5D6H11, 9G3B9, 5E8F7, 6G3D6 and / or 5E1E4, the ECD1 of the US28 protein contains TDVLNQSKPVTL (SEQ ID NO). A binding molecule according to the first aspect of the invention, having binding specificity for the first epitope within a polypeptide comprising the amino acid sequence NO:177 (and optionally also binding specificity for the second epitope within ECD3), may exhibit binding properties similar to or substantially equivalent to any one or more of the binding properties of 4H3C3, 7B1F3, 2F5B11, 4A11A11, 2G2B3, 5D6H11, 9G3B9, 5E8F7, 6G3D6 and / or 5E1E4 (and optionally 1D3, 1C10, 1A10, 1G4, 1G9 and / or 1E8, when tested under the same conditions as 1D3, 1C10, 1A10, 1G4, 1G9 and / or 1E8, respectively).

[0522] In the multispecific form, the binding molecule is specific to both the polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) within ECD1 and to ECD3. The binding molecule according to the first aspect of the invention can exhibit ECD1 binding properties similar to or substantially equivalent to those of any one or more of suitable ECD1 binding molecules described herein (such as 4H3C3, 7B1F3, 2F5B11, 4A11A11, 2G2B3, 5D6H11, 9G3B9, 5E8F7, 6G3D6 and / or 5E1E4), and / or ECD3 binding properties similar to or substantially equivalent to those of suitable ECD3 binding molecules described herein (such as 1D3, 1C10, 1A10, 1G4, 1G9 and / or 1E8).

[0523] In these cases, if tested under the same conditions as 4H3C3, 7B1F3, 2F5B11, 4A11A11, 2G2B3, 5D6H11, 9G3B9, 5E8F7, 6G3D6 and / or 5E1E4 (and / or optionally 1D3, 1C10, 1A10, 1G4, 1G9 and / or 1E8, tested under the same conditions as 1D3, 1C10, 1A10, 1G4, 1G9 and / or 1E8), the binding molecule according to the first aspect of the invention shows similarity to 4H3C3, 7B1F3, 2F5B11, 4A11A11, 2G2B3. If a binding molecule has similar or substantially equivalent binding specificity, similar or substantially equivalent unknown binding properties of viral strains, and / or similar or substantially equivalent binding affinity to 4H3C3, 7B1F3, 2F5B11, 4A11A11, 2G2B3, 5D6H11, 9G3B9, 5E8F7, 6G3D6 and / or 5E1E4 (and / or optionally 1D3, 1C10, 1A10, 1G4, 1G9 and / or 1E8), then the binding molecule can be considered to have “similar or substantially equivalent binding properties” to 4H3C3, 7B1F3, 2F5B11, 4A11A11, 2G2B3, 5D6H11, 9G3B9, 5E8F7, 6G3D6 and / or 5E1E4. Such tests may, for example, correspond to any one or more of the tests reported in this application for assessing the binding properties of 4H3C3, 7B1F3, 2F5B11, 4A11A11, 2G2B3, 5D6H11, 9G3B9, 5E8F7, 6G3D6 and / or 5E1E4 (and / or optionally 1D3, 1C10, 1A10, 1G4, 1G9 and / or 1E8), such as for determining the binding properties of HCMV-overexpressing US28-CHO-A1 cells in US28 cells. Any one or more of the following tests were performed on Ad169-infected MRC-5 cells, primary PBMCs from individuals with positive HCMV serological reactions, HCMV-infected human lung tissue and several types of invasive human tumors (such as esophageal cancer, gastric cancer, rectal cancer, liver cancer, lung cancer, pancreatic cancer, cervical cancer, malignant pheochromocytoma and locally advanced colon cancer, breast cancer and its metastases and glioblastoma grade 4) containing a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177), and the US28 ECD3 peptide.

[0524] The binding molecule according to the first aspect of the invention can be considered to have similar or substantially equivalent binding specificity to one or more ECD1 and / or ECD3 reference binding molecules of the invention if, under any one or more tests used to determine the ability to bind specifically to: US28 ECD1 and / or ECD3 peptides (compared to a negative control, such as BSA), US28-expressing cells (compared to equivalent cells not expressing US28), HCMV-infected cells (compared to equivalent cells not infected with HCMV), primary PBMCs from individuals with positive HCMV serological reactions (compared to primary PBMCs from individuals with negative HCMV serological reactions), HCMV-infected human lung tissue (compared to uninfected human lung tissue), and / or HCMV-infected human tumors. The types of cancers, particularly invasive tumors such as esophageal cancer, gastric cancer, rectal cancer, liver cancer, lung cancer, pancreatic cancer, cervical cancer, malignant pheochromocytoma and locally advanced colon cancer, breast cancer and its metastases, and glioblastoma grade 4 (compared to equivalent non-cancerous cells not infected with HCMV), show binding specificity of at least 1, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 95, or substantially 100% for the corresponding ECD1 and / or ECD3 reference binding molecules. Certain binding molecules according to the first aspect of the invention may have binding specificity similar to or substantially equivalent to that of the ECD1 and / or ECD3 reference binding molecules, however, in any one or more of the foregoing tests, their binding specificity is lower than that of the corresponding ECD1 and / or ECD3 reference binding molecules; while certain other binding molecules according to the first aspect of the invention may have higher binding specificity than the corresponding ECD1 and / or ECD3 reference binding molecules in any one or more of the foregoing tests.

[0525] The binding molecule according to the first aspect of the invention can be considered to have similar or substantially equivalent viral strain-agnostic binding properties to one or more ECD1 and / or ECD3 reference binding molecules if, under any one or more tests used to determine the ability to specifically bind to: the conserved ECD1 epitope of SEQ ID NO:177 described herein and / or each 4D variant and 4N variant US28 ECD3 peptide (compared to negative controls such as BSA), each of the 4D and 4N variant US28-expressing cells (each compared to equivalent cells not expressing US28; and optionally, the 4D and 4N variants of US28 are encoded by the US28 sequence of HCMV viral strains TB40 / E and DB, respectively, and / or further optionally, the cells are CHO cells), each of the 4D and 4N variant US28-encoded HCMV viral strains infected cells (each compared to equivalent cells not infected with HCMV), primary PBMCs from individuals seropositive for 4D and 4N variant US28-encoded HCMV viral strains (compared to primary PBMCs from individuals seronegative for HCMV), and human lung tissue infected with 4D and 4N variant US28-encoded HCMV viral strains. Each (compared to lung tissue of uninfected HCMV-infected individuals) and / or each of the 4D and 4N variants of HCMV-infected human tumors encoded by US28, particularly invasive tumors such as esophageal cancer, gastric cancer, rectal cancer, liver cancer, lung cancer, pancreatic cancer, cervical cancer, malignant pheochromocytoma and locally advanced colon cancer, breast cancer and its metastases, and glioblastoma grade 4 (compared to equivalent non-cancerous cells uninfected with HCMV), compared to the ECD1 reference binding molecule, which showed binding independent of the HCMV virus strain and / or equivalent binding to the 4D and 4N variants, which was similar to or substantially identical to the equivalent binding shown by the ECD3 reference binding molecule (e.g., ±30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% or less).

[0526] The binding molecule according to the first aspect of the invention can be considered to have a background binding similar to or substantially equivalent to the ECD1 and / or ECD3 reference binding molecules if, under any one or more tests for determining background binding to: cells not expressing US28 (compared to equivalent cells engineered to express US28), HCMV-uninfected cells (compared to equivalent cells infected with HCMV), primary PBMCs from individuals with negative HCMV serological responses (compared to primary PBMCs from individuals with positive HCMV serological responses), or human lung tissue uninfected with HCMV. (Compared to lung tissue of a person infected with HCMV) and / or the type of tumor in a person not infected with HCMV (compared to equivalent cancer cells infected with HCMV, especially aggressive tumors such as esophageal cancer, gastric cancer, rectal cancer, liver cancer, lung cancer, pancreatic cancer, cervical cancer, malignant pheochromocytoma and locally advanced colon cancer, breast cancer and its metastases and glioblastoma grade 4), background binding molecules show at least 1, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 95 or substantially 100% background binding of the corresponding ECD1 and / or ECD3 reference binding molecules. Certain binding molecules according to the first aspect of the invention may have background anisotropy similar to or substantially equivalent to the background binding of one or more ECD1 and / or ECD3 reference binding molecules, however, higher than the background binding of the corresponding ECD1 and / or ECD3 reference binding molecules in any one or more of the foregoing tests; while certain other binding molecules according to the first aspect of the invention may have lower binding specificity than the corresponding ECD1 and / or ECD3 reference binding molecules in any one or more of the foregoing tests. Alternatively or additionally, in any one or more of the above tests, certain binding molecules according to the first aspect of the invention may have lower background binding (e.g., less than 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or less than 1%) compared to the background binding of VUN100 (monovalent VUN100 and / or divalent VUN100).

[0527] The binding molecule according to the first aspect of the invention can be considered to have a binding affinity substantially equivalent to that of the ECD1 and / or ECD3 reference binding molecules (e.g., ±20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% or less) if, under any one or more tests for determining binding affinity with: US28 ECD1 and / or ECD3 peptides, US28-expressing cells, HCMV-infected cells, primary PBMCs from individuals with positive HCMV serological reactions, HCMV-infected human lung tissue, and / or the type of HCMV-infected human tumor, particularly invasive tumors such as esophageal cancer, gastric cancer, rectal cancer, liver cancer, lung cancer, pancreatic cancer, cervical cancer, malignant pheochromocytoma and locally advanced colon cancer, breast cancer and its metastases, and glioblastoma grade 4, the binding affinity shown by the binding molecule is expressed in the form of Kd, which is within, for example, an order of magnitude 6, 5, 4, 3, 2 or 1 of the binding affinity of the corresponding ECD1 and / or ECD3 reference binding molecules. Certain binding molecules according to the first aspect of the invention may have lower binding affinity than one or more ECD1 and / or ECD3 reference binding molecules in any one or more of the aforementioned tests; while certain other binding molecules according to the first aspect of the invention may have higher binding affinity than one or more ECD1 and / or ECD3 reference binding molecules in any one or more of the aforementioned tests. It should be noted that, for example, particularly in cases where high binding affinity may be less preferred for CARs, higher binding affinity is not always necessary, and CARs with higher binding specificity generally produce greater therapeutic benefits than CARs with high binding affinity.

[0528] According to the first aspect of the invention, the binding molecule can be considered to have any one or more of the aforementioned properties. For example, the binding molecule can be considered to have one or more of the following properties (each of which is described in more detail above):

[0529] 1. Binding specificity similar to or substantially equivalent to one or more ECD1 reference binding molecules;

[0530] 2. Binding specificity similar to or substantially equivalent to one or more ECD3 reference binding molecules;

[0531] 3. Unknown binding characteristics of viral strains similar to or substantially equivalent to one or more ECD1 reference binding molecules;

[0532] 4. Unknown binding characteristics of viral strains that are similar to or substantially equivalent to one or more ECD3 reference binding molecules;

[0533] 5. Binding to a background similar to or substantially equivalent to one or more ECD1 reference binding molecules;

[0534] 6. Binding to a background similar to or substantially equivalent to one or more ECD3 reference binding molecules;

[0535] 7. Lower background binding compared to the background binding of VUN100 (monovalent VUN100 and / or divalent VUN100);

[0536] 8. Viral strains with a large binding affinity to VUN100 (monovalent VUN100 and / or bivalent VUN100) have unknown binding affinity;

[0537] 9. Higher binding specificity compared to binding to VUN100 (monovalent VUN100 and / or bivalent VUN100);

[0538] 10. Binding affinity substantially equivalent to one or more ECD1 reference binding molecules; and / or

[0539] 11. Binding affinity substantially equivalent to one or more ECD3 reference binding molecules.

[0540] For example, the binding molecule may have (i) unknown binding properties to viral strains similar to or substantially equivalent to one or more ECD1 and / or ECD3 reference binding molecules; and (ii) background binding similar to or substantially equivalent to one or more ECD1 and / or ECD3 reference binding molecules. In other embodiments, the binding molecule may have (i) unknown binding properties to viral strains similar to or substantially equivalent to one or more ECD1 and / or ECD3 reference binding molecules; and (ii) lower background binding compared to background binding of VUN100 (monovalent VUN100 and / or bivalent VUN100). In other embodiments, the binding molecule may have (i) unknown binding properties to viral strains similar to or substantially equivalent to one or more ECD1 and / or ECD3 reference binding molecules; (ii) background binding similar to or substantially equivalent to one or more ECD1 and / or ECD3 reference binding molecules; and (iii) lower background binding compared to background binding of VUN100 (monovalent VUN100 and / or bivalent VUN100). In other embodiments, the binding molecule may have (i) strain-agnostic binding properties similar to or substantially equivalent to one or more ECD1 and / or ECD3 reference binding molecules; (ii) background binding similar to or substantially equivalent to one or more ECD1 and / or ECD3 reference binding molecules; (iii) background binding lower than background binding to VUN100 (monovalent VUN100 and / or bivalent VUN100); and (iv) binding specificity similar to or substantially equivalent to one or more ECD1 and / or ECD3 reference binding molecules.

[0541] Further optional analyses for characterizing the binding properties of the binding molecules according to the first aspect of the invention are discussed below.

[0542] (a) Analysis 1:

[0543] As in this application Figure 5 As shown, the exemplary ECD3 binding molecule according to the present invention, namely the monoclonal antibody 1D3 generated against the peptide sequence of ECD3 derived from US28, has the ability to specifically bind to the peptide sequence of ECD3 derived from US28 compared with the negative control BSA.

[0544] The peptide sequences used in this analysis were named: peptide 1, which has the sequence TKKNNQCMTDYDYLEVS (SEQ ID NO:6, corresponding to the 4N variant of ECD3), and peptide 2, which has the sequence TKKDNQCMTDYDYLEVS (SEQ ID NO:7, corresponding to the 4D variant of ECD3).

[0545] like Figure 5 As indicated, compared to the BSA control, the 1D3 antibody showed approximately 27 to 28 times greater specificity binding to each of peptides 1 and 2; and the observed binding levels of 1D3 to peptides 1 and 2 (both as absolute levels and normalized to the corresponding BSA controls) were substantially the same (e.g., differences less than 5%, and likely within the experimental error range). These results clearly demonstrate that 1D3 is specific to ECD3 of US28, and is also unknown to the viral strain.

[0546] In contrast, VUN100 of WO 2019 / 151865 (with the sequence of SEQ ID NO: 60 of this application) exhibits significantly different binding characteristics. It is reported to bind to an epitope in the N-terminal region of US28 (a region of US28 with a high level of sequence variation among different HCMV strains). VUN100 demonstrates a relatively low level of binding specificity; De Groof et al., 2019 (ibid.) reported a specificity score of 4 in their supporting information, Figure S1.A, and Table 2 of this application. Furthermore, VUN100 shows considerable variation in binding with HCMV VHL / E, Merlin, and TB40 / E strains, with particularly reduced binding in TB40 / E (B1 type), approximately half the binding level observed against the Merlin strain (WO2019 / 151865). Figure 8 D). Further characterization of VUN100 is reported in the preprint article by De Groof et al. 2020 (doi:https: / / doi.org / 10.1101 / 2020.05.12.071860), which is available online, with supplementary data. Figure 2Results are presented showing the percentage of HCMV IE-positive CD14+ monocytes induced by VUN100 binding from four different HCMV seropositive donors, where the HCMV viral strain in each donor was not determined. The IE positivity level induced by VUN100 binding to these cells varied by up to 14-fold between the different donors. This can be seen as another indication of the significant variation in VUN100 binding ability between cells infected with different HCMV viral strains. These disadvantageous properties of VUN100 compared to the binding molecules of the present invention are further demonstrated in the embodiments of this application, specifically referring to... Figure 21 AE, Figure 22 and Figure 23 .

[0547] Therefore, in one embodiment, in a binding assay where a reference antibody (wherein the reference antibody is 1D3) shows a greater degree of binding to peptide 1 and / or peptide 2 (preferably both) compared to the same negative control, the binding molecule of the first aspect of the invention may be characterized in that, if it shows a greater degree of binding to peptide 1 and / or peptide 2 (preferably both) compared to a negative control (such as BSA), it has, in addition to having anti-SEQ ID NO:177 binding specificity, anti-ECD3 binding specificity (and / or a second binding molecule having anti-ECD3 binding specificity, the binding molecule of the first aspect of the invention may be combined with the second binding molecule in the formulation), and binding specificity to the epitope within ECD3 of the US28 protein of HCMV. In another embodiment, the reference binding molecule may be selected from the group consisting of: 1C10, 1A10, 1G4, 1G9 and / or 1E8.

[0548] In another or alternative embodiment, in a binding assay, where a reference antibody (wherein the reference antibody is 4H3C3, 7B1F3, and / or 2F5B11) shows a greater degree of binding to peptide-N compared to the same negative control, a binding molecule of the first aspect of the invention having anti-SEQ ID NO:177 binding specificity (optionally, wherein the binding molecule further has anti-ECD3 binding specificity, and / or a first binding molecule having anti-SEQ ID NO:177 binding specificity, the binding molecule having anti-ECD3 binding specificity may be combined with the first binding molecule in the formulation) is characterized in that if it shows a greater degree of binding to peptide-N compared to a negative control (such as BSA), then it has binding specificity for the epitope within SEQ ID NO:177 of the US28 protein of HCMV.

[0549] In another or alternative embodiment, if the corresponding binding levels of the binding molecules against each of peptides 1 and 2 observed in the foregoing analysis (as absolute levels and / or when the observed binding levels are normalized to the corresponding negative control (e.g., BSA)) are substantially the same, such as within 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% or less of each other, then the binding molecule of the first aspect of the invention that has anti-ECD3 binding specificity in addition to anti-SEQ ID NO:177 specificity (and / or the second binding molecule that has anti-ECD3 binding specificity, the binding molecule of the first aspect of the invention may be combined with the second binding molecule in the formulation) can be characterized as having an unknown binding to the viral strain of ECD3.

[0550] In addition to having anti-SEQ ID NO:177 specificity, the binding specificity of the first aspect of the present invention's binding molecule (and / or a second binding molecule having anti-ECD3 binding specificity, wherein the first aspect of the present invention's binding molecule may be combined with the second binding molecule in the formulation) to the epitope within ECD3 of the US28 protein can be assessed, for example, in an ELISA, as described in the embodiments of this application, or by a variant of that method, such as by coating a peptide derived from ECD3 (e.g., bioactive peptide 1 and / or bioactive peptide 2) in a first set of wells of a microtiter plate and coating a negative control (e.g., BSA) in a second set of wells of a microtiter plate. The first set of wells may optionally be further subdivided into a first subgroup of wells containing the sequence of the 4N variant of ECD3 of US28, and a second subgroup of wells containing the sequence of the 4D variant of ECD3 of US28, to allow determination of the relative binding specificity against each variant. After coating the first and second sets of wells, the binding molecule of interest can be incubated in each of the first and second sets of wells, optionally with an additional positive control (e.g., any one or more of 1D3, 1C10, 1A10, 1G4, 1G9, and / or 1E8) tested in the corresponding first and second set of wells. After incubation, the wells can be washed and then incubated with the enzyme-conjugated second antibody. After further washing, the substrate of the conjugated enzyme can be added, which undergoes a measurable reaction (e.g., color change, absorbance) related to the amount of binding of the binding molecule and the control, providing an indication of binding specificity and / or viral strain-agnostic binding characteristics. Thus, in some embodiments, the binding molecule of interest has an absorbance value after ELISA, relative to binding with a negative control (e.g., BSA), indicating positive binding with one or more (preferably both) peptides 1 and / or 2 derived from ECD3 in the first set of wells.

[0551] By “positive binding”, we include the binding molecule of interest having a higher binding level with one or more (preferably both) of peptides 1 and / or 2 compared to the binding level with a control (e.g., BSA), which indicates higher binding specificity.

[0552] For example, under conditions where antibody 1D3 shows binding to peptide 1 and / or peptide 2 approximately 27 to 28 times more than a negative control (such as BSA), the binding to peptide 1 and / or peptide 2 may be at least about 2, at least about 5, at least about 10, at least 15, at least 20, at least 25, about 26, about 27, or about 28 times more than a negative control (such as BSA). The term "about" as used in this context may include values ​​of ±50%, 40%, 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the stated values ​​(e.g., ±10% of at least about 10 times means a range of 9 to 11 times). For instance, the conditions used for such analyses may be selected and used to generate... Figure 5 The conditions used in the analysis of the results shown are the same or equivalent.

[0553] Alternatively or additionally, "positive binding" may include the relevant binding molecule having a similar (e.g., at least ±50%, 40%, 30%, 20%, 10%, 5% or less) or higher / increased / enhanced / improved absorbance level compared to positive controls (e.g., 1D3, 1C10, 1A10, 1G4, 1G9 and / or 1E8).

[0554] (b) Analysis 2:

[0555] In another embodiment, preferably, for example, at a 1:50 (w / v) dilution, as determined by flow cytometry, the binding molecule of the present invention binds to US28-expressing cells (such as CHO cells engineered to express US28) rather than to US28-negative cells (such as wild-type CHO cells). US28-expressing cells are preferably cells characterized by exhibiting US28 protein expression on their cell surface. US28 surface expression is generally characterized by displaying the extracellular domains of US28 on the cell surface (ECDs 1, 2, 3, and 4 correspond to positions 1-37, 91-101, 167-183, and 250-273 of the US28 protein encoded by equivalent sequences of HCMV strain DB or other HCMV strains as defined by the sequence in SEQ ID NO:5, respectively).

[0556] This application Figure 4 , 7Table 2 confirms that, compared to US28 negative control CHO cells, the exemplary anti-ECD3 binding molecule of this application, namely the monoclonal antibody 1D3 generated from ECD3 against US28, has the ability to specifically bind to US28-expressing Chinese hamster ovary (CHO-US28-A1) cells, with a specificity score of approximately 15 to 21.5 under the binding conditions used. This can be analyzed using any suitable technique, such as FACS analysis, to determine the percentage of total cell count bound. As further reported in Example 1 of this application, and specifically referring to Table 2, although clone US28-13-5G6-1D3 (encoding antibody 1D3) is most fully characterized, other cloned monoclonal antibodies generated from ECD3 against US28 exhibit superior binding specificity to CHO-US28-A1 cells compared to their binding to US28 negative control CHO cells. As further reported in Example 2, other cloned monoclonal antibodies against US28 generated by ECD3 still exhibit excellent binding specificity to CHO-US28-A1 cells when compared with their binding to US28 negative control CHO cells, especially with extremely low off-target binding (e.g., compared with the higher off-target binding level shown by VUN100) and in many cases also show high binding specificity to CHO-US28-A1 cells.

[0557] These data clearly demonstrate that by following the teachings of this application, a consistent pathway for generating ECD3-produced antibodies against US28 is provided, which provides highly specific binding to US28-expressing cells (such as CHO cells) compared to binding to US28-negative cells (such as US28-negative CHO cells), preferably with lower off-target binding levels, a set of characteristics not shared by VUN100.

[0558] In contrast, VUN100 of WO 2019 / 151865 (having the sequence of SEQ ID NO: 60 of this application) exhibits significantly different binding properties. It is reported to bind to a discontinuous epitope between the N-terminal region of US28 and the ECD4 region (a region of US28 with high levels of sequence variation across different HCMV strains). When testing the binding of VUN100 to a HEK293T membrane expressing US28 (HEK+US28) or a simulated transfected HEK293T membrane, it demonstrates a relatively low level of binding specificity: DeGroof et al., 2019 (ibid.) reported a specificity score of 4 in their supporting information, Figure S1.A (summarized in Table 2 of this application). VUN100 clearly cannot provide highly specific binding to US28. These unfavorable properties of VUN100 compared to the binding molecules of this invention are further demonstrated in the embodiments of this application, specifically referring to… Figure 21 AE, Figure 22 , Figure 23 and Figure 24 .

[0559] Therefore, in a preferred embodiment, the binding molecule of the first aspect of the invention will exhibit specific binding, characterized in that its binding specificity to US28-expressing cells (such as CHO-US28-A1 cells, optionally wherein the US28 sequence corresponds to a sequence encoded by the HCMV viral strain DB or TB40 / E) is greater than the specificity achieved by VUN100 compared to US28-negative cells (such as CHO cells). For example, the specificity level of the binding molecule of the first aspect of the invention may be at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 80%, about 90%, about 100% (i.e., about 2 times), about 150 times, about 200% (i.e., about 3 times), about 300% (i.e., about 4 times), about 400% (i.e., about 5 times), or about 500% (i.e., about 6 times) greater than the specificity level achieved by VUN100 at the same molar concentration in the same analysis. In this context, the VUN100 comparative may refer to a polypeptide (e.g., monovalent VUN100, divalent VUN100, or mixtures thereof, such as 1:1 mixtures thereof, each as further described herein) comprising, substantially comprising, or comprising of any one or more of the sequences of SEQ ID NO: 60-64. In the cases of SEQ ID NO: 61 and 63, this may include proteins having or not having the specified signal peptide sequence.

[0560] In another preferred embodiment, the binding molecule of the first aspect of the invention will exhibit specific binding, characterized in that, at the same molar concentration in the same analysis, its binding specificity to US28-expressing cells (such as CHO-US28-A1 cells, optionally wherein the US28 sequence corresponds to a sequence encoded by the HCMV viral strain DB or TB40 / E) is at least approximately the same level of specificity as any one or more of 4H3C3, 7B1F3, 2F5B11, 4A11A11, 2G2B3, 5D6H11, 9G3B9, 5E8F7, 6G3D6 and / or 5E1E4 (and / or optionally 1D3, 1C10, 1A10, 1G4 and / or 1E8). As used in this context, the term "about" may include values ​​of ±80%, 70%, 60%, 50%, 40%, 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the specificity level of any one or more of 1D3, 1C10, 1A10, 1G4, and / or 1E8 at the same molar concentration in the same analysis.

[0561] In this context, the 4H3C3, 7B1F3, and / or 2F5B11 comparatives may refer to antibody molecules that contain, are substantially composed of, or are composed of the following:

[0562] The heavy chain polypeptide sequence of 4H3C3 as defined in SEQ ID NO:180 (after removal of the specified N-terminal leader sequence) and the light chain polypeptide sequence of 4H3C3 as defined in SEQ ID NO:181 (after removal of the specified N-terminal leader sequence);

[0563] The heavy chain polypeptide sequence of 7B1F3 as defined in SEQ ID NO:204 (after removal of the specified N-terminal leader sequence) and the light chain polypeptide sequence of 7B1F3 as defined in SEQ ID NO:205 (after removal of the specified N-terminal leader sequence); or

[0564] The heavy chain polypeptide sequence of 2F5B11 as defined in SEQ ID NO:226 (after removal of the specified N-terminal leader sequence) and the light chain polypeptide sequence of 2F5B11 as defined in SEQ ID NO:227 (after removal of the specified N-terminal leader sequence).

[0565] Optionally, in this case, 1D3, 1C10, 1A10 and / or 1E8 comparatives may refer to antibody molecules that comprise, are substantially composed of, or are composed of the following:

[0566] The heavy chain polypeptide sequence of 1D3 as defined in SEQ ID NO:20 (after removal of the specified N-terminal leader sequence) and the light chain polypeptide sequence of 1D3 as defined in SEQ ID NO:21 (after removal of the specified N-terminal leader sequence);

[0567] The heavy chain polypeptide sequence of 1C10 as defined in SEQ ID NO:157 (after removal of the specified N-terminal leader sequence) and the light chain polypeptide sequence of 1C10 as defined in SEQ ID NO:158 (after removal of the specified N-terminal leader sequence);

[0568] The heavy chain polypeptide sequence of 1A10 as defined in SEQ ID NO:161 (after removal of the specified N-terminal leader sequence) and the light chain polypeptide sequence of 1A10 as defined in SEQ ID NO:162 (after removal of the specified N-terminal leader sequence); or

[0569] The heavy chain polypeptide sequence of 1E8 as defined in SEQ ID NO:153 (after removal of the specified N-terminal leader sequence) and the light chain polypeptide sequence of 1E8 as defined in SEQ ID NO:154 (after removal of the specified N-terminal leader sequence).

[0570] Such analyses can be performed, for example, to determine the relative binding to US28-expressing cells (such as CHO-US28-A1 cells, optionally where the US28 sequence corresponds to a sequence encoded by the HCMV viral strain DB or TB40 / E) and to US28-negative cells (such as CHO cells), for example, at a molar ratio, for example, to a 1:5 (w / v) dilution equivalent to 4H3C3, 7B1F3 and / or 2F5B11; and optionally to a 1:50 (w / v) dilution of 1D3, 1C10, 1A10 and / or 1E8, as determined, for example, by flow cytometry analysis.

[0571] (c) Analysis 3:

[0572] In another embodiment, preferably, the binding molecule of the first aspect of the invention may bind to HCMV-infected cells (such as MRC-5 cells; cat#CCL-171, RRID: CVCL_0440, American Type Culture Collection (ATCC), Manassas, VA 20110USA) rather than to equivalent cells without HCMV infection. Figure 8 As shown, when analyzed using flow cytometry, the exemplary ECD3-binding molecule of this application, namely the monoclonal antibody 1D3 generated against ECD3 of US28, has the ability to bind to HCMV-infected MRC-5 cells but not to uninfected (mimic) cells. Under the analytical conditions used, 1D3 showed approximately 5.4% binding to HCMV-infected cells, compared to 0% binding to uninfected (mimic) cells. Figure 9 As shown in the figure, further testing demonstrated that 1D3 specifically binds to the surface of HCMV-infected MRC-5 cells (with up to 16 times the specificity) compared to uninfected cells.

[0573] Therefore, in another preferred embodiment, compared to binding to equivalent cells without HCMV infection, the binding molecules of the first aspect of the invention will exhibit preferred binding to HCMV-infected cells (such as MRC-5 cells), with a preferred binding of at least 5 times, about 6 times, about 7 times, about 8 times, about 9 times, about 10 times, about 11 times, about 12 times, about 13 times, about 14 times, about 15 times, or about 16 times. Such analysis may be, for example, based on the [materials / methods] used to generate this application. Figure 8 or Figure 9The results shown are performed using an equivalent scheme. As used in this context, the term "about" may include values ​​of ±50%, 40%, 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the stated values.

[0574] In another preferred embodiment, compared to binding to equivalent cells without HCMV infection, the binding molecule of the first aspect of the invention will exhibit preferred binding to HCMV-infected cells (such as MRC-5 cells), a preferred binding level greater than that achieved by VUN100. For example, the preferred binding level of the binding molecule of the first aspect of the invention may be at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 80%, about 90%, about 100% (i.e., about 2 times), about 150 times, about 200% (i.e., about 3 times), about 300% (i.e., about 4 times), about 400% (i.e., about 5 times), or about 500% (i.e., about 6 times) greater than the preferred binding level achieved by VUN100 at the same molar concentration in the same analysis. In this context, the VUN100 comparative may refer to a polypeptide (e.g., monovalent VUN100, divalent VUN100, or mixtures thereof, such as 1:1 mixtures thereof, each as further described herein) comprising, substantially comprising, or comprising of any one or more of the sequences of SEQ ID NO: 60-64. In the cases of SEQ ID NO: 61 and 63, this may include proteins having or not having the indicated signal peptide sequence.

[0575] Compared to binding to equivalent cells without HCMV infection, the binding molecules of the first aspect of the invention may, for example, exhibit preferred binding to HCMV-infected cells, which is or at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or substantially 100% of the reference antibody of the invention (e.g., any one or more of 4H3C3, 7B1F3, 2F5B11, 4A11A11, 2G2B3, 5D6H11, 9G3B9, 5E8F7, 6G3D6 and / or 5E1E4, and optionally any one or more of 1D3, 1C10, 1A10, 1G4, 1G9 and / or 1E8) under the same conditions. As used in this context, the term "about" may include values ​​of ±50%, 40%, 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the stated value (e.g., ±50% of 10% refers to a range of 5% to 15%). For example, the conditions for such analyses may be selected to correspond with those used to generate... Figure 8 or Figure 9The conditions in the analysis of the results shown are the same or equivalent.

[0576] (d) Analysis 4:

[0577] In another embodiment, preferably, the binding molecule of the first aspect of the invention may preferentially bind to the epitope in SEQ ID NO:177 (see Example 4) compared to any one or more markers represented by “List A” and / or “List B”. For example, “peptide 3” (TDVLNQSKPVTL) can be used to evaluate preferential binding to the epitope in SEQ ID NO:177.

[0578] The determination of selective binding may optionally be evaluated using the techniques described in Example 4. For example, preferential binding of peptide 3 may be a point intensity (F635) / AU of at least 10-fold, 50-fold, 100-fold, 200-fold, 500-fold, 1,000-fold, 2,000-fold, 5,000-fold, 10,000-fold, or higher than that of preferential binding to any one or more targets from List A and / or List B (including but not limited to HSPD1 (also known as HSP60) and / or ITGA6 (integral α6, also known as CD49f)).

[0579] Alternatively or additionally, the determination of selective binding can be evaluated using the techniques described in Example 5. For example, preferential binding of peptide 3 may result in increased hit rate compared to any one or more (e.g., all) other human membrane proteins as defined in Table C and / or human heterodimers as defined in Table D (based on analysis of repeating plaques by fluorescence on ImageQuant (e.g., using AF647 and ZsGreen 1)).

[0580] (e) Analysis 5:

[0581] In another embodiment, preferably, the binding molecule of the first aspect of the invention exhibits strain-agnostic binding to the epitope within SEQ ID NO:177 of US28. Strain-agnostic binding can be assessed using, for example, two, three, or all four US28 proteins encoded by HCMV strains VHL / E, DB, TB40 / E, and / or Merlin.

[0582] For example, the techniques described in Example 8 can be used to assess the determination of strain-agnostic binding. For example, strain-agnostic binding can be characterized by showing a binding variation level between two, three, or all four US28 proteins encoded by HCMV strains VHL / E, DB, TB40 / E, and / or Merlin that is lower than (e.g., at least 50, 40, 30, 20, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 times lower) the binding variation level between the same US28 proteins, as demonstrated by the bivalent VUN100 used in Example 8. Alternatively or additionally, strain-agnostic binding can be characterized by showing a binding variation level between two, three, or all of the US28 proteins encoded by HCMV strains VHL / E, DB, TB40 / E, and / or Merlin that is substantially equivalent to the variation level demonstrated by any one or more of antibodies 2F5B11, 4H3C3, and 7B1F3 described in Example 8. As used herein, the term "substantially equivalent" may optionally include levels that, when tested under the same conditions, show a difference of less than 50, 40, 30, 20, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 compared to the levels of change shown by any one or more of antibodies 2F5B11, 4H3C3, and 7B1F3.

[0583] polypeptide

[0584] The binding molecule according to the first aspect of the invention comprises, is substantially composed of, or is composed of one or more polypeptide chains.

[0585] The term “polypeptide” is used in its broadest sense herein to refer to a compound containing two or more seed unit amino acids, amino acid analogs, or other peptide mimics. Therefore, the term “polypeptide” includes short peptide sequences as well as longer polypeptides and proteins. The term “amino acid” as used herein includes the standard twenty genetically encoded amino acids and their corresponding stereoisomers in the “D” form (compared to the natural “L” form), Ω amino acids, other naturally occurring amino acids, unconventional amino acids (e.g., α,α-disubstituted amino acids, N-alkyl amino acids, etc.), and chemically derived amino acids (see below).

[0586] Amino acids in this document may be referred to by their full names, three-letter codes, or single-letter codes. When a specific amino acid is listed, such as "alanine," "Ala," or "A," the term refers to both L-alanine and D-alanine unless otherwise explicitly stated. Other unconventional amino acids may also be suitable components of the polypeptides of this invention, provided that the polypeptide retains the desired functional properties. For the peptides shown, each encoded amino acid residue is represented by a single-letter name where appropriate, corresponding to the common name of a conventional amino acid.

[0587] In one embodiment, the polypeptide, as defined herein, comprises or is composed of L-amino acids.

[0588] Those skilled in the art will understand that the present invention and / or the polypeptides used as described herein in conjunction with the present invention may comprise or consist of one or more modified or derived amino acids.

[0589] Chemical derivatives of one or more amino acids can be achieved through reactions with functional side groups. Such derivative molecules include, for example, those in which the free amino group has been derivatized to form amine hydrochloride, p-toluenesulfonyl, carboxyphenoxy, tert-butoxycarbonyl, chloroacetyl, or formyl. The free carboxyl group can be derivatized to form salts, methyl esters, ethyl esters, or other types of esters and hydrazides. The free hydroxyl group can be derivatized to form O-acyl or O-alkyl derivatives. Also included are peptides containing derivatives of naturally occurring amino acids of the twenty standard amino acids as chemical derivatives. For example: 4-hydroxyproline can replace proline; 5-hydroxylysine can replace lysine; 3-methylhistidine can replace histidine; homoserine can replace serine; and ornithine can replace lysine. Derivatives also include peptides containing one or more additions or deletions, provided that the necessary activity is maintained. Other included modifications are amidation, amino-terminal acylation (e.g., acetylation or thioglycolic acid amidation), terminal carboxyl amidation (e.g., with ammonia or methylamine), and similar terminal modifications.

[0590] Those skilled in the art will further understand that peptide mimicry compounds can also be useful. The term "peptide mimicry" refers to a compound that mimics the conformation and desired characteristics of a specific peptide as a therapeutic agent.

[0591] For example, the polypeptide includes not only molecules in which amino acid residues are linked by peptide (-CO-NH-) bonds, but also molecules in which peptide bonds are reversed. Such reverse-peptide mimics can be prepared using methods known in the art, such as those described in Meziere et al. (1997, J. Immunol., 159(7):3230-3237). This method involves preparing pseudopeptides containing a change in orientation involving the main chain rather than the side chains. Reversed peptides containing NH-CO bonds instead of CO-NH peptide bonds are much more resistant to proteolysis. Alternatively, the polypeptide can be a peptide mimic compound in which one or more amino acid residues are linked by -γ(CH2NH)- bonds instead of conventional amide bonds.

[0592] In another alternative, peptide bonds can be completely omitted, provided that a suitable linker portion is used that retains the spacing between carbon atoms of the amino acid residues; this can facilitate the linker portion having substantially the same charge distribution and substantially the same planarity as the peptide bond.

[0593] It will also be learned that the peptide may be blocked at its N-terminus or C-terminus to help reduce susceptibility to extracellular protein hydrolysis.

[0594] Various non-coding or modified amino acids (such as D-amino acids and N-methyl amino acids) have also been used to modify mammalian peptides. Furthermore, it is hypothesized that bioactive conformations can be stabilized by covalent modifications (such as cyclization) or by incorporation of lactams or other types of bridging bonds, see, for example, Veber et al. (1978, Proceedings of the National Academy of Sciences of the United States of America, 75:2636) and Thursell et al. (1983, Biochem. Biophys. Res. Comm. 111:166), which are incorporated herein by reference.

[0595] Combining molecular structure:

[0596] The “binding molecule” according to the first aspect of the invention generally comprises, is substantially composed of or is composed of one or more polypeptides.

[0597] In some implementations, the binding molecule (or a portion thereof) may be formed via a combination of multiple polypeptides. For example, V H Polypeptides can interact with V L Peptide assembly, in which Fab fragments are formed. The assembly of peptides can be a V from an exemplary ECD1-binding molecule. H The peptide binds to the same exemplary ECD1-binding molecule V L Combinations of peptides, or V with different exemplary ECD1 binding molecules L Combinations of peptides. In a further multispecific form incorporating an ECD3-binding domain, the combination of peptides with the ECD3-binding domain can be a V from an exemplary ECD3-binding molecule. H The peptide binds to the same exemplary ECD3-binding molecule V L Combinations of peptides, or V with different exemplary ECD3 binding molecules L Polypeptide combination.

[0598] In some preferred embodiments, the binding molecule is selected from antibodies and chimeric antigen receptors (CARs).

[0599] As discussed above and further illustrated in Table 2 of Example 1 and Example 2, this application describes a large number of antibodies against the polypeptide consisting of SEQ ID NO: 177 of ECD1 or ECD3 of US28, produced according to the methods described herein, which have highly beneficial binding properties to US28, including ECD1 antibodies 4H3C3, 7B1F3, 2F5B11, 4A11A11, 2G2B3, 5D6H11, 9G3B9, 5E8F7, 6G3D6, and 5E1E4; and ECD3 antibodies 13-5G6-1D3 (generally abbreviated as "1D3" herein), 13-5C6-1 B5, 14-1H3-1A6, 13-1C10-1C10 (generally abbreviated as "1C10" in this article), 14-1H3-1A10 (generally abbreviated as "1A10" in this article), 14-2C2-1G4 (generally abbreviated as "1G4" in this article), 13-1C10-1G9 (generally abbreviated as "1G9" in this article), and 14-4E4-1E8 (generally abbreviated as "1E8" in this article).

[0600] As further discussed in part N of this application, this application also provides a method for obtaining an additional antibody with binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) within ECD1 of the US28 protein of HCMV, according to the thirty-fourth aspect of the present invention. For example, the method may include:

[0601] (a) A peptide containing an amino acid sequence present in one or more polypeptides corresponding to the amino acid sequence of TDVLNQSKPVTL (SEQ ID NO:177) within ECD1 of the US28 protein, wherein each of the one or more peptides comprises, is substantially composed of or is composed of the polypeptide sequence TDVLNQSKPVTL (SEQ ID NO:177) and / or an immunogenic fragment thereof.

[0602] (b) Providing one or more candidate antibodies (which optionally are generated in response to said peptide); and

[0603] (c) Determine the binding specificity and / or binding affinity of one or more candidate antibodies to one or more peptides.

[0604] As further discussed in section N of this application, this application also provides a method for obtaining an additional antibody with binding specificity to the epitope within ECD3 of the US28 protein of HCMV according to the thirty-fourth aspect of the present invention. For example, the method may include:

[0605] (a) Provide one or more peptides corresponding to the amino acid sequence present in ECD3 of the US28 protein, such as one or two peptides comprising, substantially consisting of, or consisting of the following: polypeptide sequence TKKDNQCMTDYDYLEVS (SEQ ID NO:7) and / or TKKNNQCMTDYDYLEVS (SEQ ID NO:6) and / or an immunogenic fragment of either or both;

[0606] (b) Provide one or more candidate antibodies (optionally cultured in response to one or both of the peptides); and

[0607] (c) Determine the binding specificity and / or binding affinity of one or more candidate antibodies to one or both of the peptides.

[0608] In some preferred embodiments, the binding molecule of the first aspect of the invention comprises one, two, three, four, five or six complementarity-determining regions (CDRs) corresponding to any one, two, three, four, five or all six of the CDR sequences of antibody 4H3C3 as defined in SEQ ID NO:196, 197, 198, 199, 200 and 201, having binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO:177, and / or any one or more functional variants of the CDR sequence of antibody 4H3C3 (such as humanized variants of 4H3C3), and optionally wherein the binding molecule is selected from antibodies and CARs.

[0609] The sequence and identity of the CDR sequences of antibody 4H3C3 as defined by SEQ ID NO: 196, 197, 198, 199, 200 and 201 are as follows:

[0610]

[0611] The sequence and identity of the CDR sequence of the 4H3C3 humanized antibody can be defined as follows: SEQ ID NO:

[0612]

[0613] In some preferred embodiments, the binding molecule of the first aspect of the invention comprises one, two, three, four, five or six complementarity-determining regions (CDRs) corresponding to any one, two, three, four, five or all six of the CDR sequences of antibody 7B1F3 as defined respectively as SEQ ID NO:219, 220, 221, 199, 222 and 223, having binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO:177, and / or any one or more functional variants of the CDR sequence of antibody 7B1F3 (such as humanized variants of 7B1F3), and optionally wherein the binding molecule is selected from antibodies and CARs.

[0614] The sequence and identity of the CDR sequence of antibody 7B1F3 as defined by SEQ ID NO:219, 220, 221, 199, 222 and 223 are as follows:

[0615] SEQ ID NO:219 NYWMH <![CDATA[V of 7B1F3 H -CDR1 sequence]]> SEQ ID NO:220 YVNPRTGYTEYNQKFKD <![CDATA[V of 7B1F3 H -CDR2 sequence]]> SEQ ID NO:221 ILNGTGFAY <![CDATA[V of 7B1F3 H -CDR3 sequence]]> SEQ ID NO:199 KSSQSLLYSSNQKNYLA <![CDATA[V of 7B1F3 L -CDR1 sequence]]> SEQ ID NO:222 WASTRES <![CDATA[V of 7B1F3 L -CDR2 sequence]]> SEQ ID NO:223 QQYYSFPLT <![CDATA[V of 7B1F3 L -CDR3 sequence]]>

[0616] The sequence and identity of the CDR sequence of the 7B1F3 humanized antibody can be defined as follows:

[0617]

[0618]

[0619] In some preferred embodiments, the binding molecule of the first aspect of the invention comprises one, two, three, four, five or six complementarity-determining regions (CDRs) having binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO: 177, corresponding to any one, two, three, four, five or six of the CDR sequences of antibody 2F5B11 as defined respectively as SEQ ID NO: 242, 243, 244, 199, 245 and 246, and / or any one or more functional variants of the CDR sequences of antibody 2F5B11, and optionally wherein the binding molecule is selected from antibodies and CARs.

[0620] The sequence and identity of the CDR sequence of antibody 2F5B11 as defined by SEQ ID NO:242,243,244,199,245 and246 are as follows:

[0621] SEQ ID NO:242 SYWIH <![CDATA[V of 2F5B11 H -CDR1 sequence]]> SEQ ID NO:243 YINPNTAYTEFNQKFMD <![CDATA[V of 2F5B11 H -CDR2 sequence]]> SEQ ID NO:244 LRSDRTGFAY <![CDATA[V of 2F5B11 H -CDR3 sequence]]> SEQ ID NO:199 KSSQSLLYSSNQKNYLA <![CDATA[V of 2F5B11 L -CDR1 sequence]]> SEQ ID NO:245 WASTREY <![CDATA[V of 2F5B11 L -CDR2 sequence]]> SEQ ID NO:246 QQYYSFPLT <![CDATA[V of 2F5B11 L -CDR3 sequence]]>

[0622] In some preferred embodiments, the binding molecule of the first aspect of the invention further comprises (and / or a second binding molecule that can be used in conjunction with the binding molecule of the first aspect of the invention comprises) one, two, three, four, five or six complementarity-determining regions (CDRs) having binding specificity to a second epitope within the ECD3 of the US28 protein of HCMV, corresponding to any one, two, three, four, five or all six of the CDR sequences of antibody 1D3 as defined respectively as SEQ ID NO: 8, 9, 10, 14, 15 and 16, and / or any one or more functional variants of the CDR sequences of antibody 1D3, and optionally wherein the binding molecule or each binding molecule is selected from antibodies and CARs.

[0623] The sequence and identity of the CDR sequences of antibody 1D3 as defined in SEQ ID NO:8, 9, 10, 14, 15 and 16 are as follows:

[0624] SEQ ID NO:8 GFTFTDYY <![CDATA[V of 1D3 H - CDR1 sequence]]> SEQ ID NO:9 IRSKANGYTT <![CDATA[V of 1D3 H -CDR2 sequence]]> SEQ ID NO:10 ARDERRTAWLAY <![CDATA[V of 1D3 H -CDR3 sequence]]> SEQ ID NO:14 QSIVHSNGNTY <![CDATA[V of 1D3 L - CDR1 sequence]]> SEQ ID NO:15 KVS <![CDATA[V of 1D3 L -CDR2 sequence]]> SEQ ID NO:16 FQGSHVPTWT <![CDATA[V of 1D3 L -CDR3 sequence]]>

[0625] In another embodiment, the binding molecule of the first aspect of the invention further comprises (and / or a second binding molecule that can be used in conjunction with the binding molecule of the first aspect of the invention comprises) one, two, three, four, five or all six complementary determinant regions (CDRs) having binding specificity to a second epitope within ECD3 of the US28 protein of HCMV in the CDR sequence of antibody 1C10 as defined in SEQ ID NO: 112, 113, 114, 117, 83, 118, respectively, and / or any one or more functional variants of the CDR sequence of antibody 1C10, and optionally wherein the binding molecule or each binding molecule is selected from antibodies and CARs.

[0626] The sequence and identity of the CDR sequence of antibody 1C10 as defined by SEQ ID NO: 112, 113, 114, 117, 83, 118 are as follows:

[0627] SEQ ID NO:112 SHALS <![CDATA[V of 1C10 H -CDR1 sequence]]> SEQ ID NO:113 SISSRGRTYYPDSVKG <![CDATA[1C10 V H -CDR2 sequence]]> SEQ ID NO:114 GGTHYSYGNGFDF <![CDATA[V of 1C10 H -CDR3 sequence]]> SEQ ID NO:117 SVSSSVSYMH <![CDATA[V of 1C10 L -CDR1 sequence]]> SEQ ID NO:83 DTSKLAS <![CDATA[V of 1C10 L -CDR2 sequence]]> SEQ ID NO:118 QQWSNNPPIT <![CDATA[V of 1C10 L -CDR3 sequence]]>

[0628] In another embodiment, the binding molecule of the first aspect of the invention further comprises (and / or a second binding molecule that can be used in conjunction with the binding molecule of the first aspect of the invention comprises) one, two, three, four, five or all six complementary determinant regions (CDRs) having binding specificity to a second epitope within ECD3 of the US28 protein of HCMV in the CDR sequence of antibody 1A10 as defined in SEQ ID NO: 112, 113, 114, 117, 83, 118, respectively, and / or any one or more functional variants of the CDR sequence of antibody 1A10, and optionally wherein the binding molecule or each binding molecule is selected from antibodies and CARs.

[0629] The sequence and identity of the CDR sequence of antibody 1A10 as defined by SEQ ID NO: 112, 113, 114, 117, 83, 118 are as follows:

[0630]

[0631]

[0632] In another embodiment, the binding molecule of the first aspect of the invention further comprises (and / or a second binding molecule that can be used in conjunction with the binding molecule of the first aspect of the invention comprises) one, two, three, four, five or six complementary determinant regions (CDRs) having binding specificity to a second epitope within ECD3 of the US28 protein of HCMV in the CDR sequence of antibody 1G9 as defined in SEQ ID NO: 76, 77, 78, 82, 83 and 84, respectively, and / or any one or more functional variants of the CDR sequence of antibody 1G9, and optionally wherein the binding molecule or each binding molecule is selected from antibodies and CARs.

[0633] The sequence and identity of the CDR sequences of antibody 1G9 as defined by SEQ ID NO:76, 77, 78, 82, 83 and 84 are as follows:

[0634] SEQ ID NO:76 SYAMS <![CDATA[V of 1G9 H -CDR1 sequence]]> SEQ ID NO:77 SISSGGSTYYPDSVKG <![CDATA[V of 1G9 H -CDR2 sequence]]> SEQ ID NO:78 GGSTMITTGLGFAY <![CDATA[V of 1G9 H -CDR3 sequence]]> SEQ ID NO:82 SASSSVSYMH <![CDATA[V of 1G9 L -CDR1 sequence]]> SEQ ID NO:83 DTSKLAS <![CDATA[V of 1G9 L -CDR2 sequence]]> SEQ ID NO:84 QQWSSNPPLT <![CDATA[V of 1G9 L -CDR3 sequence]]>

[0635] In another embodiment, the binding molecule of the first aspect of the invention further comprises (and / or a second binding molecule that can be used in conjunction with the binding molecule of the first aspect of the invention comprises) one, two, three, four, five or six complementarity-determining regions (CDRs) having binding specificity to a second epitope within ECD3 of the US28 protein of HCMV, corresponding to any one, two, three, four, five or all six of the CDR sequences of antibody 1E8 as defined in SEQ ID NO: 76, 95, 96, 82, 99 and 100, respectively, and / or any one or more functional variants of the CDR sequences of antibody 1E8, and optionally wherein the binding molecule or each binding molecule is selected from antibodies and CARs.

[0636] The sequence and identity of the CDR sequences of antibody 1E8 as defined by SEQ ID NO:76, 95, 96, 82, 99 and 100 are as follows:

[0637]

[0638]

[0639] In other embodiments, the binding molecule of the first aspect of the invention comprises one, two, three, four, five, or six complementarity-determining regions (CDRs) that are specific for binding to a first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO:177, any one, two, three, four, five, or all six CDR sequences (and / or any one or more functional variants of said CDR sequences) of any other antibody (such as 4A11A11, 2G2B3, 5D6H11, 9G3B9, 5E8F7, 6G3D6, and / or 5E1E4) that is specific for binding to the epitope within SEQ ID NO:177 of the ECD1 of US28 (and preferably has viral strain-agnostic binding specificity); and / or optionally further comprises one, two, three, four, five, or six complementarity-determining regions that are specific for binding to a second epitope within the ECD3 of the US28 protein of HCMV. (CDR), which corresponds to any one, two, three, four, five, or all six (and / or any one or more functional variants of the CDR sequence) of any other antibody having binding specificity (and preferably virus strain unknown binding specificity) to ECD3 of US28, such as either antibody 13-5C6-1B5 or 14-1H3-1A6 as described herein, and / or any antibody obtained by means of obtaining other antibodies having binding specificity to epitopes within extracellular domain 3 (ECD3) of the US28 protein of HCMV, as described above.

[0640] It will be understood that molecules containing three or fewer CDR regions (in some cases, only a single CDR or a portion thereof) are able to maintain the antigen-binding activity of the antibody from which the CDR is derived. For example, Gao et al. (1994, *Journal of Biochemistry* 269:32389-93) described a complete V-type antibody with high affinity for its substrate. L Chain (including all three CDRs).

[0641] Molecules containing two CDR regions are described, for example, by Vaughan and Sollazzo (2001, Combinatorial Chemistry & High Throughput Screening, 4:417-430). On page 418 (right column - 3 Our Design Strategy), microantibodies consisting only of the hypervariable regions of the H1 and H2 CDRs interspersed within the frame region are described. Microantibodies are described as capable of binding to the target. Vaughan and Sollazzo referenced Pessi et al. (1993, Nature, 362:367-9) and Bianchi et al. (1994, J. Mol. Biol., 236:649-59) and described the H1 and H2 microantibodies and their properties in more detail. Qiu et al. (2007, *Nature Biotechnology*, 25:921-9) demonstrated that molecules composed of two linked CDRs can bind antigens (Abstract and page 926, right column). Quiocho (1993, *Nature*, 362:293-4) provided an overview of the “microantibody” technology by Pessi et al. Ladner (2007, *Nature Biotechnology*, 25:875-7) reviewed Qiu et al.'s paper and commented that molecules containing two CDRs can maintain antigen-binding activity (page 875, right column).

[0642] Laune et al. (1997, JBC, 272:30937-44) described molecules containing a single CDR region, demonstrating that a series of hexapeptides derived from CDRs exhibited antigen-binding activity (Abstract), and noted that synthetic peptides with a completely single CDR showed strong binding activity (page 30942, right column). Monnet et al. (1999, JBC, 274:3789-96) demonstrated that a series of 12-meric peptides and associated framework regions possessed antigen-binding activity (Abstract), and commented that a single CDR3-like peptide could bind antigens (page 3785, left column). Heap et al. (2005, J. Gen. Virol., 86:1791-1800) reported that “microantibodies” (molecules containing a single CDR) could bind antigens (Abstract and page 1791, left column), and demonstrated that cyclic peptides derived from anti-HIV antibodies possessed antigen-binding activity and function. Nicaise et al. (2004, Protein Science, 13:1882-91) demonstrated that a single CDR can confer antigen-binding activity and affinity to its lysozyme antigen.

[0643] When referring to functional variants of a specific CDR sequence of an antibody, it will be understood that one or more CDRs in an antibody, as defined, may vary. Thus, in the case where an antibody is defined as containing light chain or heavy chain CDRs (e.g., CDRs 1-3), each having a specific sequence, at most one, two, or three of those specific sequences may vary. Similarly, when an antibody is defined as containing light chain and heavy chain CDRs (e.g., six CDRs), each having a specific sequence, at most one, two, three, four, five, or all six of those specific sequences may vary. Functional variants are typically conserved amino acid substitutions and / or may include amino acid deletions and / or insertions, as further described below. Alternatively or additionally, functional variants may be humanized variants as described herein.

[0644] For example, V in 1D3 H The -CDR1 sequence is an 8-amino acid sequence GFTFTDYY (SEQ ID NO: 8). Its functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, or 5) amino acid deletions and / or one or more amino acid insertions. V of 4H3C3, 7B1F3, 2F5B11, 1C10, 1A10, 1G9, and 1E8 HThe -CDR1 sequence is a 5-amino acid sequence (SEQ ID NO: 196, 219, 242, 112, 112, 138, 76, and 76, respectively). Its functional variants may include one or more (e.g., 1, 2, 3, 4, or 5) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1 or 2) amino acid deletions and / or one or more amino acid insertions.

[0645] 1D3 of V H The -CDR2 sequence is a 10-amino acid sequence IRSKANGYTT (SEQ ID NO: 9). Its functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) amino acid deletions and / or one or more amino acid insertions. V of 1C10, 1A10, 1G9, and 1E8 H The -CDR2 sequence is a 16-amino acid sequence (SEQ ID NO: 113, 113, 77, and 95, respectively). Its functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13) amino acid deletions and / or one or more amino acid insertions. The V of 4H3C3, 7B1F3, and 2F5B11 H The -CDR2 sequence is a 17-amino acid sequence (SEQ ID NO: 197 (or humanized variants SEQ ID NO: 293 and 294), 220 (or humanized variants SEQ ID NO: 296 and 297), and 243, respectively). Functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17) conserved amino acid substitutions, as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) amino acid deletions and / or one or more amino acid insertions.

[0646] 1D3 of V HThe -CDR3 sequence is the 12-amino acid sequence ARDERRTAWLAY (SEQ ID NO: 10). Its functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9) amino acid deletions and / or one or more amino acid insertions. 1G9 of V H The -CDR3 sequence is a 14-amino acid sequence (SEQ ID NO: 78). Its functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11) amino acid deletions and / or one or more amino acid insertions. V of 1C10, 1A10, and 1E8 H The -CDR3 sequence is a 13-amino acid sequence (SEQ ID NO: 114, 114, and 96, respectively). Its functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid deletions and / or one or more amino acid insertions. The V of 4H3C3 and 2F5B11 H The -CDR3 sequence is a 10-amino acid sequence (SEQ ID NO: 198 and 244, respectively). Functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) conserved amino acid substitutions, as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) amino acid deletions and / or one or more amino acid insertions. 7B1F3 V H The -CDR3 sequence is a 9-amino acid sequence (SEQ ID NO:221 or humanized variant SEQ ID NO:298). Functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8 or 9) conserved amino acid substitutions, as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5 or 6) amino acid deletions and / or one or more amino acid insertions.

[0647] 1D3 of V LThe -CDR1 sequence is an 11-amino acid sequence QSIVHSNGNTY (SEQ ID NO: 14). Its functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) amino acid deletions and / or one or more amino acid insertions. V of 1C10, 1A10, 1G9, and 1E8 L The -CDR1 sequence is a 10-amino acid sequence (SEQ ID NO: 117, 117, 82, and 82, respectively). Functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) amino acid deletions and / or one or more amino acid insertions. Functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) amino acid deletions and / or one or more amino acid insertions. V of 4H3C3, 7B1F3, and 2F5B11 L The -CDR1 sequence is a 17-amino acid sequence (SEQ ID NO:199 (or humanized variant SEQ ID NO:295), 199 (or humanized variant SEQ ID NO:295), and 199, respectively). Functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17) conserved amino acid substitutions, as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) amino acid deletions and / or one or more amino acid insertions.

[0648] 1D3 of V L The -CDR2 sequence is a 3-amino acid sequence KVS (SEQ ID NO:15). Its functional variants may include one or more (e.g., 1, 2, 3) conserved amino acid substitutions as further described below, and / or may include one or more amino acid deletions and / or one or more amino acid insertions. V of 4H3C3, 7B1F3, 2F5B11, 1C10, 1A10, 1G9, and 1E8 LThe -CDR2 sequence is a 7-amino acid sequence (SEQ ID NO:200 (or humanized variant SEQ ID NO:222), 222, 245, 83, 83, 145, 83, and 99, respectively). Functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1, 2, 3, or 4) amino acid deletions and / or one or more amino acid insertions.

[0649] 1D3 of V L The -CDR3 sequence is a 10-amino acid sequence FQGSHVPTWT (SEQ ID NO: 16). Its functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) amino acid deletions and / or one or more amino acid insertions. V of 1C10, 1A10, 1G9, and 1E8 L The -CDR3 sequence is a 10-amino acid sequence (SEQ ID NO: 118, 118, 84, and 100, respectively). Its functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) conserved amino acid substitutions as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) amino acid deletions and / or one or more amino acid insertions. The V of 4H3C3, 7B1F3, and 2F5B11 L The -CDR3 sequence is a 9-amino acid sequence (SEQ ID NO: 201, 223, and 246, respectively). Functional variants may include one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9) conserved amino acid substitutions, as further described below, and / or may include one or more (e.g., 1, 2, 3, 4, 5, or 6) amino acid deletions and / or one or more amino acid insertions.

[0650] One or more functional variants of the CDRs can be generated by any of a variety of methods well known in the art. For example, the binding properties of binding molecules comprising 1, 2, 3, 4, 5, or 6 CDRs can be generated by maturation methods. For example, the binding affinity of the CDRs providing the binding molecule can be modified (increased or decreased) by maturation steps; and / or the binding specificity of the CDRs providing the binding molecule can be modified (generally increased) by maturation steps. It should be understood that high or increased binding affinity levels for US28 may not always be desirable, especially at the cost of unacceptably high levels of binding affinity to off-target cells such as healthy human cells. Binding molecules, including but not limited to CARs and CAR-expressing cells, may benefit, for example, from lower levels of binding affinity, but will generally always benefit from optimized levels of binding specificity.

[0651] In one example of a mature approach, the affinity effect can be modified using a monovalent display phage-particle system during antigen binding screening. Two alternative or combined approaches, non-targeted mutagenesis and oligonucleotide-directed mutagenesis, can be used to construct random or restricted sublime libraries to introduce mutants with a large number of original binding molecules. Then, by modifying screening criteria, such as in stringency analysis, binding molecules with the desired modified properties (e.g., increased specificity and / or increased or decreased affinity) that bind to US28-expressing cells and / or HCMV-infected cells are selected.

[0652] The binding molecule of a first aspect of the invention comprises one or more sequences providing binding specificity to a first epitope within a polypeptide consisting of the amino acid sequence of TDVLNQSKPVTL (SEQ ID NO: 177), wherein said one or more sequences comprise a functional variant of any one, two, three, four, five, or all six CDR sequences of an antibody:

[0653] (a) 4H3C3, as defined in SEQ ID NO: 196, 197, 198, 199, 200 and 201 respectively;

[0654] (b)7B1F3, as defined in SEQ ID NO:219, 220, 221, 199, 222 and 223 respectively; and / or

[0655] (c)2F5B11, as defined in SEQ ID NO:242, 243, 244, 199, 245 and 246 respectively;

[0656] (d) Humanized variants of 4H3C3, as defined in SEQ ID NO: 196; 293 or 294; 198; 199 or 295; 200 or 222; and 201, respectively;

[0657] (e) 7B1F3 humanized variants, as defined in SEQ ID NO: 219; 296 or 297; 221 or 298; 199 or 295; 222; and 223, respectively;

[0658] Furthermore, as described above, when tested under the same conditions as 4H3C3, 7B1F3 and / or 2F5B11, it is preferable to have one or more binding properties with peptides and / or US28 proteins having the sequence of SEQ ID NO:177 that are similar to or substantially equivalent to the binding properties of 4H3C3, 7B1F3 and / or 2F5B11.

[0659] Optionally, the binding molecule of the first aspect of the invention, such as as described in the preceding paragraph, further comprises one or more sequences having binding specificity to a second epitope within the extracellular domain 3 (ECD3) of the US28 protein of HCMV, wherein said one or more sequences comprise (and / or can be used in combination with the binding molecule of the first aspect of the invention and / or the formulated second binding molecule comprises) a functional variant of any one, two, three, four, five, or all six CDR sequences of the following antibodies:

[0660] (f)1D3, as defined in SEQ ID NO:8, 9, 10, 14, 15 and 16 respectively;

[0661] (g)1C10, as defined in SEQ ID NO:112, 113, 114, 117, 83 and 118 respectively;

[0662] (h)1A10, as defined in SEQ ID NO:112, 113, 114, 117, 83 and 118 respectively;

[0663] (i) 1G9, as defined in SEQ ID NO: 76, 77, 78, 82, 83 and 84 respectively; and / or

[0664] (j)1E8, as defined in SEQ ID NO:76, 95, 96, 82, 99 and 100 respectively;

[0665] Furthermore, as described above, when tested under the same conditions as 1D3, 1C10, 1A10, 1G9 and / or 1E8, it is preferable to have a peptide with a sequence of one or both of the 4N variant and / or 4D variant of ECD3 of the US28 protein having HCMV and / or a US28 protein having a sequence of one or both of the 4D and / or 4N variant ECD3 sequences that have similar or substantially equivalent binding properties to 1D3, 1C10, 1A10, 1G9 and / or 1E8.

[0666] In one embodiment, the binding molecule of the first aspect of the present invention may comprise:

[0667] (a) The variable heavy chain (V) of the following antibodies H One, two, or all three of the CDR 1, 2, and 3 sequences:

[0668] i.4H3C3, as defined in SEQ ID NO:196, 197 and 198 respectively (and / or any one, two or three functional variants of the CDR sequence);

[0669] ii.7B1F3, as defined in SEQ ID NO:219, 220 and 221 respectively (and / or functional variations of any one, two or three of the CDR sequences); and / or

[0670] iii.2F5B11, as defined in SEQ ID NO:242, 243 and 244 respectively (and / or any one, two or three functional variants of the CDR sequence);

[0671] And optionally further include:

[0672] iv.1D3, as defined in SEQ ID NO:8, 9 and 10 respectively (and / or any one, two or three functional variants of the CDR sequence);

[0673] v.1C10, as defined in SEQ ID NO:112, 113 and 114 respectively (and / or any one, two or three functional variants of the CDR sequence);

[0674] vi.1A10, as defined in SEQ ID NO:112, 113 and 114 respectively (and / or any one, two or three functional variations of the CDR sequence);

[0675] vii.1G9, as defined in SEQ ID NO:76, 77 and 78 respectively (and / or functional variations of any one, two or three of the CDR sequences); and / or

[0676] viii.1E8, as defined in SEQ ID NO:76, 95 and 96 respectively (and / or any one, two or three functional variants of the CDR sequences);

[0677] and / or

[0678] (b) The variable light chain (V) of the following antibodies L One, two, or all three of the CDR sequences 1, 2, and 3:

[0679] i.4H3C3, as defined in SEQ ID NO:199, 200 and 201 respectively (and / or any one, two or three functional variants of the CDR sequence);

[0680] ii.7B1F3, as defined in SEQ ID NO:199, 222 and 223 respectively (and / or functional variations of any one, two or three of the CDR sequences); and / or

[0681] iii.2F5B11, as defined in SEQ ID NO:199, 245 and 246 respectively (and / or any one, two or three functional variants of the CDR sequence);

[0682] And optionally further include:

[0683] iv.1D3, as defined in SEQ ID NO:14, 15 and 16 respectively (and / or any one, two or three functional variants of the CDR sequence);

[0684] v.1C10, as defined in SEQ ID NO:117, 83 and 118 respectively (and / or any one, two or three functional variants of the CDR sequence);

[0685] vi.1A10, as defined in SEQ ID NO:117, 83 and 118 respectively (and / or any one, two or three functional variations of the CDR sequence);

[0686] vii.1G9, as defined by SEQ ID NO:82, 83 and 84 respectively (and / or functional variations of any one, two or three of the CDR sequences); and / or

[0687] viii.1E8, as defined in SEQ ID NO:82, 99 and 100 respectively (and / or any one, two or three functional variants of the CDR sequence).

[0688] Alternatively or concurrently, the binding molecule of the first aspect of the present invention may comprise:

[0689] (a) at least one variable weight chain (V H A polypeptide comprising CDR 1, 2, and 3 sequences having the following sequences:

[0690] i. SEQ ID NO: 196, 197 and 198 respectively (and / or any one, two or three functional variants of the CDR sequence), and optionally the at least one of the variable heavy chains (V HThe polypeptide contains the sequence of SEQ ID NO:187 (or a functional variant thereof), is substantially composed of, or is composed of;

[0691] ii. SEQ ID NO: 219, 220 and 221 respectively (and / or any one, two or three functional variants of the CDR sequence), and optionally wherein at least one of the variable heavy chains (V H The polypeptide contains the sequence of SEQ ID NO:211 (or a functional variant thereof), is substantially composed of or consists of the sequence of SEQ ID NO:211; and / or

[0692] iii. SEQ ID NO: 242, 243 and 244 respectively (and / or any one, two or three functional variants of the CDR sequence), and optionally wherein at least one of the variable heavy chains (V H The polypeptide contains the sequence of SEQ ID NO:233 (or a functional variant thereof), is substantially composed of, or is composed of;

[0693] And optionally the following sequences:

[0694] iv. SEQ ID NO:8, 9 and 10 respectively (and / or any one, two or three functional variants of the CDR sequence), and optionally at least one of them, a variable heavy chain (V H The polypeptide contains the sequence of SEQ ID NO:12 (or a functional variant thereof), is substantially composed of or is composed of the sequence of SEQ ID NO:12;

[0695] v. SEQ ID NO: 112, 113 and 114 respectively (and / or any one, two or three functional variants of the CDR sequence), and optionally at least one of the variable heavy chains (V H The polypeptide contains the sequence of SEQ ID NO:104 (or a functional variant thereof), is substantially composed of or is composed of the sequence of SEQ ID NO:104;

[0696] vi. SEQ ID NO: 112, 113 and 114 respectively (and / or any one, two or three functional variants of the CDR sequence), and optionally at least one of them, a variable heavy chain (V H The polypeptide contains the sequence of SEQ ID NO:122 (or a functional variant thereof), is substantially composed of or is composed of the sequence of SEQ ID NO:122;

[0697] vii. SEQ ID NO:76, 77 and 78 respectively (and / or any one, two or three functional variants of the CDR sequence), and optionally at least one of the variable heavy chains (V H The polypeptide contains the sequence of SEQ ID NO:68 (or a functional variant thereof), is substantially composed of, or is composed of; and / or

[0698] viii. SEQ ID NO:76, 95, and 96 respectively (and / or any one, two, or three functional variants of the CDR sequence), and optionally at least one of the variable heavy chains (V H The polypeptide contains the sequence of SEQ ID NO:88 (or a functional variant thereof), is substantially composed of or is composed of the sequence of SEQ ID NO:88;

[0699] and / or

[0700] (b) at least one variable light chain (V L A polypeptide comprising CDR 1, 2, and 3 sequences having the following sequences:

[0701] i. SEQ ID NO: 199, 200 and 201 respectively (and / or any one, two or three functional variants of the CDR sequence), and optionally wherein at least one of the variable heavy chains (V L The polypeptide contains the sequence of SEQ ID NO:189 (or a functional variant thereof), is substantially composed of or is composed of the sequence of SEQ ID NO:189;

[0702] ii. SEQ ID NO: 199, 222 and 223 respectively (and / or any one, two or three functional variants of the CDR sequence), and optionally wherein at least one of the variable heavy chains (V L The polypeptide contains the sequence of SEQ ID NO:213 (or a functional variant thereof), is substantially composed of or consists of the sequence of SEQ ID NO:213; and / or

[0703] iii. SEQ ID NO: 199, 245 and 246 respectively (and / or any one, two or three functional ...

Claims

1. A binding molecule comprising one or more polypeptide chains, wherein the binding molecule has binding specificity to a first epitope in a polypeptide consisting of the amino acid sequence of TDVLNQSKPVTL (SEQ ID NO: 177) in the extracellular domain 1 (ECD1) of the US28 protein of human cytomegalovirus (HCMV), and wherein the ECD1 of the US28 protein and SEQ ID NO: 177 each comprise an amino acid sequence present in the US28 protein, the positions of which correspond to positions 1 to 37 and 26 to 37 of the US28 protein encoded by human cytomegalovirus (HCMV) as set forth in SEQ ID NO: 5, respectively, and Optionally wherein if the binding molecule is an antibody, the binding molecule is a monoclonal antibody.

2. The binding molecule according to claim 1, wherein: (a) the binding molecule is selected from an antibody (such as a monoclonal antibody) and a chimeric antigen receptor (CAR); and / or (b) The binding molecule is a monospecific binding molecule or a multispecific (e.g., bispecific or trispecific) The binding molecule, the monospecific binding molecule or the multispecific binding molecule comprises one or more regions having binding specificity for the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO: 177 within ECD1.

3. The binding molecule according to claim 1 or 2, wherein the first epitope is completely present within the amino acid sequence of SEQ ID NO: 177 of the US28 protein of HCMV.

4. The binding molecule according to any one of the preceding claims, wherein the first epitope is a linear epitope within the amino acid sequence of SEQ ID NO: 177 of the US28 protein of HCMV.

5. The binding molecule according to any one of the preceding claims, which has HCMV strain-agnostic binding specificity for the first epitope in the amino acid sequence of SEQ ID NO: 177 of the US28 protein of HCMV, For example, the binding molecule: (a) has binding specificity for the first epitope and / or the second epitope of the US28 protein of HCMV, and the binding specificity is agnostic to two or more (such as all) HCMV strains; and / or (b) has agnostic binding specificity for two or more (such as all) HCMV strains selected from the group consisting of: DB, Towne, AF1, VHL / E, AD169, BL, DAVIS, JP, Merlin, PH, TB40 / E, Toledo, TR and VR1814 (FIX).

6. A binding molecule according to any one of the preceding claims, comprising one, two, three, four, five or six CDRs corresponding to any one, two, three, four, five or all six of the complementary determining region (CDR) sequences of the following antibodies, said CDRs having binding specificity to said first epitope in a polypeptide consisting of the amino acid sequence of SEQ ID NO: 177: (a) 4H3C3 as defined in SEQ ID No: 196, 197, 198, 199, 200 and 201, respectively, and / or a functional variant of any one or more of the CDR sequences of antibody 4H3C3; (b) 7B1F3 as defined in SEQ ID No: 219, 220, 221, 199, 222 and 223, respectively, and / or a functional variant of any one or more of the CDR sequences of antibody 7B1F3; and / or (c) 2F5B11 as defined in SEQ ID No: 242, 243, 244, 199, 245 and 246, respectively, and / or a functional variant of any one or more of the CDR sequences of antibody 2F5B11; and Optionally, the binding molecule is selected from an antibody and a CAR.

7. The binding molecule according to claim 6, comprising: (a) Variable heavy chain (V H ), wherein the sequences have binding specificity to the first epitope in a polypeptide consisting of the amino acid sequence of SEQ ID NO: 177, and the antibody is selected from: (i) 4H3C3, as defined in SEQ ID Nos: 196, 197 and 198, respectively; (ii) 7B1F3, as defined in SEQ ID Nos: 219, 220 and 221, respectively; and / or (iii) 2F5B11, as defined in SEQ ID Nos: 242, 243 and 244, respectively; and / or (b) variable light chain (V L ), wherein the sequences have binding specificity to the first epitope in a polypeptide consisting of the amino acid sequence of SEQ ID NO: 177, and the antibody is selected from: (i) 4H3C3, as defined in SEQ ID Nos: 199, 200 and 201, respectively; (ii) 7B1F3, as defined in SEQ ID Nos: 199, 222 and 223, respectively; and / or (iii) 2F5B11, as defined by SEQ ID No: 199, 245 and 246, respectively.

8. The binding molecule according to claim 6 or 7, comprising: (a) at least one variable heavy chain (V H ) polypeptide, which comprises CDR 1, 2 and 3 sequences of an antibody having binding specificity to the first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO: 177 having the following sequence: (i) SEQ ID Nos: 196, 197 and 198 of antibody 4H3C3, respectively, and Optionally, the at least one variable heavy chain (V H ) The polypeptide comprises, consists essentially of, or consists of the sequence of SEQ ID NO: 187; (ii) SEQ ID Nos: 219, 220 and 221 of antibody 7B1F3, respectively, and Optionally, the at least one variable heavy chain (V H ) The polypeptide comprises, consists essentially of, or consists of the sequence of SEQ ID NO: 211; (iii) SEQ ID Nos: 242, 243 and 244 of antibody 2F5B11, respectively, and Optionally, the at least one variable heavy chain (V H ) the polypeptide comprises, consists essentially of, or consists of the sequence of SEQ ID NO: 233; and / or i. At least one variable light chain (V L ) polypeptide, which comprises CDR 1, 2 and 3 sequences of an antibody having binding specificity to the first epitope within a polypeptide consisting of the amino acid sequence of SEQ ID NO: 177 having the following sequence: (iv) SEQ ID Nos: 199, 200 and 201 of antibody 4H3C3, respectively, and Optionally, the at least one variable heavy chain (V H ) The polypeptide comprises, consists essentially of, or consists of the sequence of SEQ ID NO: 189; (v) SEQ ID Nos: 199, 222 and 223 of antibody 7B1F3, respectively, and Optionally, the at least one variable heavy chain (V H ) The polypeptide comprises, consists essentially of, or consists of the sequence of SEQ ID NO: 213; (vi) SEQ ID Nos: 199, 245 and 246 of antibody 2F5B11, respectively, and Optionally, the at least one variable heavy chain (V H ) polypeptide comprises, consists essentially of, or consists of the sequence of SEQ ID NO:

235.

9. The binding molecule according to any one of the preceding claims, wherein the binding molecule is selected from the group consisting of: (a) bivalent antibodies, such as IgG-scFv antibodies (e.g., wherein the first binding domain is an intact IgG and the second binding domain is an scFv, the scFv being attached to the first binding domain at the N-terminus of the light chain of the IgG and / or at the C-terminus of the light chain and / or at the N-terminus of the heavy chain and / or at the C-terminus of the heavy chain, or vice versa), including but not limited to TDVLNQSKPVTL (SEQ ID NO: 177) for the US28 protein of HCMV a bivalent antibody having binding specificity for the first epitope within a polypeptide consisting of an amino acid sequence of, for example, wherein the first epitope is as defined in any one of the preceding claims; (b) Monovalent antibodies, such as or “knob-in-hole” bispecific antibodies (e.g., scFv-KIH, scFv-KIH r , BiTE-KIH or BiTE-KIH r ); (c) scFv2-Fc antibody; (d) bispecific antibodies, such as bispecific T cell engager (BiTE) antibodies; (e) dual variable domain (DVD)-Ig antibodies; (f) Dual-affinity retargeting (DART)-based antibodies (e.g., DART2-Fc or DART); (g) a trispecific antibody, such as a DNL-Fab3 antibody or a trispecific antibody having binding specificity for the first epitope within a polypeptide consisting of the amino acid sequence of TDVLNQSKPVTL (SEQ ID NO: 177) of the US28 protein of HCMV, optionally wherein the trispecific antibody is a trispecific immune cell engager antibody, such as a trispecific T cell engager (TiTE), and optionally wherein the TiTE antibody comprises a CD3 binding domain; (h) scFv-HSA-scFv antibody; (i) single domain antibodies; (j) heavy chain only IgG (hcIgG), such as camelid IgG (e.g. VHH antibodies) and shark immunoglobulin new antigen receptors (IgNARs), and single chain antibodies thereof; and (k) A chimeric antigen receptor (CAR) comprising the extracellular domain according to claim 1 or any claim dependent therefrom, such as the extracellular domain of any one of options (a) to (h) of the present claim or a combination thereof.

10. A binding molecule according to any one of the preceding claims, wherein the binding molecule: (i) is a bispecific immune cell engager antibody, such as a bispecific T cell engager (BiTE), and Optionally, the BiTE antibody comprises a CD3 binding domain; or (ii) is or comprises an antibody, wherein the antibody is a monoclonal antibody or a functional fragment thereof, and is optionally a recombinant monoclonal antibody or a functional fragment thereof, such as a monoclonal antibody or a functional fragment thereof recombinantly produced by CHO cells.

11. A functional fragment of a binding molecule according to any one of the preceding claims, wherein the functional fragment: (a) comprising or consisting of an antigen-binding fragment of a binding molecule according to any one of the preceding claims, or a variant, fusion or derivative thereof, selected from the group consisting of an Fv fragment (such as a single-chain Fv fragment (scFv) or a disulfide-bonded Fv fragment), a Fab-like fragment (such as a Fab fragment, a Fab' fragment or a F(ab)2 fragment) and a single domain antibody (dAb, including single and dual formats, such as dAb-linker-dAb and Nanobodies); (b) providing a bonding feature according to any one of claims 1 to 5; (c) comprising a CDR sequence according to any one of claims 6 to 8; and / or (d) comprising V according to claim 8 H and / or V L sequence.

12. The binding molecule according to any one of claims 1 to 10 or the functional fragment of the binding molecule according to claim 11, wherein the binding molecule or its functional fragment comprises a fusion polypeptide sequence, The fusion polypeptide sequence comprises a first amino acid sequence fused to a second amino acid sequence, wherein The first amino acid sequence comprises or consists of: at least one of the polypeptide chains of the binding molecule or its functional fragment, and The second amino acid sequence is a fusion partner.

13. A chimeric antigen receptor (CAR), comprising: (i) an extracellular domain, wherein the extracellular domain comprises or consists of: A binding molecule according to any one of claims 1 to 10 or 12 or a functional fragment of the binding molecule according to claim 11 or 12; (ii) a transmembrane domain; and (iii) intracellular domain; wherein the extracellular domain of the CAR has binding specificity to a first epitope within a polypeptide consisting of an amino acid sequence of TDVLNQSKPVTL (SEQ ID NO: 177) within ECD1 of the US28 protein of human cytomegalovirus (HCMV), and Wherein ECD1 and SEQ ID NO:177 of the US28 protein each comprise an amino acid sequence present in the US28 protein, the positions of which correspond to positions 1 to 37 and 26 to 37 of the US28 protein encoded by human cytomegalovirus (HCMV) as set forth in SEQ ID NO:5, respectively.

14. A nucleic acid molecule or a combination of multiple different nucleic acid molecules, Wherein the nucleic acid molecule comprises, or the combination of the multiple different nucleic acid molecules jointly comprises, one or more nucleic acid sequences, and the one or more nucleic acid sequences encode, individually or in combination, the binding molecule according to any one of claims 1 to 12 or the CAR according to claim 13.

15. A vector comprising the nucleic acid molecule according to claim 14 or a combination of a plurality of different nucleic acid molecules.

16. A cell comprising the nucleic acid molecule according to claim 14 or a combination of a plurality of different nucleic acid molecules or the vector according to claim 15, Optionally, wherein the cell expresses one or more binding molecules according to any one of claims 1 to 12 and / or one or more CARs according to claim 13, and the one or more binding molecules and / or CARs are encoded by a nucleic acid molecule according to claim 14 or a combination of multiple different nucleic acid molecules or a vector according to claim 15.

17. A cell comprising a binding molecule according to any one of claims 1 to 12 and / or a nucleic acid encoding the binding molecule, optionally wherein the nucleic acid is a nucleic acid or a vector according to claim 14 or 15.

18. A method of producing a cell, the method comprising introducing a nucleic acid molecule according to claim 14 or a combination of a plurality of different nucleic acid molecules and / or a vector according to claim 15 into a cell.

19. A method for producing a binding molecule according to any one of claims 1 to 12 or a CAR according to claim 13, the method comprising: expressing the nucleic acid molecule according to claim 14 or a combination of a plurality of different nucleic acid molecules and / or the vector according to claim 15 in a cell, and Optionally wherein the method further comprises the step of isolating the binding molecules so produced from the cells.

20. A conjugate comprising a moiety conjugated to a binding molecule according to any one of claims 1 to 10 or 12 or to a functional fragment of the binding molecule according to claim 11 or 12, Optionally, the moiety is a therapeutic, prophylactic, diagnostic, prognostic or theranostic moiety, and / or the moiety is a drug (e.g., wherein the conjugate is an antibody-drug conjugate ("ADC")) and / or a radioactive moiety (e.g., wherein the conjugate is suitable for radioimmunotherapy ("RIT")).

21. A method of combating HCMV or a disease or condition associated with HCMV, the method comprising administering to a subject or to an ex vivo or in vitro cellular material any one or more agents selected from the group consisting of: i. A binding molecule according to any one of claims 1 to 10 or 12, ii. A functional fragment of the binding molecule according to claim 11 or 12, iii. A nucleic acid molecule according to claim 14 or a combination of a plurality of different nucleic acid molecules, iv. The vector according to claim 15, v. A cell according to claim 16 or 17, and vi. The conjugate according to claim 20.

22. One or more agents for use against a disease or condition associated with HCMV in a subject or in ex vivo or in vitro cellular material, wherein the one or more agents are selected from or are each individually selected from the group consisting of: i. A binding molecule according to any one of claims 1 to 10 or 12, ii. A functional fragment of the binding molecule according to claim 11 or 12, iii. A nucleic acid molecule according to claim 14 or a combination of a plurality of different nucleic acid molecules, iv. The vector according to claim 15, v. A cell according to claim 16 or 17, and vi. The conjugate according to claim 20.

23. Use of one or more agents for the manufacture of a medicament for combating a disease or condition associated with HCMV in a subject or in ex vivo or in vitro cellular material, wherein the one or more agents are selected from or are each individually selected from the group consisting of: i. A binding molecule according to any one of claims 1 to 10 or 12, ii. A functional fragment of the binding molecule according to claim 11 or 12, iii. A nucleic acid molecule according to claim 14 or a combination of a plurality of different nucleic acid molecules, iv. The vector according to claim 15, v. A cell according to claim 16 or 17, and vi. The conjugate according to claim 20.

24. An agent for use in medicine, wherein the agent is selected from the group consisting of: i. A binding molecule according to any one of claims 1 to 10 or 12, ii. A functional fragment of the binding molecule according to claim 11 or 12, iii. A nucleic acid molecule according to claim 14 or a combination of a plurality of different nucleic acid molecules, iv. The vector according to claim 15, v. A cell according to claim 16 or 17, and vi. The conjugate according to claim 20.

25. A vaccine composition suitable for vaccinating against, reducing the risk of, preventing or combating a disease or condition associated with human cytomegalovirus (HCMV), wherein the vaccine is an active or passive vaccine, wherein the vaccine triggers and / or provides an immune response against a first epitope within a polypeptide consisting of the amino acid sequence of TDVLNQSKPVTL (SEQ ID NO: 177) present within ECD1 of the US28 protein of HCMV, and Wherein ECD1 and SEQ ID NO:177 of the US28 protein comprise an amino acid sequence present in the US28 protein, and their positions correspond to positions 1 to 37 and 26 to 37 of the US28 protein encoded by HCMV as set forth in SEQ ID NO:5, respectively.

26. A method of vaccinating against, reducing the risk of, preventing and / or combating a disease or condition associated with HCMV, the method comprising administering to a subject a vaccine according to claim 25, Optionally, the disease or disorder is latent HCMV infection, or is a disease or disorder associated with latent HCMV infection.

27. The vaccine according to claim 25, for use in vaccinating a subject against, reducing the risk of, preventing and / or combating a disease or condition associated with HCMV, Optionally, the disease or disorder is latent HCMV infection, or is a disease or disorder associated with latent HCMV infection.

28. Use of the vaccine according to claim 25 in the manufacture of a medicament for vaccinating a subject against, reducing the risk of, preventing and / or combating a disease or condition associated with HCMV, Optionally, the disease or disorder is latent HCMV infection, or is a disease or disorder associated with latent HCMV infection.

29. A method of assessing one or more biological conditions and / or biological characteristics of a subject and / or ex vivo biological material, wherein the method comprises: (a) contacting the subject and / or the ex vivo biological material with a binding molecule according to any one of claims 1 to 12 or a conjugate according to claim 20; and (b) assessing the subject and / or the ex vivo biological material based on direct and / or indirect measurement of binding of the binding molecule or conjugate to the subject and / or the ex vivo biological material.

30. A method for combating HCMV infection (such as latent HCMV infection and / or lytic HCMV infection and / or multi-strain HCMV infection) of a live ex vivo biological material, the method comprising contacting the live ex vivo biological material with any one or more agents selected from the group consisting of: i. A binding molecule according to any one of claims 1 to 10 or 12, ii. A functional fragment of the binding molecule according to claim 11 or 12, iii. A nucleic acid molecule according to claim 14 or a combination of a plurality of different nucleic acid molecules, iv. The vector according to claim 15, v. A cell according to claim 16 or 17, and vi. The conjugate according to claim 20.

31. A living ex vivo biological material obtained or obtainable by the method according to claim 30.

32. A method of treating a subject in need thereof, the method comprising administering to the subject an ex vivo living biological material according to claim 31, optionally wherein the method is a method of transplanting the ex vivo living biological material, such as an organ transplant or a tissue transplant.

33. A method for screening a binding molecule having binding specificity to a first epitope in a polypeptide consisting of the amino acid sequence TDVLNQSKPVTL (SEQ ID NO: 177) in ECD1 of the US28 protein of human cytomegalovirus (HCMV), wherein the ECD1 and SEQ ID NO: 177 of the US28 protein comprise an amino acid sequence present in the US28 protein, the positions of which correspond to positions 1 to 37 and 26 to 27, respectively, of the US28 protein encoded by the HCMV as set forth in SEQ ID NO: 5, The method comprises: (a) providing one or more peptides or polypeptides, wherein the one or more peptides or polypeptides comprise the sequence TDVLNQSKPVTL (SEQ ID NO: 177) or an immunogenic fragment thereof, or consisting essentially of, or consisting of; (b) providing one or more candidate binding molecules; as well as (c) determining the binding specificity and / or binding affinity of one or more candidate binding molecules to the one or more peptides, thereby selecting one or more binding molecules that have binding specificity to the first epitope within the polypeptide consisting of the amino acid sequence of SEQ ID NO:

177.

34. A peptide or polypeptide comprising, consisting essentially of, or consisting of the sequence TDVLNQSKPVTL (SEQ ID NO: 177), or comprising the sequence of an immunogenic fragment of SEQ ID NO: 177, wherein the peptide or polypeptide is not the US28 protein, and Preferably, the only US28-derived sequence in the peptide or polypeptide is the sequence of SEQ ID NO:177 or the sequence of an immunogenic fragment of SEQ ID NO:

177.

35. A fusion protein comprising, consisting essentially of, or consisting of a first amino acid sequence fused directly or via one or more linker amino acid sequences to a second amino acid sequence, wherein The first amino acid sequence is the sequence of the peptide or polypeptide according to claim 34; and The second amino acid sequence is a fusion partner, optionally wherein the fusion partner is a carrier protein, such as a carrier protein selected to provide a fusion protein suitable for immunization and production of antibodies against the first amino acid sequence, Preferably, the only US28-derived sequence in the fusion protein is the sequence of SEQ ID NO: 177 or the sequence of an immunogenic fragment of SEQ ID NO: 177, and Optionally, the carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), human serum albumin (HSA), bovine serum albumin (BSA), ovalbumin (OVA), tetanus toxoid (TT), diphtheria toxoid (DT), genetically modified diphtheria toxoid cross-reactive material (CRM), meningococcal outer membrane protein complex (OMPC) and Haemophilus influenzae protein D (HiD).

36. An MHC tetramer comprising a peptide or polypeptide according to claim 34, optionally wherein the peptide comprises or corresponds to SEQ ID NO: 177 or an immunogenic fragment thereof, For example, where the MHC tetramer is for antigen-specific CD8 + Class I MHC tetramers for T cell detection, for antigen-specific CD4 + MHC class II tetramers for T cell detection, fluorophore-labeled tetramers for flow cytometry or fluorescence microscopy.